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of LED 40X increased in comparison with Ziehl-Neelsen (ZN) reading in the early
phases of the evaluation (2.6% and 2.7% vs 0% in the validation and implementation
phases vs continuation phase, respectively), probably due to lack of experience among
technicians, but no significant difference was found (P>0.05). In the last phase, no
false positive result was recorded. Although the reading time of fluorescence-LED
(FM-LED) and ZN reading were less than 2 minutes, ZN-light microscope (ZN-LM)
reading time was shorter than that of FM-LED40X, especially in positive smears
(P=0.007) in the early study phase. By the end of the study, FM-LED reading time
was shorter than ZN-LM which was recorded in the early phase. With high
experienced technicians there may be little or no additional benefit to case detection if
a light microscope is replaced by a fluorescence microscope.
In general, MODS and LED microscopy are reliable methods for use in diagnosis of
TB in resource limited settings due to their accuracy, reliability and low costs. Large
scale operational projects should be conducted to evaluate the feasibility and cost-
effectiveness of these methods in countries where these techniques are to be
implemented.
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Chapter 1
INTRODUCTION
1.1 HISTORY OF TUBERCULOSIS
It is known that humans have suffered from tuberculosis (TB) since ancient times;
DNA of the causative organisms, Mycobacterium tuberculosis (M.tuberculosis) has
been isolated from 3000 year old Egyptian mummies (140). In addition, literature
described tuberculosis in India and China as early as 3300 years ago and 2300 years
ago, respectively (91). Around 460BC, Hippocrates reported that phthisis, an ancient
term to describe tuberculosis, usually occurred at a young age and was always fatal.
Its presentation was described by Clarissimus Galen as cough, fever, pus and
malnutrition with ulceration in the respiratory system (91). These are also the classical
symptoms of pulmonary tuberculosis recognized today: prolonged productive cough,
fever, night-sweats and weight loss (232). The gradual wasting experienced by TB
patients over a period of months or years led to the term 'consumption' for the
disease. However, only when the TB epidemic reached its peak in Europe and North
America during the 18th and 19th centuries, scientists started focusing on the
pathogenesis of this disease (55); and Theophil Laennec was the first leader in this
era. At this time, TB was perceived as a heritable disease in Northern Europe, and a
disease infectious in nature in Southern Europe, Laennec found that in some lesions, a
grey and semi-transparent matter is formed which then gradually turns yellow,
opaque, and dense. When it softens and becomes liquid, it is expelled through the
airways and leaves cavities (168). Following this discovery was the demonstration of
Chapter 1-Introduction Page 20
transmissibility of a specific organism from human to cattle and from cattle to rabbits
by injection by Jean-AntoinVillemin in 1865 (168). It is important that both Theophil
Laennec and Jean-Antoin Villemin did not identify the causative agent; they only
described the phenomena they observed. Twenty years later (1882), Robert Koch
confirmed that tuberculosis is an infectious disease which is caused by M
tuberculosis. One of his major contributions was the development of a method for
staining tubercle bacillus which was named after him as the Koch's bacillus, although
this term is rarely used today (23). In 1907, Clemens Von Pirquet developed the
tuberculin skin test (205), which was recommended as an aid to diagnosis of
tuberculosis in children (169). At the same time, the French bacteriologists Calmette
and Guerin used specific culture media to reduce the virulence of Mycobacterium
bovis (Mbovis) through serial passage to create Bacillus Calmette-Guerin (BCG)
which was subsequently used as the BCG vaccine strain administered worldwide for
TB prevention and control (218). Unfortunately, this vaccine is not completely
effective and meta-analyses suggest the effectiveness ranges from 0 - 80% (154), with
the reasons for observed discrepancies in various settings unknown. Suggestions have
included variation in prior exposure to environmental Mycobacteria, the age of
administration, or differences in the vaccine strain administered (5). It is still widely
used today due to its effectiveness in preventing the most severe forms of TB in
young children, especially TB meningitis and military TB (203, 218).
Besides understanding the disease, the search for a cure is also a priority. In the pre-
antibiotic era, sanatoria (116) and surgery (260) were the only available options for
treatment during the late 19th and early 20th centuries. However, bed-rest in sanatoria
was lengthy, with many patients spending years in isolation with cure rates of
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approximately 30%. The experience of a European sanatorium patient is most
famously recreated in Thomas Mann's The Magic Mountain, which won the Nobel
Prize for Literature in 1929 (142). Many treatments were tried in the desperate search
for a cure and some, such as sanocrysin and gold therapy created widely reported
rumors of success, only to be disproved in treatment trials (45,95,97). Itwas not until
the discovery of streptomycin and Para-aminosalycylic acid (PAS) in the 1940's that
effective chemotherapy was possible (87).
The purpose of TB treatment is to sterilize all tuberculous lesions in a short duration
with low or ideally no relapse rate. Streptomycin was extracted from Streptomycin
griscus in 1943 and was administered to critically ill TB patients one year later.
Despite the seemingly miraculous recovery of the first TB meningitis patients given
streptomycin (26), initial hopes that a cure had been found were dashed when it
became apparent in the first cohorts that relapse rates were high (187, 199). It was
realized that monotherapy led to relapse due to the rapid emergence of resistant
organisms and PAS was added to the regimen and shown to reduce the risk of relapse
(19). As new TB drugs were discovered they were added to the regimen in a landmark
series of randomized controlled trials conducted by the British Medical Research
Council and the International Union Against Tuberculosis and Lung Disease
(IUATLD) (84). In the decades following the discovery of Streptomycin and PAS,
several new antibiotics were discovered: Isoniazid (INH; 1952), Pyrazinamide (PZA;
1954), Cycloserine (1955), Ethambutol (EMB; 1962) and Rifampicin (RIF; 1963).
After the discovery of Rifampicin (RIF) in 1963, research into new TB drugs
stagnated. No potent novel classes of anti-tuberculous agents was discovered in the
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subsequent decades until the development of second and third generation
fluoquinolones in the 1980's (62, 177), although several modifications of existing
drugs such as rifabutin and aminoglycosides were developed. The recognition of
widespread emergence of resistance to the first line drugs has precipitated calls for
action (143) and since the millennium, renewed efforts have been made to develop
novel anti TB agents (48, 188). The TB Alliance (189) and STOP TB (167) have co-
ordinated efforts to bring new TB drugs to phase 3 trials, beginning with the later
generation quinolones: levofloxacin, gatifloxacin and moxifloxacin.
Phase 3 trials are now underway evaluating gatifloxacin or moxifloxacin for use as
first line agents in a shortened four month regimen and several agents, including
TMC207 (Tibotec - Johnson & Johnson) and PA-824 (Chiron Corporation-USA) are
in phase 2 trials (111, 177, 227). Despite the progress made in the last decade, the
pipeline for novel TB drugs is weak, with the probability that a significant number of
candidate drugs will fail efficacy and safety evaluations, and the discovery of further
new agents is needed to enable completely novel replacement regimens and prevent
the widespread emergence of resistance to existing and new agents (111).
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1.2 EPIDEMIOLOGY OF TUBERCULOSIS GLOBALLY
1.2.1 Prevalence and incidence
Tuberculosis is transmitted by aerosol and it is estimated by the World Health
Organisation (WHO) that more than one-third of the world population is latently
infected with the causative organism. TB is called the "disease of poverty" because it
principally affects the poor and young adults in developing countries (176, 222).
Despite many efforts and strategies of international and national organizations, the
tuberculosis pandemic still causes more mortality than any other infectious disease. It
is estimated that there were 9.4 million incident TB cases and 14 million prevalent
cases causing 1.7 million deaths in 2009 according to WHO data from 196 countries
and territories (accounting for 99.7% of the world population), resulting in estimated
death rates of 1.3 million HIV negative TB cases and 0.4 million HIV positive TB
cases. Importantly, most cases were from South and South-East-Asia (35%), Africa
(30%) and Western Pacific region (20%) (244). Although there was an increase in the
absolute number of incidence, prevalence and mortality as a result of population
growth, the number of cases per 100,000 population is slightly decreasing by less than
1% each year from 1996 to 2007 (237). The speed of decrease is much slower in
regions with accompanying severe HIV epidemics, and for the sub-Saharan African
region overall, where the HIV burden is greatest, TB incidence per capita has
increased marginally (60).
Children who are under 15 years old and living in close contact with an infectious
source - a smear positive pulmonary TB case - are at high risk of TB infection,
especially children under 4 years old presumably because of the immaturity of their
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immune system. HIV infection and malnutrition are also key risk factors for TB
infection in children. Children less than 4 years old have a higher risk of progressing
from TB infection (latent TB) to active TB disease. Generally, it takes approximately
1 year for this process in adults or older children; but in children less than 4 years of
age progression is often shorter, a few weeks or months. Furthermore, the immaturity
of the immune system often fails to localise M tuberculosisis in the lungs and
dissemination to other organs occurs more frequently. Therefore, extra pulmonary TB
occurs more frequently in children than in adults; and children are more likely to
suffer from severe and disseminated TB forms. This is well-documented in the
literature; however, paediatric TB does not have a priority in TB control and
prevention programmes, particularly in high burden countries. In comparison with
adult cases, fewer children than adults have TB disease; children are usually not
infectious due to sparse, paucibacillary disease and not coughing strongly enough to
generate infectious airborne droplets. Identifying and treating cases which are an
infectious source is the priority in resource-limited settings and it had been assumed
that if adult TB cases are treated, childhood TB will also decline, therefore childhood
TB has historically been neglected by the TB research community. In recent years,
increasing calls have been made to prioritise a childhood TB research agenda (166)
and the new WHO Stop TB Strategy, 2006 - 2015 was launched in 2006. This
strategy aims to ensure all TB patients, including children, have equal access to
international standard care. This document provides a recommended approach to
diagnosing paediatric TB, treatment regimens, contact screening and management,
recording and reporting and BCG vaccination for children under 15 years old in high
burden countries (225). This document has increased focus on pediatric TB and the
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development of systematic approaches to the management of pediatric TB has
increased within national TB programs. It is estimated that of 9 million annual TB
cases, approximately 11% were diagnosed in children less than 15 years of age.
Especially, 75% of these estimated cases were from high burden countries (225).
1.2.2 Drug resistant TB
Drug resistant Mtuberculosis has the ability to exist in the presence of anti-TB drug
that would normally kill it or inhibit its growth. Clinically, drug resistant TB is the
disease caused by M tuberculosis that is resistant to any drug, most commonly the
first line antituberculosis drugs (Isoniazid, Rifampicin, Ethambutol, Streptomycin and
Pyrazynamide). In prokaryotes, drug resistance usually occurs due to horizontal
genetic transfer through transmissible genetic elements or plasmids (76, 184).
However, this mechanism has never been documented in Mtuberculosis (73). The
development of drug resistance in Mtuberculosis normally occurs through bacterial
chromosomal mutations, including single nucleotide polymorphisms or homologous
recombination. The resulting mutations may be insertions, deletions or point
mutations. For example, resistance to RIF is associated with point mutations on ropB
gene (most commonly in codons 516, 526 or 531) which encodes the beta subunit of
the RNA polymerase. These mutations prevent RIF binding without preventing the
transcription and elongation of bacterial RNA (262). Mutations occur spontaneously
in M tuberculosis at between 1 in 106_108 and are selected under drug pressure,
usually due to poor adherence with therapy of the patients or suboptimal (dose or
duration) therapy. Other mechanisms, such as drug efflux pumps, playa role in
M tuberculosis drug resistance or drug tolerance, but are incompletely understood
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(52). The relative fitness cost of drug resistance mutations is also not yet clear but it is
known that drug resistant strains retain virulence and transmit successfully within in
the community (18). In the fourth report of WHO/IUATLD Global Project on Anti-
Tuberculosis Drug Resistance Surveillance, data collected from 1994 - 2007 in 114
countries showed that any resistance among new cases and previously treated cases
were 17% (95%CI: 13.6,20.4) and 35% (95%CI: 24.1,45.8), respectively. For all TB
cases, the resistance to any TB drug was 20% (95%CI: 16.1,23.9) (231).
1.2.3 Multidrug resistant TB (MDR) - extremely drug resistant TB (XDR)
Multidrug-resistant TB (MDR-TB) is caused by Mtuberculosis that is resistant to at
least rifampicin and isoniazid, the two most powerful drugs of the first line TB drugs
which are used for TB treatment in DOTS (Direct Observation Treatment Short
Course) strategy. Extensively drug-resistant TB (XDR-TB) is the result of infection
with M tuberculosis that is resistant to at least rifampicin and isoniazid in combination
with resistance to a fluoquinolone and one of the second-line anti TB injectable drugs
(amikacin, kanamycin or capreomycin). Both of these forms do not respond to the
standard first-line treatment regimen (6 or 8 months) recommended by WHO.
Therefore, an appropriate treatment regimen is urgently needed to target these
populations. The current standard regimens are not effective (table 1.3). A multi-
country clinical trial conducted by the British Medical Research Council (MRC) is
now being established in Ethiopia, South Africa and Viet Nam (110). The
Standardised Treatment Regimen of Anti-TB drugs for patients with MDR-TB
(STREAM trial- Registration code: ISRCTN78372190), aims to evaluate if a newly
developed 9 month treatment regimen containing high dose fluoquinolone and
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clofazimine (4KCMEHZP/5MEZC) is better than the standard minimum I8-month
MDR- TB treatment regimen approved by WHO. Recruitment is expected to start in
mid-201l. If this trial has positive results, it will be a major advance towards the
control of MDR- TB worldwide.
By 2008, there were 27 high MDR- TB burden countries, including Viet Nam,
classified by WHO. These countries had at least 4000 new MDR-TB cases annually
or 10% of newly registered TB cases with MDR- TB. The global distribution of MDR-
TB is shown in figure 1.1 Fifty eight countries had confirmed identifying at least one
XDR-TB case by 2008 (245). However, this number had increased to 69 by the end of
2010 (252). Countries reporting XDR-TB cases are shown in figure 1.2.
It is estimated that there were approximately 440,000 MDR-TB cases detected
globally in 2008, accounting for 3.6% of all new TB cases of that year and resulting in
150,000 deaths. Almost 50% of MDR- TB cases in the world are estimated to occur in
China and India (245).
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Figure 1.1 Distribution of proportion of MDR- TB among new TB cases, 1994 -
2009
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Different colours depict different proportions of MDR-TB among new cases worldwide from
1994-2009.
Source: WHO. 2010. MDR-TB andXDR-TB (245)
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Figure 1.2 Countries and territories reporting at least one XDR- TB case as of
January 2010
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Red regions indicate settings reporting at least one XDR-TB case.
Source: WHO. 2010. MDR-TB andXDR-TB (245)
A report from WHO showed that there were 5.8 million TB cases notified in 2009,
generating an estimated global detection rate of 63% (increased by 2% in comparison
with 2008) (244). Among notified TB cases, an estimated 250,000 cases were infected
with multidrug resistant strains. Practically, only 12% (>30,000 cases) of these
estimated cases were diagnosed and notified with MDR and approximately 82%
(n=24,500/30,000) of notified MDR- TB cases were enrolled into treatment.
Therefore, over 10% of notified MDR- TB cases were lost to follow-up by national TB
programmes. Standards for treatment of MDR- TB differ widely between countries.
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Low income countries have an opportunity to provide high quality treatment for their
patients through the Green Light Committee (GLC) (245). By the end of 2009, only
78% (n=19,000/24,500) of patients on MDR-TB treatment received treatment in
quality assured programmes provided by GLC, representing only 1% of total
estimated MDR-TB cases globally in 2008. The untreated MDR-TB cases and cases
treated with substandard regimens are the transmission source generating and
sustaining drug resistant M tuberculosis population worldwide and represent an
enormous challenge to global TB control.
1.2.4 Global TB in HIV burden
Transmission of the human immunodeficiency virus (HIV) occurs via contact with
infected bodily fluids, usually through sexual intercourse, contaminated blood
transfusion or injection with contaminated needles and syringes. HIV infects T-
lymphocytes, predominantly CD4+ cells, which play an important role in the cell
mediated defense against Mtuberculosis of an individual. HIV infection destroys
these T-lymphocytes, leading to a gradual decline in numbers or malfunctioning of
surviving cells. Once the decline in T-lymphocytes exceeds the limit required for a
healthy immune response, the cell-mediated immune response of HIV infected
individuals is progressively impaired but the mechanisms are still not completely
understood; the decline in T-cells exceeds the number directly infected and lysed by
HIV virions. After infection with HIV (acute HIV infection), 40%-60% patients
develop symptomatic illness in 2-4 weeks, usually presenting with a 'flu-like'
syndrome (fever, rash), arthralgia and lymphadenophathy. Neurological syndromes
may occur in some cases. Since serological tests normally first become positive after
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4-12 weeks of infection, serological tests are usually negative at this stage and the
general nature of symptoms means HIV infection is rarely identified accutely. The
most accurate diagnosis of acute HIV infection is based on measurement of HIV RNA
in plasma, which is rarely available in high burden HIV settings. In untreated adults,
the chronic phase of HIV infection to the onset of HIV disease (Acquired immune
deficiency syndrome - AIDS) is approximately 10 years, defined as the chronic stage.
There may be few clinical symptoms during the chronic stage. However, in children
or infants, this lag phase is shorter, usually from a few months to a few years. During
this phase, lymph nodes serve as reservoirs for multiplying HIV , leading to the
gradual enlargement of the lymphoid tissues bilaterally, which is diagnosed as
persistent generalized lymphadenopathy (PGL). If untreated, all HIV-infected
individuals will develop an HIV -related disease or AIDS. The rate of this progression
depends on the type of HIV and host characteristics. In the AIDS stage, usually
occurring when the CD4 count falls below or equal 200 cells/ml, the patient is more
susceptible to opportunistic infections, including TB, pneumonia, fungal infections
and herpes. Chronic diarrhoea with weight loss can also occur in this stage. Since the
immune system of the host is less effective in preventing the growth and spread of
Mtuberculosis, disseminated and extrapulmonary are more common in this group
(221).
The interaction between HIV and TB has implications for TB control among HIV-
infected patients. HIV infection causes immunodeficiency of the host, increasing
susceptibility to TB infection and increasing risk of progression to active TB disease.
It is known that HIV negative individuals with latent TB have 5% - 10% risk of
developing active TB during their lifetime. However, in HIV positive individuals, this
Chapter 1 - Introduction Page 32
risk is 50% during their lifetime or 10% per year (221). TB infection increases TNFa
and Mep-l levels that may activate HIV replication in lymphocytes, monocytes and
macrophages. This vicious circle leads to progressive and severe status in TB co-
infected HIV patients (46). HIV associated TB is a major challenge for TB control
programmes and HIVIAIDS programmes.
HIV infection is a global pandemic. It was estimated that 33 million prevalent cases
existed in 2007, of which 2.7 million were new infections (213). The most affected
population is aged from 15 to 49, the age group who are the primary drivers of
economic development of countries. It is estimated one-third of people living with
HIV are co-infected with tuberculosis worldwide and the majority of them are from
Sub-Saharan Africa (206). HIV is the main cause of TB treatment failure and TB is
the main cause of death in patients living with HIV; up to half of all AIDS patients
died from TB (206). A report from WHO showed that among an estimated 9.4 million
new TB cases in 2008, 1.4 million were HIV positive, accounting for 15% of all
incident cases. Almost 80% of HIV co-infected TB cases were from Africa and
estimated 13% was from South East Asia region. Among an estimated 1.3 million
deaths from TB of all forms worldwide in 2008, one estimate suggests 40% of them
were new HIV/TB cases (236). The availability of HIV antiretroviral therapy (ART)
has been massively scaled up during the last decade in resource limited settings. The
aim of this treatment is to maintain HIV viral load in the body at a low or
'undetectable' level to prevent the progressive impairment of the immune system,
dramatically slowing progression to AIDS, and reducing the probability of
transmission. The WHO recommendations on ART were made after review of
different levels of evidence from clinical trials, cohort data and expert opinions but
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the long term consequences of ART scale-up are still unclear since therapy is life-
long and issues such as sustainability, provision of second and third line regimens,
and drug resistance amplification will need to be addressed. Further, concerns have
been raised that reducing viral load in infective individuals may not result in the
predicted decrease in transmission if sustained health results in more potential
infective contacts over a lifetime (241).
1.2.5 Risk factors of infection
Tuberculosis is an infectious disease and the risk of infection is largely related to the
source of infection, contact time and the host immune response. Exposure to
pulmonary TB patients, especially smear positive TB cases will generate a higher risk
of TB infection than extrapulmonary TB and smear negative TB patients, although
significant transmission can occur from smear negative cases who may intermittently
expectorate bacilli (15). In addition, close contact with an infectious source over a
long time, such as household members or in healthcare facilities will also increase the
risk. Especially, if an individual suffers from malnutrition, chronic disease, HIV
infection or other immuno suppressive diseases, they are at high risk of TB infection
and are likely to develop active TB disease (89, 170). However, not all individuals
infected with Mituberculosis will develop TB disease. The levels of the risk factors
will contribute to the risk of development of the disease; therefore it is estimated that
5% - 10% of infected individuals will develop active TB with the highest risk in the
first 2 years after exposure (denoted primary TB), a further 5% -10% will have latent
TB and subsequently develop active disease over their life-times (denoted post-
primary or reactivation TB) (37) and the remaining will maintain latent infection and
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never develop active symptomatic TB. In HIV positive individuals, a lifetime risk of
50% of developing active TB has been recorded (221).
1.2.6 Transmission and pathogenesis
TB transmission occurs via infectious aerosol droplets containing M tuberculosis
which are released from TB patients, usually via coughing, circulate in the air and
then are inhaled into the respiratory tract of other individuals through inhalation.
Droplet size is the most important factor for transmission, all heavy droplets will
settle down onto the floor after release except nuclei droplets which remam
suspended in the air at a height of 3 metres for up to 24 hours in an internal
environment and can be inhaled by other individuals. Generally, only droplets from 1
- 3J.1min size will penetrate into the lungs to potentially establish infection. To
minimize TB transmission, infection control procedures have been established which
include administrative control, environmental control and personal protective
equipment. Of which, administrative control is the most important measure because it
controls infectious sources by isolation, early diagnosis and treatment for TB cases.
Ideal infection control scenarios can be extremely difficult to apply in resource-
limited settings.
Once inhaled, the larger infectious droplets (>5J.1min size) are trapped and eliminated
from the upper airway by the mucocilliary clearance on the surface of epithelial cells.
This is the first-line of physical defense of the host to TB infection. Smaller infectious
droplets have a higher chance to reach the alveoli where they can be surrounded and
engulfed by alveolar macrophages, which constitute the second line of host defense.
The interaction between macrophage and bacilli triggers a signaling cascade which
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activates lymphocytes; and the accumulation of activated T lymphocytes and
macrophages in alveoli may result in eradication of the infection or in the progressive
formation of a granuloma, the third defensive system of the host, which contains the
bacilli and limits the spread of infection to other sites. The anaerobic environment
within the granuloma destroys macrophages and produces a solid necrosis in the
center of granulomas. The necrotic environment results in a lack of oxygen and low
pH with limited nutritients which inhibits further growth of mycobacteria. In
individuals with an adequate immune response, this lesion becomes fibrosed and
calcified; and finally the infection is controlled but not eradicated, resulting in 'latent'
infection. However, in individuals with a less effective immune response, the bacilli
may multiply and disseminate to other alveoli and organs where TB disease can
become established. Mechanisms of dissemination are not well understood but it is
thought the cells of the immune system act as 'trojan-hourses' carrying the
Mtuberculosis bacilli to the lymph nodes. Failure to contain the infection within the
lungs may result in transient bacteraemia which 'seeds' other locations in the body
and can result in extrapulmonary forms of disease, which account for approximately
20% ofTB cases (100,208). Disseminated forms occur more frequently in individuals
with an impaired or immature immune system, such as HIV-infected individuals or
children. Figure 1.3 describes the pathogenesis of tuberculosis.
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Figure 1.3 Pathogenesis of Tuberculosis.
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Source: CDC-Selfstudy modules on tuberculosis (39)
(A) Droplet nuclei containing tubercle bacilli are inhaled and travel to the alveoli. (B)
Tubercles multiply in the alveoli. (e) A small number of bacilli enter the blood stream and
spread through the body. (D) Macrophages surround the bacilli and Jorm granulomas or
shells to contain injection. (E) If the immune system becomes weaker, the shell loses integrity;
bacilli escape, multiply rapidly and spread to other alveolar or organs.
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1.3 MYCOBACTERIUM TUBERCULOSIS - THE BACTERIA
1.3.1 Morphology
Mycobacterium tuberculosis is a bacterium belonging to the prokaryote kingdom,
Mycobacteriaceae family, mycobacterium genus and tuberculosis species. They are
small bacilli with a size of 0.2-0.6 urn wide and 1-10 pm long. They have a rod-like
and slightly curved shape, no motility, no encapsulation and no spore formation.
Some recent research has suggest sporulation may occur in mycobacteria, but this is
widely disputed (71). M tuberculosis complex is an obligate aerobe (186). In addition,
it is a slow growing bacterium with a generation time of 18 - 24 hours. These bacteria
can resist low concentrations of disinfectants but are susceptible to pasteurization and
UV light. Because of their unique cell wall characteristics, they are not classified as
Gram positive or Gram negative bacteria, although they stain as weakly Gram
positive and are therefore sometimes described as such. Zeihl-Neelson or Acid-fast
staining (carbolfushin-phenol) is used to detect these bacteria. This technique is
described in detail in materials and methods (chapter 2, section 2.6.3).
1.3.2 Colony morphology
When grown on solid media, such as Lowenstein Jensen media, mycobacteria often
form colonies. M tuberculosis often forms typical cream colored colonies with dried
and rough nature (214). In contrast, Mycobacterium Other Than Tuberculosis
(MOTT) displays yellow, orange or cream colonies with smooth and moist properties.
The presumptive identification of these two classifications based on shape and
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characteristics of colonies is used often as a screening test for further biochemical
identification tests to identify these bacteria.
1.3.3 Cord formation
M tuberculosis often shows characteristic serpentine cording in liquid culture media
which is an aggregate of tight rope-like strings in which the long axis of the bacteria is
paralleled with the long axis of the cord (Figure 1.4). Recently, the characteristic of
cord formation has been evaluated for the presumptive identification of
M.tuberculosis by microscopy (10, 135). The sensitivity of this method very much
depended on the personal skills, training and time of the technician: with poor
training, the sensitivity of cord formation for the identification of M tuberculosis was
approximately 60% while it was 75% for those with specific training (8). In addition,
the number of bacilli also contributed to the formation of this characteristic (115). In
McCarter's study (115), almost 90% of M.tuberculosis exhibited cording when the
growth index (cfulml) was between 100 and 200. Another study showed that if the
growth index was below 100, only 29% of M tuberculosis cultures exhibited cording
(135).
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Figure 1.4 Cording characteristic of M.tuberculosis
Arrows indicate Mtuberculosis cording in liquid culture
1.3.4 Cell wall structure
Figure 1.5 Components of a mycobacterium cell wall
Copyright © Gary E. Kaiser(94)
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The cell wall of Mycobacteria (figure 1.5) consists of three layers: inner layer, cell
wall core and outer layer. The inner layer is a lipid bilayer which covers the
cytoplasm and plays a vital role for the mycobacterium (53). The cell wall core is the
main structure of the cell wall in which peptidoglycan cross-links to arabinogalactan
(D-arabinose and D-galactose), and then this complex links to high molecular weight
mycolic acid. This layer has been known to play an important role in pathogenicity of
the bacteria (21). The outer layer is composed of extractable, noncovalent lipid,
glycolipid (lipoarabinomannan and phosphatidyinositolmannosides (PIM) and protein
which is essential for the host immune response. The lipid components make up
almost 60% of the cell wall weight. The physical organizational structure of this cell
wall forms the primary hydrophobic barrier that protects the bacteria from external
enemies. Disrupting this basic structure enhances permeability of the cell wall and
endangers the growth, viability and reproducibility of mycobacteria and is therefore a
drug target for drugs such as INH. Porin channels are required for transportation of
hydrophilic molecules through the cell membrane.
The cell wall structure of mycobacteria is very different from Gram positive and
Gram negative bacteria in terms of lipid and glycolipid components.
1.3.5 Mauberculosis genotyping
It was long thought that M tuberculosis was a highly clonal organism due to the lack
of diversity identified through typing techniques such as 186110 RFLP and
spoligotyping. However, these techniques were developed to identify polymorphism
using strains from Europe and America (173) and therefore did not identify diversity
between isolates from Africa and Asia, where most Mtuberculosis occurs. The advent
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of whole genome sequencing and micro array techniques has allowed a more complete
picture of variation within M tuberculosis genomes and projects are now establishing
the global diversity of M tuberculosis strains (9).
M tuberculosis does not carry plasmids or undergo lateral gene transfer therefore the
principal sources of diversity within Mtuberculosis are homologous recombination
and Single Nucleotide Polymorphisms (SNPs) arising spontaneously or through
selection pressure (59). Mycobacterium tuberculosis strains have evolved via genomic
deletions called large sequence polymorphism (LSP) or regions of difference (RD).
Phylogenetic analysis of these gene deletions forms the basis of LSP genotyping
method. Based on this analysis, there are six major lineages worldwide of
Mtuberculosis (figure 1.6): Indo-Oceanic lineage, East Asian lineage, East African-
Indian lineage, Euro-American lineage, West African lineage I and West African
lineage II (69). The distribution of these lineages is associated with regions of origin
(24, 162) (figure 1.7).
Insertion sequences, small mobile genetic elements which are widely distributed in
the bacterial genome, are the target of Restriction Fragment Length Polymorphism
(RFLP) for epidemiology research and detection of laboratory errors or cross-
contamination (114). RFLP to detect IS6110 insertion elements has been the standard
typing method for TB epidemiology since 1999. IS6110 insertion elements are
scattered in the entire length of the genome and occur in different numbers and
locations between strains (ranging from 1 to 26 copies). The patterns oflS6110 RFLP
are stable over approximately 1-2 years with respect to time but quite polymorphic so
they are useful for studies in transmission dynamics at local and population levels.
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However, IS6110 RFLP has limited capacity in discrimination of strains with less
than five IS6110 copies (which are common in South East Asia and the Western
Pacific region), requires a large amount of chromosomal DNA, is time consuming,
laborious and inter-laboratory comparisons are unreliable (102). .
The Spoligotyping method detects the presence of spacers that separate direct repeats
(DRs) in a specific locus of the Mtuberculosis genome. This method can discriminate
strains with less than 5 copies of the IS6110 fragment but does not discriminate
strains of the East-Asian/Beijing genotype, which are highly prevalent in Asia. Since
it targets a single locus that presents less than 0.1% of the Mtuberculosis genome, its
discriminatory is lower than IS6110 RFLP. However, since it is a simple technique
and requires less labour and DNA material, it is a common method applied for
epidemiology studies. The resolving capacity of Spoligotyping is increased if used in
combination with IS6110 RFLP (102). In this thesis, Spoligotyping was used for
detection of laboratory cross-contamination due to its advantages over RFLP IS6J10
method.
Mycobacterial interspersed repetitive units (MIRV) is the specific name of variable
number of tandem repeats (VNTR) typing when applied to Mtuberculosis. MIRV
typing has become an important method in distinguishing Mtuberculosis strains
based on the difference in the number of copies of tandem repeats at specific regions,
or loci, of the Mtuberculosis genome. A total of 41 MIRV loci have been reported
(183); however, most laboratories target only 12 loci for discrimination clinical
isolates. The discriminatory power of MIRV-VNTR analysis is proportional to the
number of loci evaluated. When 12 loci are used, the discriminatory rate of MIRV-
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VNTR is lower than that of 186110 RFLP genotyping for isolates with more than 5
copy-number 186110 insertions. However, it provides a higher discriminatory power
than IS6110 RFLP for isolates with low-copy-number 186110 (114). MIRU-VNTR
genotyping has been used in a number of molecular epidemiologic studies, as well as
to elucidate the phylogenetic relationships of clinical isolates and cross-
contamination.
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Figure 1.6 Global pbylogeny of Mycobacterium tuberculosis
s
9
Gagneux at al. PNAS (68)
Lineage specific LSP marker and phylogeny. Numbers in rectangles refer to linear-specific
large sequence polymorphism (LSP) markers or the names of regions of difference. The
geographic regions associated with specific lineages are indicated.
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Figure 1.7 Global distribution ofM.tuberculosis major lineages.
Source: Gagneux et at. (69)
The genetic diversity of M tuberculosis is thought to have an impact on clinical
phenotype, although evidence to date is sparse and often conflicting. Differences in
study design, host ethnicity variation and diversity in the background M tuberculosis
strains circulating may be some contributing factors accounting for some of these
different findings.
Studies have been conducted locally in Vietnam to address this question. In one study
conducted at Pham Ngoc Thach Hospital (PNT) and Hospital for Tropical Diseases
(HTD), 397 strains isolated from HIV negative pulmonary TB and tuberculous
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meningitis (TBM) patients in Viet Nam were classified into 3 lineages: East
Asian/Beijing lineage (RDI05 deletion), Indo-Oceanic lineage (RD239 deletion) and
Euro-American lineage (pksJ5/J deletion) (35, 193). The other major lineages of
Mtuberculosis have not been isolated in Vietnam. In this study; the Euro-American
lineage was significantly associated with lung consolidation on chest X-ray of
pulmonary tuberculosis; and in TB meningitis, the East Asian/Beijing lineage was
associated with a shorter duration of illness, severe disease status and resistance to the
first-line antituberculosis drugs. In these patients, the Euro-American lineage was
preferentially associated with pulmonary, rather than meningeal TB in the Vietnamese
population and an association was shown between a host susceptibility polymorphism
in toll-like receptor 2 (TLR2 T597C) and susceptibility to TB meningitis in those
infected with the Beijing genotype of Mtuberculosis. This was the first demonstration
of interaction between a host polymorphism and a bacterial genotype in TB disease
resulting in a specific disease phenotype. However, characterization of over 2000
M tuberculosis complex isolates collected from London, UK showed no association
between lineage and pulmonary or extrapulmonary sites of TB disease (24). East
AsianlBeijing lineage had higher risk for relapse, but not treatment failure, than other
lineages, especially among Asian-Pacific Islanders (27). A collection of
M tuberculosis strains from the Tuberculosis Trials Consortium study 28 was
analyzed by Nahid et al. In this study, the authors showed that the Euro-American
sublineage 724 was associated with severe disease and East Asian lineage was
associated with low bacteriologic conversion after 8 weeks of treatment (138). In
Gambia, the two most common lineages found were West African II and Europe-
American. Pulmonary TB patients infected with West African II lineage were more
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likely to have worse abnormality on chest X-ray, severe malnourishment and less
likely to have a positive ESAT -6/CRP-I 0 ELISPOT result than the Europe-American
lineage (56).
These findings provide strong evidence for genetic diversity which may result in
phenotypic polymorphism of Mtuberculosis population. These findings may also help
to explain geographical differences in clinical features and response to treatment and
vaccination among TB patients. However, the complexity of interaction between
environmental, host and pathogen factors and the relative influence of each on
outcome will require large, detailed global studies to unravel completely and may
never be possible.
1.4 DIAGNOSIS OF TB, DRUG RESISTANT TB AND MDR- TB
1.4.1 Diagnosis ofTB
The diagnosis of TB disease is ideally based on microbiological confirmation.
Unfortunately, current microbiological tests are not sensitive enough to detect all TB
cases. Therefore, a clinical evaluation is used for diagnosis of smear negative TB
cases. The clinical diagnosis is based on clinical and radiological symptoms consistent
with tuberculosis, microbiological testing, evaluation of risk factors such as TB
history, history ofTB contact and exclusion of differential diagnoses.
Clinical diagnosis
The clinical symptoms of pulmonary tuberculosis are not specific. The most common
symptom is productive cough, usually for more than two or three weeks at
presentation. In addition, systematic signs including fever, night sweats and weight
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loss are often present. Other local symptoms consistent with extra-pulmonary
tuberculosis such as lymphadenopathy, pleural fluid and neurological signs may be
recorded, especially in immune-deficient individuals (204).
Although the majority of pulmonary tuberculosis patients have cough when
presenting to health care facilities, cough is not a sensitive and specific symptom for
prediction of tuberculosis. A study from Peru showed that approximately 55% of TB
suspects submitting sputum samples reported cough for < 2 weeks and 3% of them
were smear positive (145). A cross-sectional study conducted in 3 hospitals from
Tanzania reported that smear positive pulmonary TB rate was higher in patients with
more than 2 weeks of cough compared to patients reporting cough for less than 2
weeks (141). Coughing is a reflex action in response to any stimuli in the airway and
to keep the trachea clear of secretions, irritants, foreign particles and microbes.
Therefore, any acute or chronic infectious and chronic non-infectious diseases in the
sinuses, upper airways, lower airways and lungs may lead to acute or prolonged
cough. As a result, in patients presenting with chronic cough, suspicion of
tuberculosis will depend on the prevalence of tuberculosis in the community. Patients
with chronic cough in high prevalence TB countries are likely to suffer from
tuberculosis (164). Conversely, in low prevalence TB countries, they are more likely
to have other diseases such as asthma, pneumonia, bronchitis or cancer.
WHO guidelines recommend patients with a cough of more than 2 weeks are screened
for TB in high prevalence settings. If the threshold for TB screening is 2 weeks of
cough, the number of TB suspects and laboratory workload greatly increases and the
prevalence of true TB cases among those screened will decrease (204). A study from
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India showed that the number of TB suspects and the number of sputum smear
positive cases increased overall by 58% and 23%, respectively when the screening
criteria were modified from cough lasting for 3 weeks or more to cough lasting for 2
weeks or more and 3 sputum samples were collected for examination (192). This
would overburden existing laboratory capacity in many settings. Since the sensitivity
of smear microscopy reached 90% to 95% from the first two sputum samples (216), it
would be reasonable to access 2 sputum samples for microscopy instead of three
samples to reduce workload in settings where both finance and human resource are
limited.
Among systemic symptoms, loss of appetite, weight loss, weakness, night sweats and
malaise are also common but are more difficult to quantify and may relate to co-
existing diseases.
In HIV -infected individuals suspected of tuberculosis, clinical manifestations are
rather different from HIV -negative individuals. A two year study conducted by the
U.S. Center for Disease Control and Prevention (US CDC) from 2006 to 2008 in
Cambodia, Thailand and Viet Nam found that fatigue (75%), fever (74%), weight loss
(73%) and cough (71%) were the most common symptoms of HIV positive
individuals suspected of tuberculosis presenting to outpatient clinics (29). In this
study, cough was not a sensitive indicator. As a TB screening criteria, cough lasting
for 2 weeks yielded a higher sensitivity than cough for 3 weeks, which was 33% and
22%, respectively. The authors also presented an algorithm for TB screening and
diagnosis in HIV positive individuals, in which the combination of cough of any
duration, fever of any duration or night sweats lasting for 3 weeks or more during the
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previous 4 weeks had a sensitivity, specificity, negative predictive value and positive
predictive value of 93%, 36%, 97% and 21%, respectively. Therefore, this algorithm
would rule out tuberculosis in the majority of suspects and provide evidence for safe
initiation of isoniazid preventive therapy (IPT) for HIV positive patients who had
none of the three predictive symptoms. IPT is intended for use in HIV positive
individuals infected with Mtuberculosis (latent TB) to eradicate the latent infection
and therefore reduce the development of active TB in this population. There have
been concerns that wide spread use of IPT may generate increased INH resistance. A
meta analysis study reviewing all data published since 1951 showed that isoniazid
resistance is not significantly associated with the provision of IPT; and IPT should be
used after excluding the diagnosis of active TB (11). Importantly, IPT was found to
have an important impact on reducing TB incidence among adults and children living
with HIV (67, 74). In 2008, WHO has endorsed the use of IPT for people living with
HIV, including children, after ruling out active TB (235); and a completed guideline
for IPT therapy for people living with HIV in resource limited settings has recently
been released by WHO in 2011 (251).
Extrapulmonary tuberculosis accounts for approximately 15 - 20% of TB cases in low
HIV prevalence populations (204). However, in settings with high HIV prevalence,
this figure is higher, for example 40% in South Africa (259) because Mtuberculosis
bacteria disseminate to other organs due to host immune system impairment.
Microbiological confirmation is rarely achieved because of low bacterial load in
samples other than sputum.
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Diagnosis of tuberculosis in children is even more challenging than HIV /TB
coinfected adults and extrapulmonary TB because of poor quality samples obtained
for diagnosis. In children, TB is most common between 1 and 4 years of age. Children
of this age are rarely able to articulate symptoms clearly and may simply cry or
complain of discomfort. The physical manifestations tend to differ by age of onset.
Therefore, disease history should be carefully considered. If a history of close contact
or infrequent contact with a source case is detected, TB disease should be considered
in the differential diagnosis. According to WHO guidelines on the management of
tuberculosis in children, the commonest clinical symptoms are chronic cough for
more than 3 weeks, fever for more than 2 weeks, weight loss and failure to thrive
(225).
Radiological diagnosis
Chest-Xray (CXR) is valuable to assist TB diagnosis because of its high sensitivity.
However, the low specificity of chest-Xray requires it to be used in combination with
clinical assessment. Pulmonary TB is traditionally classified as primary or
secondary/post-primary TB (reactivated TB). Primary TB is more common in
children and usually accompanied with enlarged hilar or mediastinal lymphonodes
(70% - 80%). Post primary TB, as a result of reactivation of dormant bacteria in
tissues or macrophages, is more common in adults (148). The common CXR
manifestations are nodular and cavitations. Pleural effusion and miliary TB are more
often present in immunocompromised individuals suspected of tuberculosis.
CXR is an essential test to assist the evaluation of an individual suspected of TB but it
should be interpreted in combination with clinical features due to the following
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reasons: First, an abnormality identified on a CXR may be due to tuberculosis or a
variety of other pulmonary diseases or conditions such as pneumonia or tumors.
Therefore, patterns on CXR are not specific for the diagnosis of active pulmonary TB;
but changes on a CXR in combination with suspicious clinical" features may be an
indication. Second, a normal CXR or lack of typical TB signs on CXR will make a
diagnosis of TB unlikely in the majority of cases but in some cases may lead to TB
being excluded incorrectly (false negative), especially in immunocompromised
patients. Third, missed diagnosis on CXR may be due to proficiency of film readers
such as failure to recognize hilar or mediastinal lymphadenopathy of primary disease
in adults and tuberculoma (261). However, a repeat CXR may be helpful for
comparison in some cases of clinically suspected tuberculosis. Last but not least, in
cases without microbiological confirmation, CXR and clinical features in combination
can be helpful in the decision to treat for TB.
Microbiological diagnosis: smear microscopy and culture
Microbiological diagnosis is the gold standard to confirm active TB in patients
presenting with clinical symptoms suspected of tuberculosis. Clinical symptoms,
CXR and microbiological methods (smear microscopy and culture) are the three
conventional methods applied by national TB programmes (NTP) for the diagnosis of
TB.
It is estimated that a sputum sample containing at least 5000 - 10,000 Acid-fast bacilli
(AFB) per milliliter is likely to have a positive result on smear microscopy (216). A
positive smear result is recorded if at least one AFB is found per 100 immersion fields
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when observing a smear under a microscope. The WHO system for grading of smear
results is described in chapter 2, table 2.1.
Smear microscopy is applied for TB diagnosis worldwide, especially in high burden
countries, for early detection of infectious cases. Since it is a simple and rapid test, it
is applied at all laboratory levels, including peripheral, intermediate and reference
laboratories. Although this test has relatively low sensitivity, its specificity is very
high, almost 100% when correctly performed, and thus it is thought to be very rare for
patients to be diagnosed as false positive. The majority of false positive diagnoses are
in cases with MaTT (Mycobacterium Other Than Tuberculosis), due to the inability
of acid-fast staining to accurately distinguish some MaTT from Mtuberculosis, from
cross contamination of slides during slide preparation or administrative errors in
assigning sample codes or results. To increase TB case detection rates, culture
methods can be used. The sensitivity of culture is higher than smear microscopy but it
cannot be applied at all laboratory levels because infrastructure for biosafety is
required for implementation, which is not usually available at peripheral and
intermediate levels, often only at a single reference laboratory, if at all. Since most TB
suspects in low and middle income countries present at local clinics for TB screening
and since the specificity of smear microscopy is high, this test is reliable for use in the
primary health care system for TB detection in high burden and low income countries.
The priority is to detect the most infectious TB cases for the lowest cost in such
settings and therefore, due to lack of resources, smear microscopy is often the only
test applied. In contrast, in low burden settings or in high income countries, culture
methods are applied for TB diagnosis because of high sensitivity and affordability of
the test. Therefore, the application of available diagnostic methods highly depends on
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the prevalence of disease and capacity of the setting. The simplest approach to
increase case detection is to improve the efficacy of smear microscopy, sample
processing method (to prepare homogenous smear) and fluorescent microscopy have
been evaluated. Sample processing methods can increase the "mean sensitivity of
smear microscopy by approximately 9% (181) and fluorescent microscopy improves
the sensitivity of conventional smear microscopy by approximately 10% with similar
specificity (180).
The number of samples examined per patient for smear microscopy influences the
cost effectiveness of the test. Before 2007, it had been recommended by WHO that a
TB suspect should provide 3 sputum samples for smear microscopy ('spot, morning
and spot'). However, in a systematic review Mass et ai, concluded that the third
sputum increased the TB detection rate by only about 2 - 5% (113). Therefore, if only
2 sputum samples are applied for microscopy, the case detection rate may not be
affected remarkably but reduction of laboratory workload would be approximately
30%. In 2007, WHO modified recommendations from 3 sputum specimens (spot-
morning-spot) to 2 sputum specimens, based on accumulated evidence that the third
sputum specimen did not add sufficiently to the detection rate to justify a 33%
increase in laboratory workload (228). In addition, in 2010, the GRADE process (The
Grading of Recommendations, Assessment, Development and Evaluation) provided
sufficient evidence for WHO to conclude that same-day-diagnosis approach (spot-
spot sputa) is equivalent to the conventional approach (spot-morning-spot sputa), in
terms of diagnostic accuracy for smear microscopy (sensitivity reduces approximately
3% but specificity is equivalent). WHO therefore endorsed" same-day-diagnosis
approach for TB screening. This approach would reduce patient-related cost and
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patient loss during diagnostic pathway (247). This recommendation is under
consideration but has not yet been implemented in Viet Nam NTP in 2011.
Culture methods have a higher sensitivity than microscopy. A sample containing 100
bacilli/ml can be positive by these methods. Therefore, culture helps to detect cases
earlier, often before they become infectious. Culture also generates bacterial isolates
for drug susceptibility testing and other tests. Solid culture methods (eg. Lowenstein
Jensen - (LJ) media or Middlebrook 7H10 agar) have been used as the
microbiological gold standard for the diagnosis of TB worldwide. Although culture
provides high sensitivity and increases case detection in comparison to smear
microscopy, its main disadvantage is long turnaround time, almost one month, due to
the long generation time of Mtuberculosis. Culture also requires laboratories to be
equipped with biological safety cabinet, centrifuge, incubator, and shaking machine
which are usually only available in some intermediate and reference laboratories; and
well-trained staff. Liquid culture methods such as the commercial automated system
BACTEC MGIT 960 - ( Becton Dickinson, USA) are approximately 10% more
sensitive than solid culture (49) and provide shorter isolation time (10 - 14 days) than
the conventional culture method. Liquid culture methods have been endorsed by
WHO for use in routine TB diagnosis in low and middle income countries since 2007
(230) but costs of the technique limits its scale-up potential.
1.4.2 Detection of Drug resistance and MDR.
Drug susceptibility testing (DST) is performed to identify isolates that are resistant to
antibiotics currently used for TB treatment. The most common method is the
proportion method (indirect DST method) that provides a turnaround time of
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approximately 42 days after inoculation from a positive culture. Four first line TB
drugs are usually tested initially, including Isoniazid (0.2J..lg/ml), Rifampicin
(40Jlg/ml), Streptomycin (4.0Jlg/ml) and Ethambutol (Zug/ml). Conventional DST is
currently the gold standard for all novel DST methods. Pyrazinamide (PZA) DST is
not recommended for routine testing because of the difficulty in standardization of
drug susceptibility testing for this drug due to the sensitivity of pyrazinamide activity
to pH (219).
1.4.3 Recent advances in diagnostic methods
In the last ten years, efforts to develop new TB diagnostic methods have been made
globally and The Foundation for Innovative Diagnostics (FIND) played an important
role in this process. With the initial grant of $30 million from the Bill & Melinda
Gates Foundation and a mission to improve the health for poor people, FIND was
established in 2004. FIND has established collaborations with many companies and
organizations including Becton Dickinson (BD), Eiken Chemical Co, LTD-Japan,
Hain Lifescience GmBH, TAUNS-Japan,Carl Zeiss-Germany, Cepheid-USA to
develop and/or evaluate new TB diagnostic technologies for example MGITTMculture
and DST techniques, loop-mediated isothermal amplification (LAMP) assay,
Genotype®MTBDR Genotype®MTBDRplus,MTB identification test - Capilia TB
test, LED fluorescence microscope and Xpert MTBIRIF (63). By 2011, many of these
tests have been endorsed by WHO for early detection of TB and MDR-TB in high
burden countries (229, 238, 248). With the effort from FIND and other organisations,
new diagnostic methods have been introduced to settings where urgently needed with
reasonable prices. It is hoped that the implementation of new' diagnostic methods
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would improve TB case detection rate, shorten time to diagnosis and increase
diagnostic accuracy. To date, MGIT culture has been adopted internationally but
MGIT-DST is not widely applied due to high cost. Commercial Imunochromatograhic
tests for the detection of MPB64 antigen have been developed to differentiate
M tuberculosis isolates from non-tuberculous mycobacteria, such as SD TB Ag
MPT64 Rapid (Standard Diagnostics, Seoul, South Korea) and Capilia TB test
(Tanus, Namazu Japan). Genotype®MTBDR and Genotype®MTBDRplus are now
used as screening tests for detection of MDR-TB in an international project funded by
WHO and GLe. MDR-TB patients detected via this project are-enrolled into MDR-
TB treatment with second line drug regimens and GeneXpert are introduced in 11 out
of27 countries with high burden ofMDR-TBIXDR-TB.
In the stream of development new diagnosis methods, WHO has developed a list of
characteristics that make novel diagnostic tests appropriate for use in target settings,
including ASSURED (Affordable by those at risk of infection, §.ensitive, §.pecific,
User.:triendly, Rapid, Equipment-free and Deliverable to those in need) (207). The
new tests that have been evaluated are classified into culture based methods and non-
culture-based methods.
a. Culture -based methods: MGIT culture, DST-MGIT, -MODS, Thin layer
Agar, Nitrate Reductase Assay
The Bactec commercial automated liquid culture system (BACTEC MGIT 960 -
Becton Dickinson) is used to detect bacterial growth in tubes containing 7H9 broth,
OADC and PANTA by detection of fluorescence emission from a substance coating
the bottom of the culture tube which is quenched by dissolved oxygen in the broth.
Chapter 1- Introduction Page58
Replicating microorganisms consume oxygen in the broth and allow fluorescence to
be emitted and detected. Detection of growth is not specific to M tuberculosis
although growth of other organisms is suppressed by antibiotics and anti-fungal
supplements in the media (13). Similarly, the commercial automated liquid drug
susceptibility testing (BACTEC MGIT960 SIRE kit - Becton Dickinson) uses the
same system to detect bacterial growth in tubes with or without antibiotic (14). The
test is based on growth of the Mtuberculosis in a drug-containing tube in comparison
with a drug-free tube. The instrument automatically interprets the results and reports
the result as susceptible or resistant. For both systems, the result is available in
approximately 4-13 days, which is much faster than traditional culture method (LJ
culture) (214) and traditional drug susceptibility methods (proportional method) (14).
In 2007, WHO endorsed the use of liquid culture and DST for early diagnosis of TB
and drug resistant TB (230); however, its implementation was limited because of
challenging cost in high burden countries.
Microscopic Observation Drug Susceptibility Assay (MODS): MODS is a liquid
culture-based technique which was developed by a group of scientists in Peru for
early detection of MDR-TB. The present thesis evaluates this technique in Viet Nam
for diagnosis of TB and MDR-TB. Details are described in chapter 3, section 1
(MODS introduction).
Thin layer Agar (TLA) on samples is a direct solid culture based method to detect
M tuberculosis under light microscope. This method provides time to positive from 9-
14 days and allows the recognition of Mtuberculosis based on colony morphology
and the characteristic of growing on 7Hl1 media but not 7Hl1 + PNB (para-
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nitrobenzoic acid) media (4). A review reported that the pooled sensitivity and
specificity of TLA were both 100% for detection of rifampicin and isoniazid
resistance (124). However, this review was based on very few available data (3
publications) and therefore in 2009, the WHO Strategic and Technical Advisory
group (STAG) experts concluded that there was insufficient evidence to recommend
the use of TLA for rapid screening MDR-TB patients, but operational evaluation
should proceed (249).
Nitrate reductase assay (NRA) is a non-commercial test which can be based on solid
or liquid culture method to detect drug resistant isolates. The test can be applied to
samples or positive cultures. The principle of this test is to detect the ability of
mycobacteria to reduce nitrite into nitrate, by using nitrate reductase enzyme, which is
detected by a colour reaction. A systematic review and meta-analysis of 15 studies
revealed that the accuracy ofNRA for detection of rifampicin and isoniazid resistance
were higher than 94% and 92%, respectively when applied to isolates. However, this
accuracy was decreased and ranged from 88% to 100% when applied directly to
sputum. This test has turnaround time of approximately 10 days. This test has been
endorsed by WHO in 2009 for screening MDR- TB suspects in low and middle
income countries (238).
b. Non culture-based methods
~ Fluorescence smear microscopy:
Fluorescence microscopy (FM) appears to have several advantages over light
microscopy (LM) because it has a simple staining procedure, is easy to recognize
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AFB on the dark background, has higher sensitivity than conventional staining
method (Ziehl-Neelsen staining - ZN staining) and shorter reading time (180).
Unfortunately, despite many apparent advantages against LM, FM has not been
widely implemented, especially in low resource settings with a high burden of TB
because of high price for FM and the lack of robustness and sustainability.
Primo Star iLED (iLED) is a new generation of fluorescence microscope, which was
developed by Carl Zeiss, Inc company in agreement with the Foundation for
Innovative New Diagnostics (FIND), using the ultra bright LED (light emitting diode)
technology as a light source to detect bacilli on a fluorescent smear (6). Detailed
characteristics and evaluation of this microscope is presented in chapter 4. In 2009,
WHO has endorsed the application of LED fluorescence microscope to detect TB in
all settings, including in both high and low-volume laboratories (238). This
microscope is evaluated for use in Vietnam in chapter 4.
~ Nucleic acid amplification tests: TB-LAMP tests, Molecular line probe
assay (INNO-LiPA and Hain test) and GeneXpert
TB-LAMP test (TB-Loop mediated isothermal amplification) is a novel nucleic
acid amplification method, which was developed by Eiken chemical Co.Ltd-Japan, to
detect Mtuberculosis complex, Mavium and Mintracellulerae directly (gyrE gene)
from sputum samples. The result is available in two hours and can be observed by
naked eye (fluorescence signal, green colour). The detection limit of TB-LAMP is 50
target DNA copies (88). The performance of this test requires a customized extraction
device, simple decontamination process and isothermal amplification. In 2007, the
first clinical evaluation of TB-LAMP for the detection of .Mituberculosis was
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conducted by FIND in microscopy centers in Peru, Bangladesh and Tanzania. The
sensitivities of TB-LAMP against smear microscopy or LJ culture as the gold
standard were 97.7% for smear positive/culture positive samples and 48.8% for smear
negative/culture positive samples. The specificity ofTB-LAMP was 99% (16). Since
2008, TB-LAMP has been evaluated in Viet Nam to evaluate its feasibility. TB-
LAMP technology is expected to be presented to WHO scientific and Technical
Advisory Group (WHO-STAG) in May 2011 (65). The main drawback to this
technology is likely to be subjective interpretation of results by the reader, which may
result in reduced specificity in wide scale application.
Molecular line probe assays (LPA) are PeR-based hybridization assays, marketed
in strip formats and used for identification of M tuberculosis complex and drug
resistant isolates. There are currently two commercial LPA formats: INNO-LiPA
assay (produced by Innogenetics-Belgium, including INNO-LiPA Mycobacteria and
INNO-LiPARif.TB) and genotype assay (produced by Hain Lifescience-Germany,
including Genotype Mycobacteria, Genotype MTBDR and Genotype MTBDR-plus).
INNO-LiPA-Mycobacteria detects amplified 16S-23S rRNA spacer region to identify
Mtuberculosis complex and other Mycobacterium species, Mkansasit, Mxenopi,
Mgordonae, Mgenavense, Mstmiae, M'marinum, Mulcerans, Mcelatum, MA/S,
Mavium, Mintracellulare, Mscrofulaceum, Mhaemophilum, Mchelonae complex,
Mfortuitum complex and Mtsmegmatis (85). INNO-LiPARif.TB detects rifampicin
resistant isolates by amplification of the rifampicin resistant determining region
(RRDR) of the ropB gene, followed by hybridization of the amplicon to membrane-
immobiliased probes for specific mutations or wild-type sequences. A probe to
confirm the presence of M tuberculosis is also included (86). Genotype mycobacteria
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detects Mtuberculosis complex and some other Mycobacterium Other Than
tuberculosis (MOTT) such as Mtavium, Mintracellulare, Mkansasii and
Mmalmoense (78). Both Genotype MTBDR and Genotype MTBDR plus detects
Mtuberculosis complex and its resistant patterns related to rifampicin and isoniazid.
However, while Genotype MTBDR detects mutations in the ropE gene which confer
rifampicin resistance and mutations in the katG gene which confer isoniazid
resistance, Genotype MTBDR plus detects all of above resistant patterns plus
mutations in promoter regionof inhA gene which confer isoniazid resistance (127),
leading to the increasing of the sensitivity of Genotype MTBDR plus in detection of
INH resistance. Genotype MTBDR plus has now replaced Genotype MTBDR. A
systematic review of INNO-LiPARif.TB by Morgan et al.in 2005 showed that on
positive cultures the pooled sensitivity of this test was 95%. When applied on clinical
samples, the sensitivity was lower and ranging from 80% to 100%. The specificity
was 100% for both isolate and clinical sample (134). In 2008, a study to assess the
performance and feasibility of MTBDRplus assay on smear 'positive and smear
negative samples in high volume laboratory in Africa revealed that for smear positive
sputum, the sensitivity and specificity were 98.9% and 99.4%, respectively for
detection of rifampicin resistance and 94.2% and 99.7%, respectively for detection of
isoniazid resistance. For smear negative sputum, 20% (n=4/20) uninterpretable results
were recorded for rifampicin and 26% (n=5/19) were recorded for isoniazid (12).
WHO has now endorsed the use of line probe assay for early diagnosis of patients
infected with rifampicin and isoniazid resistant isolates in high burden countries.
Therefore, WHO also recommended that this assay should only be applied on smear
positive samples for the highest accuracy (233, 235). GenXpert MTBlRiftest is a one-
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step automated nucleic acid amplification test developed by Cepheid (California, US)
for detection of Mtuberculosis complex and rifampicin resistant Mtuberculosis
directly from clinical samples (sputum). In this test, unprocessed sputum sample is
treated with sample reagent and the three steps of molecular-based tests (sample
preparation, amplification and detection) are automated within a cartridge based
system. The result is available in less than two hours with minimal hands-on technical
time (66). For pulmonary tuberculosis, when three samples per patient were tested for
TB diagnosis, the sensitivity of GenXpert MTB/rif was 99.8% for smear
positive/culture positive sample and 90.2% for smear negative/culture positive
sample, the specificity was 98.1%. The sensitivity decreased by approximately 5% for
each sample dropped. For detection of rifampicin resistance and MDR-TB, the
sensitivities of GenXpert MTB/rif were 97.6% and 97.5%, respectively against
phenotypic DST as the gold standard. The specificity was 98.1% (17). The sensitivity
of this test was lower in non-respiratory specimens (urine, gastric fluid, tissue, pleural
fluid, cerebrospinal fluid and stool samples) and differed markedly among sample
types. The overall sensitivity and specificity were 77.3% and 98.2%, respectively. The
highest sensitivity was recorded 100% for stool (n=2/2) and urine samples (n=5/5)
and the lowest sensitivity was recorded for tissue sample (69%, n=20/29). However,
the low sample size does not allow us to draw conclusions about the accuracy of the
test on non-respiratory samples and further evaluation is required. In addition, the
detection of rifampicin resistant isolates from these samples was not reliable in terms
of sensitivity, according to Hillemannet al (81). Despite high accuracy of the test in
sputum samples, high cost is the main challenge for implementation of this test
worldwide. In 2010, GenXpert MTBlRif has been endorsed by WHO for use as the
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initial diagnostic test in individuals suspected of MDR-TB or HIV-associated TB in
high burden countries (248). WHO also developed a roadmap for implementation of
this test for target settings, including negotiation with Cepheid to achieve an
agreement on reasonable and fixed price for 116 high burden and all low and middle
income countries (246). Negotiated prices for eligible countries included GenXpert
system-4 module with desktop computer (17,000 USD, 75% reduction relative to the
standard market price), GenXpert system -4 module with laptop computer (17,500
USD), cartridge (16.86 USD) annual calibration (1,800 USD) and other services. The
current running cost is 18 US$ltest for low-income countries. Evaluation and
implementation of GenXpert in Viet Nam will commence in late 2011.
» Commercial serological tests
Immunological tests would seem to offer benefits for early detection of TB cases in
resource-limited regions because of their speed and simplicity. Commercial
serological tests are mainly based on the detection of the humoral (serological)
antibodies in response to Mtuberculosis (172), interferon-gamma T cell based assay
(99) or antigens (lipoarabinomannan-LAM) in samples other than sera (44, 92, 150).
Commercial serological tests- antibody detection
A systematic review from 68 studies evaluating commercial serological tests for
diagnosis of pulmonary tuberculosis revealed that the accuracy of these tests is
inconsistent; the sensitivity was estimated ranging from 10% to 90% and the
specificity fluctuated between 47% and 100% against culture or smear as the gold
standard. Interestingly, this review also stated that none of the reviewed assays
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performed accurately enough to replace sputum smear microscopy (178). For
diagnosis of extrapulmonary tuberculosis, the sensitivity and specificity of serological
tests ranged from 0% to 100% and 59% to 100%, respectively against culture, smear
or histology as the gold standard. The accuracy of serological tests in diagnosis of
extrapulmonary tuberculosis was highly variable among investigators and specific
forms of extrapulmonary tuberculosis. The estimated ranges of sensitivity of this test
in diagnosis of lymphnode TB and pleural TB were 23% to 100ro and 26% to 59% ,
respectively (179). In this review, 56 studies on tuberculous meningitis were screened
but most of them were excluded from analysis due to low sample size «25 TBM
cases), inappropriate sample type (CSF samples instead of serum) and inappropriate
gold standard (clinical gold standard instead of bacteriologicallhistological gold
standard). Only one eligible TBM study in this review was recorded and the
sensitivity and specificity of a commercial test (AMRAD ICT, TB03 LotOl0110,
French's Forest, NSW, Australia) were 48% and 82%, respectively (117). In
September 2010, the WHO Strategic and Technical Advisory Group for Tuberculosis
(STAG-TB) issued a policy statement recommending against the application of
commercial TB serodiagnostic tests for diagnosis of active TB disease and detection
of latent TB in low and middle-income countries. This was an unprecedented step as
the first negative policy statement on a diagnostic test issued by WHO and
precipitated by the finding that the market for such tests in India alone is worth over
15 million US dollars (136). There is now compelling evidence for lack of accuracy,
with false results outnumbering true results for most tests (178).
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Biomarker discovery programs are attempting to identify novel antigen/antibody
targets for improved point-of-care serodiagnostic tests, but progress to date has not
been encouraging.
M tuberculosis Antigen Detection: LAM test
MTB LAM ELISA test (Chemogen-USA) is a commercialized test to detect the
presence of lipoarabinomannan (LAM), a component of the bacilli cell wall, in
clinical samples as a surrogate marker for TB detection. The result is available in 3
hours. Several studies have evaluated this test in settings with high burden of TB and
HIV. Klaus Reither et al. clinically assessed the diagnostic value of this test in urine
samples collected from patients suspected with pulmonary tuberculosis in Tanzania
against smear microscopy/culture as the gold standard. The sensitivity and specificity
were 50.7% and 87.8%, respectively. The sensitivity was higher in HIV positive
patients (62.0%) than HIV negative patients (21%) (163). Another study in Africa
evaluated this test on sputum and urine samples and showed similar sensitivity for
urine LAM as that from the Tanzania study; sputum LAM had high sensitivity but
extremely low specificity (86% and 15%, respectively) (57). Comparable results were
obtained from CSF samples (152). In general, MTB LAM ELISA does not have any
advantage over smear microscopy.
Detection ofimmunological response: Interferon gamma release assay
Interferon gamma release assays (IGRAs) have been developed for diagnosis of
Mtuberculosis infection in terms of host immunological response in vitro. The
principle of this test is to stimulate peripheral blood T cells with Mtuberculosis
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specific antigens (Early secretory antigenic target - ESAT-6 and culture filtrate
protein - CFP-10). If memory T cells are present, they will be stimulated by specific
TB antigens leading to the induction of interferon gamma (IFN-y). Two commercial
assays are available: QuantiFeron TB test assay (QFT) (Cellestis Ltd, Australia) that
measure IFN-y using ELISA (36) and the T-SPOTTB assay (Oxford Immunotec Ltd,
UK) which is based on the counting of cells releasing IFN-y with enzyme-linked
immunospot technique (ELISPOT) (146). A systematic review evaluating the two
commercial IGRAs in diagnosis of active TB disease reported that the pooled
sensitivity of QFT and T-SPOT were 81% (95%CI: 78%, 83%) and 88% (95%CI:
86%, 90%), respectively. The sensitivity varies significantly between studies, ranging
58% to 100% for QFT and 50% to 100% for T-SPOT. The pooled specificity was
99.2% and 86.3% for QFT and T-SPOT, respectively. It is apparent that higher
sensitivity was reciprocal to lower specificity and sensitivity is lower in high burden
countries. Importantly, 3-5% indeterminate results were recorded for each test and
the number of indeterminate results increased in immunosuppressed patients and
children (32, 58, 112). Due to compelling evidence demonstrating the poor
performance of commercial IGRAs in low and middle income countries, especially in
settings with high TB/ and HIV burden, WHO released a policy to discourage the use
ofIGRAs in these settings in December 2010 (248).
1.4.4 Integration of novel diagnostic tests in the health system for diagnosis of
tuberculosis in high burden countries.
In 2010, WHO has produced a framework for implementation of endorsed novel
diagnostic methods in low and middle income countries. Below is the expected
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implementation of new tools in the health system recommended by WHO (figure 1.8
and figure 1.9).
Figure 1.8 Intergrating new tools in tiered health systems
Integrating new tools in tiered health systems
Solid
culture
&DST
Automated
liquid
culture lPA
&DST
In-house DST
(MODS. NRA, CRI)
'Screening"
'Passive case finding
'Detee t and treat
'dinltal
'pending WHO endorsement
Source: WHO: Frameworkfor implementation of new TB diagnostics (243)
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Figure 1.9 Recommended laboratory levels for application of diagnostic tests
Ve. Technology Turnaround time
Sensitivity
gain
Be1ore2007
ZN microscopy 2-3days Baseline
Solid Culture 30.s0days
2007
Liquid Culture I CST
1S-30days
+10% compared
to LJ
At this time for
2008 2-4 days $+ only
LED-based FM '-2 days +10% compared
2001 toZN
Inhouse DST 15-30 days 11lline only(MODS, CRI, NRA)
+40% compared
90minutes toZN
Red circle: ImportantJor early diagnosis and care
Yellow circle: ImportantJor smear negative TB
Pink circle: Important for rapid MDRlXDR detection
Source: FIND diagnostics: hupr/www.finddiagnosttc.org
Although many novel diagnostic methods have been launched, evaluated and
recommended by WHO, the implementation of these methods should carefully be
considered based on infrastructure, finance, maintenance, personnel and technical
issue at the site. GenXpert, for example, has been endorsed by WHO as the initial
diagnostic test for MDR-TB suspects and irnmunocompromised patients suspected of
TB. The majority of these cases are from high burden countries where financial
resources are lacking. Even though the negotiated cost for a GenXpert system is
17,000 USD and cost of each test is markedly reduced to18USD, the wide application
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of this test is still challenging because the target population for this test is very
impoverished. In addition, national TB programmes cannot implement this test in all
district laboratories, as mentioned in the roadmap for implementation of GenXpert by
WHO, due to financial shortage. Therefore, the application of novel tests highly
depends on the capacity of the site. Another consideration is the sustainability of the
test if the smear microscopy network is dismantled or if GenXpert can replace smear
microscopy in wide scale implementation. Aside from cost, technical issues and
maintenance, other foreseen challenges include storage conditions for cartridges and
the likelihood that Genexpert will not be a suitable test for follow-up and monitoring
of patients on treatment. It is suggested by the manufacturer that cartridges should be
stored between 4De - 30De but the room temperature in high TB burden countries,
including Viet Nam often exceeds this limit. Since GenXpert detects genetic material
of Mtuberculosis present in samples, it cannot distinguish between living and dead
bacilli. Therefore the classification of TB patient treatment outcome after 2, 5 and 8
months of treatment, which is currently based on the smear result, cannot be made
using Genxpert. Although smear is also unable to distinguish dead bacilli, smear test
is less sensitive and therefore false positives due to dead organisms are likely to be
less frequent. A new classification is needed for follow-up patients if GenXpert is
implemented in place of smear and further research is required on the programmatic
integration of Genxpert.
Several funding agencies, such as TB REACH, have prioritized funding to support
projects to increase implementation of GeneXpert, including in Viet Nam.
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1.5 TB TREATMENT REGIMENS
1.5.1 Purpose of TB treatment
The objective of anti-tuberculous treatment is to achieve cure of the disease and
prevent the emergence or amplification of drug resistance. Therefore, the treatment
regimen should include multiple drugs to which the organisms are susceptible. With
existing 1st line drugs (Isoniazid, Rifampicin, Pyrazynamide, Ethambutal and
Streptomycin), a minimum 0(6 months therapy is required to achieve high cure rates
and prevent relapse. The treatment course includes two phases: intensive bactericidal
phase and continuation (sterilization) phase. A combination of at least 3 drugs in the
intensive phase and at least 2 drugs in the continuation phase is required to protect
against drug resistance. By 2007, more than 99% of all notified TB cases reported to
WHO were in DOTS (Direct Observation Treatment Short Course) programmes
(244).
1.5.2 Direct Observation Treatment Short Course (DOTS strategy)
The DOTS strategy has been recommended for application in national TB
programmes by WHO from 1993 to improve the efficacy of TB control and
management. This strategy aims to ensure high cure rate and follow-up of TB patients
during the treatment course. There are 5 components to the DOTS strategy which are
critical for DOTS implementation: government commitment, case detection by
passive-case finding, standardized short course therapy for all sputum smear-positive
patients, regular drug supply and a monitoring system for programme supervision and
evaluation (217). Based on DOTS implementation, two targets for TB control were
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established - detection of at least 75% of estimated new smear positive cases and cure
of at least 85% of detected cases by 2000. The number of TB patients under the
DOTS programme has been scaled up rapidly since the Millennium. By 2009, 49
million patients were treated in DOTS programme, of whom 41 million people have
been successfully treated and approximately 6 million lives saved through DOTS and
stop TB strategy. The case detection rate reached 63% and the treatment success rate
exceeded 85% worldwide in 2009 (244).
The private sector in which practitioners are not employed by the government, plays
an important role in increasing the TB detection rate and the number of TB cases on
TB treatment. Unfortunately, limited information about TB management in the private
sector has been reported by WHO globally (83). In Viet Nam, it was documented that
if all TB suspects presenting to private sectors in Ho Chi Minh City were sent to NTP
for diagnosis, the case detection rate of new smear positive TB cases would be
increased by 18% (157). Another study reported that at least 40% ofTB cases in this
city received TB treatment from private clinics (108). At national level,
approximately 8% of TB cases in Viet Nam seek private clinics for TB treatment,
mostly in southern Viet Nam (12%) and especially in urban areas (13%) (82). The
treatment outcome of these patients depends on the collaboration level between
private and public sectors. If TB diagnosis and treatment within private sectors are not
quality controlled by the NTP (low quality of smear microscopy, use of poorly
validated diagnostic tests, no DOTS and non-standard treatment regimen), low
treatment success and high default rates are likely, 60% and 37%, respectively in one
study (158) which is much lower than the targets recommended by NTP. However, if
private clinics controlled by the NTP in terms of technical and management issues,
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the treatment success can exceed the target (105) and private-public mix models
should be scaled up worldwide.
1.5.3 TB drugs
Antituberculous treatment is usually based on five first line TB drugs approved by
WHO, including Rifampicin (RIF), Isoniazid (INH), Streptomycin (STR), Ethambutol
(EMB) and Pyrazinamide (PZA). The activity against TB and mechanism of these
drugs are described in table 1.1
Table 1.1 The 1st line TB drugs and their mechanisms
t" line Drug class Activity against Mechanism
TBdrug TB
RIP Rifamycin Bactericidal Protein synthesis.
INH Isonicotinic acid Bactericidal Mycolic acid
hydrazide synthesis (cell wall).
STR Amynoglycoside Bactericidal Protein synthesis.
EMB Unspecified Bacteriostatic Inhibition of cell wall
synthesis. If used for a
long time, EMB
protects against
further development
of resistance.
Bactericidal Only at the high end
of dosing range.
PZA Synthetic derivative of Bacterlcidal for Unclear
nicotinamide dormant
tuberculosis
Source: Reference (91)
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For MDR- TB, second line drugs (table 1.2), in addition to any 1st line drugs to which
organism remains susceptible, are recommended by WHO. These include injectable
drugs, fluoroquinolone, oral bacteriostatic second line drugs and drugs with an
unclear role in treatment of drug resistant TB. The last group (group 5) is only
prescribed if it is impossible to design adequate regimens using agents from group 1-4
4 and prescribed with consultation due to high toxicity and weak efficacy (239).
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Table 1.2 TB regimens recommended for MDR-TB treatment
Group Drugs (abbreviations)·
Group 1:
First-line oral agents
• pyrazinamide (Z)
• ethambutol (E)
• rlfabutin (Rfb)
Group 2:
Injectable agents
• kanamycin (Km)
• amlkacln (Am)
• capreomycln (Cm)
t streptomycin (5)
Group 3:
Fluoroquinolones
• levofloxacln (Lfx)
• moxlfloxacln (Mfx)
• ofloxacln (OfX)
Group 4:
Oral bacteriostatic second-line
agents
• para-aminosalicylic acid (PAS)
• cycloserine (Cs)
• terlzldone (Trd) .
• ethionamide (Eto)
• protionamide (Pto)
• clofazlmlne (Cfz)
• IInezolid (Lzd)
• amoxlclllin/clavulanate (Amx/elv)
• thioacetazone (Thz)
• Imlpenem/cllastatln (lpm/Cln)
• high-dose Isoniazid (high-dose H)b
• clarfthromycln (Clr)
Group 5:
Agents with unclear role In
treatment of drug resistant-TB
Source: Reference (239)
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1.5.4 Treatment regimens
The standardized regimens for TB treatment recommended by WHO apply to four
patient groups, which are classified according to the bacteriology result and history of
TB treatment. These categories are new smear-positive patients (Category I), relapse
_ treatment after default or treatment failure of Category I in settings with low rate of
MDR- TB (Category II), new smear-negative pulmonary patients or less severe
extrapulmonary TB forms (Category III), and treatment failure of cat I in settings with
high rate of MDR- TB (Category IV). Table 1.3 shows the TB treatment regimens
recommended for corresponding diagnostic categories.
Chapter 1-Introduction Page 77
Table 1.3 Recommended treatment regimens for different diagnostic categories
byWHO
TB patient Recommended TB treatment regimens in Remark
diagnostic 2010*
Category
I 2HRZE/4HR (preferred) Applied for new 'PTB,
2(HRZE)3/4(HR)3 (optional) EPTB (except TB of
eNS, bone or joint)
II 2HRZES/IHRZE/SHRE (preferred) Applied only if specific
2(HRZES)J/l (HRZE)3/S(HRE)3( optional) country data show low
or medium MDR-TB
rate in this population or
data is unavailable
III 2HRZE/4HR (preferred)
2HRZE/6HE (optional)
2(HRZE)3/4(HR)J (optional)
IV Designed standardized regimen based plus
2nd line drugs
Source: Reference (239)
=Numbers preceding regimens indicate the length of treatment in months. Subscript numbers
following regimens indicate the frequency of administration per week. If no subscription
numbers are given, the regimen is daily.
H (Isoniazid), R (Rifampicin), S (Streptomycin), E (Ethambutol) and Z (Pyrazinamide)
"Preferred" indicates a strong recommendation.
"Optional" expresses a conditional recommendation. It means "may" or "is not
recommended. In this case, alternatives are often listed
PTB: Pulmonary TB, EPTB: Extrapulmonary TB, CNS: Central nervous system.
In 2009, WHO recommended some important changes in the previous treatment
guidelines for the improvement of treatment outcome (239). First, 2HRZE/6HE
regimen should be phased-out because this regimen uses rifampicin in only the first 2
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months which significantly increased relapse, failure and acquired drug resistance
after 8 months of treatment in comparison with 2HRZE/4HR in IUATLD'study A'
(120), Second, the retreatment regimen with the first line drugs
(2HRZES/1HRZE/SHRE) is ineffective in MDR- TB patients because these patients
are already infected with rifampicin and isoniazid resistant isolates. Therefore, while
there is no ideal regimen for this group, it is important to detect MDR- TB as soon as
possible and start an individual regimen based on the DST profile. However, this is
not possible in many settings. Third, in settings where rapid molecular DST tests are
available for MDR- TB detection, an effective regimen (consisting of effective drugs
among the first line drugs and S groups of second line drugs) can be started 1-2 days
after diagnosis. However, molecular DST tests do not accurately detect resistance to
the remaining first line drugs, (STR, PZA and EMB). Therefore, the ideal regimen
cannot be determined from molecular testing. In countries where molecular tests are
not available, traditional DST methods are used; and treatment will be based on an
empirical regimen until the DST results are available. Fourth, in new TB patients
who are infected with INH resistant isolates, they are more likely to develop acquired
MDR-TB. Therefore, adding Ethambutol to the continuation phase of treatment
course (HRE) is recommended' in settings with a high prevalence of INH resistance',
however, a 'high prevalence' is not defined and this recommendation is not evidence-
based. Ethambutol has side effects, including ocular toxicity. Therefore, a study is
needed to determine efficacy 'of the regimen and at what level of INH resistance it
should be applied programmatically, if at all.
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1.5.5 Treatment regimens currently applied in the Vietnamese NTP
There are 4 regimens currently used in Viet Nam (137):
Regimen I: 2HRZE/6HE (the first two months with HRZE daily then the last 6
month with HE daily) (only provided if DOTS is applied). This regimen is still used
for treatment of new cases in Viet Nam even though it has been recommended to
phase out by WHO since 2009. It is currently being phased out in a stepwise
approach. Sputum examination is required at the end of month 2, 5 and 8.
Regimen I: 2S(E)RHZl4RH (only provided if DOTS is applied). This treatment
course is for new TB cases who have never received TB treatment or have undergone
TB treatment course less than 1 month. Sputum examination is required at the end of
month 2, 4 and 6.
Regimen II: 2SHRZE/1HRZE/5H3 R3 E3. (the first 2 months with SHRZE daily,
then the third month with HRZE daily and finally the last 5 months with HRE three
times a week). This regimen is for patients who have relapsed or failed with regimen
I, retreatment after default and some severe cases based on TB treatment histories.
Sputum examination is required in the end of month 3, 5 and 7 (or 8).
Regimen Ill: 2HRZE/4HR or 2HRZl4HR. Recommended for all pediatic TB
cases in Vietnamese National guidelines. In severe cases, additional streptomycin can
be prescribed. Sputum examination is required at the end of month 2, 4 and 6.
For smear negative TB cases, Sputum examination is required at the end of month 2
and 5 of treatment.
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Anti tuberculous drugs and related doses are presented in the table 1.4:
Table 1.4 Antibiotics and related doses in TB treatment
Daily Three times a week
Antibiotics Dose
Dose (mg/kg)
(mg/kg)
Isoniazid 5 (4-6) 10 (8 -12)
Rifampicin 10 (8-12) 10 (8 -12)
Pyrazinamid 25 (20-30) 35 (30-40)
Ethambutol Children 20 (15-25)
Adults 15 (15-20)
30 (25-35)
Streptomycin 15 (12-18) 15 (12-18)
Source: Reference (137)
1.6 TUBERCULOSIS CONTROL PROGRAMME IN VIET NAM
1.6.1 Epidemiology
Viet Nam is a developing country in the South East Asia region with an estimated
population of 86 million in 2009. It is classified by WHO as a high TB burden, high
HIV burden and high MDR-TB burden country. The annual report from WHO
showed that Viet Nam was ranked 13th among high TB burden countries in the world
in 2009 with the following estimates and notifications (244) (table 1.5):
Chapter 1-Introduction Page 81
Estimated Incidence ofHIV+/TB
(new HIV+/TB/I00,000 population)
Estimated case detection rate (%) of all forms
Estimated (%) new MDR-TB cases
Estimated (%) retreatment MDR-TB cases
All pediatric TB cases notified «15 years)
8.4
Table 1.5 Data on TB control activities of Viet Nam reported by WHO
Population, 2009 85,789,573
Estimated prevalence (all cases/l00,000 population) 333
Estimated incidence (new sputum smear positive/l00,000 200
population)
54
2.7
19
88
Source: Reference (244)
Although the detection rate has officially exceeded the WHO target of 70% of
infectious cases since 2000, reaching 82% in 2007, the overall incidence rate has
decreased only marginally each year, about 1% per year (237). It is likely that
previous estimated TB incidence figures for Vietnam were an underestimate, as
suggested by the 2006 - 2007 intensified prevalence survey (253): TB prevalence was
found to be 1.6 times higher than the previous estimate; and the estimated case
detection rate of all TB forms was re-estimated at 56% which is lower than the 70%
target. This may account for the slow decline in incidence figures, despite apparently
high case detection rates. The escalation of HIV infection and TBIHIV co-infection is
likely to be a contributing factor for the high prevalence of TB in Viet Nam (202).
Increasing case notification is now a priority of the national TB programme.
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1.6.2 TB control network and laboratory TB network
Viet Nam consists of 65 provinces, 685 districts and 10,934 communes. The TB
control network (established in 1957) functions with 4 levels: national, provincial,
district and commune level (figure 1.10). The district TB unit at the commune is the
place where almost all TB suspects come for screening, diagnosis and treatment.
Since 2001 TB control and prevention activities in prisons and rehabilitation centers
have been covered by the National TB programme (NTP). Aside from passive
detection, active screening is also performed to increase TB case detection at these
centers, inmates of which are at high risk of TB infection and development of active
TB disease.
The tuberculosis laboratory network acts as "the spine" of the TB control programme.
The laboratory network is organized according to 3 levels: peripheral (district)
laboratory, provincial laboratory and national laboratory. There is an intermediate
(regional) laboratory in the South of Viet Nam, hosted at Pham Ngoc Thach hospital,
which is responsible for quality assurance and quality control of laboratory activities
in the southern region. Smear is performed at all levels for TB diagnosis. Culture (LJ
and MOlT), DST (proportional DST method) and other tests (molecular genotyping
tests and identification tests) are performed at regional and national laboratories. In
the south of Viet Nam, there are 5 laboratories in 5 provinces equipped for performing
TB culture (Dong Nai, Dong Thap, Binh Thuan, PNT hospital and Can Tho) and one
laboratory performing DST located at PNT hospital. At peripheral level, on average,
each peripheral TB laboratory has one technician responsible for the activity of the
laboratory. According to the national TB programme (NTP), there were 1,709,628
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smears made in 2008 for TB diagnosis, of them 131,966 (7.7%) were positive smears.
Personnel shortages and inconsistence lead to excess workload at almost half of the
TB units (80).
Figure 1.10 Diagram ofTB control network in Viet Nam
M
NATIONAL HOSPITAL OF TB AND LUNG
inistry of Health ~•••••••••••••
DISEASES
NATIONAL TB AND PREVENTION
PROGRAMME
PHAM NGOC THACH HOSPITAL
TB PROGRAMME IN HO cm MINH
CITY
I Health Service I•···• TBPROGRAMME TB PROGRAMMES··· NORTHERN-MIDDLE SOUTHERN·1··············· PROVINCES PROVINCES···
District
Healthcare
District
Tuberculosis
Primary
Healthcare
Unit
TB staff
Administration management
----- Technical management
•...............
Chapter 1 - Introduction Page 84
1.7 AIMS
1. Evaluate the MODS technique (Microscopic Observation Drug Susceptibility
Assay) for early diagnosis of tuberculosis in 3 groups; pediatric TB, HIV-
associated TB and TB meningitis.
2. Evaluate the MODS technique for early diagnosis of multidrug resistant
tuberculosis.
3. Evaluate the effectiveness of a fluorescence LED microscope in diagnosis of
tuberculosis.
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Chapter 2
MATERIALS AND METHODS
In this project, the MODS study was conducted at the Hospital for Tropical Diseases
and PNT hospital; the LED study was performed at District Tuberculosis Units in Ho
Chi Minh City and at PNT hospital.
2.1 STUDY SETTINGS
The studies described in this thesis were conducted at 3 sites in Ho Chi Minh City,
Viet Narn:
~ Pham Ngoc Thach Hospital for Tuberculosis and Lung diseases (PNT
hospital)
~ Hospital for Tropical Diseases (HTD)
~ Three District Tuberculosis Units (DTUs) in Ho Chi Minh City: DTUl,
DTU5 and DTU8
The evaluation of MODS
The pilot evaluation of the MODS technique for diagnosing TBM described in
chapter 3, section 2 was conducted at HTD and the Oxford University Clinical
Research Unit (OUCRU) laboratory based at HTD.
All other evaluations of the MODS technique described in chapter 3 were conducted
at PNT hospital.
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The implementation phase of MODS for TBM diagnosis (chapter 3 - section 2), the
evaluation of MODS in early diagnosis of tuberculosis in children (chapter 3 -
section 3) and in HIV infected adults (chapter 3 - section 4), and the accuracy of
MODS in detection of multidrug resistant tuberculosis (chapter 3 - section 5) were
organized at TB ward, pediatric wards, TBIHIV wards and Out Patient Department of
PNT hospital, respectively, from May to December 2008.
The evaluation of iLED microscope
Evaluation of iLED microscope on panel slides was performed at the Microbiology
laboratory at PNT hospital. Patient recruitment, sample collection and smear
preparation were performed at district tuberculosis units. The study was supervised by
the microbiology laboratory at PNT hospital and conducted as part of a multi-country
evaluation by FIND (South Africa, Russia, Peru, Lesotho, Ethiopia, Tanzania and
VietNam).
2.1.1 Pham Ngoc Thach Hospital for Tuberculosis and Lung Diseases - The
microbiology laboratory.
Pham Ngoc Thach hospital (PNT hospital) was founded in 1906 and served the
French military at that time. In 1960, it was used as a TB hospital. Since 1989, it
functions as a TB and Lung disease hospital. PNT hospital is a tertiary referral
hospital for tuberculosis and lung disease in southern Viet Nam. This hospital has
approximately 800 beds (320 beds for TB wards, of which 55 beds for TBIHIV
patients; 60 beds for children with TB and lung diseases) working in 5 main sections:
Emergency and Out Patient department (OPD), Tuberculosis and Intensive care unit
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(ICU), non-TB, surgery and subclinics (microbiology, biochemistry and haematology,
and radiology). In 2009, there were 321,482 patients visiting OPD, of which 20,267
were inpatients. TB patients occupied 45% of all cases. From 2005 to 2009, the
number of TBIHIV patients admitting to the hospital decreased (15%, from 2313 to
2018) due to many HIV /TB projects in collaboration with international organizations
conducted at peripheral TB units. The Paediatric Department received approximately
10,000 children in 2009, of which 1200 cases were hospitalized and 100 cases were
diagnosed with tuberculous meningitis (TBM).
The microbiology laboratory at PNT hospital is a regional TB laboratory and is part of
the NTP laboratory network. It plays a role as a reference laboratory for all TB
laboratories in southern Viet Nam, including Ho Chi Minh City, in terms of technical
support, technical assurance, supervision and training. The laboratory is responsible
for the preparation of staining reagents and slide rechecking for all TB units in Ho Chi
Minh City.
The microbiology laboratory is equipped with 2 Biosafety laboratory level 2+ (BSL
2+) laboratories for doing TB culture and DST. The laboratory has 65 staff, including
one PhD.MD, one MSc.MD, two medical doctors, and the remaining staffs are BSc
graduates and technicians. There are approximately 1000 samples of all types for TB
diagnosis and around 30 samples for other microbiology diagnosis sent to the
laboratory daily. The workload for smear reading is from 80 to 150 slides/technician!
per day.
Any patient presenting to the Out Patient Department (OPD) at PNT hospital with
clinical symptoms suggestive of tuberculosis is asked to produce 3 sputum samples
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and a new chest X-ray for TB diagnosis. Currently, smear microscopy (direct or
homogenous smear, light microscope or conventional fluorescence microscope),
MGIT culture and proportional drug susceptibility testing methods (DST) are used as
routine microbiological tests. With any positive smear sample or positive MGIT
sample, the patient is diagnosed with tuberculosis and is eligible to receive TB
treatment according to NTP guidelines. If all three samples are smear negative but
chest X-ray suspected of tuberculosis, the patient will be asked to submit another
three sputum samples after 2 weeks for further diagnosis or consultation as needed. In
cases with moderate and severe general status, the patients are asked to admit to the
hospital for treatment and follow-up. DST is not done for all TB patients because of
limitation in finance and human resource. Only for TB patients in high risk groups
(retreatment, default, failure and HIV/TB patients), DST are performed upon request
of the treating clinician. From 2009, genotype MTBDR-plus (Hain Lifescience-
Germany) is used to detect smear positive pulmonary TB patients infected with MDR
isolates presenting to all District Tuberculosis Units in Ho Chi Minh City. This is a
project of National TB programme (NTP) funded by WHO and Green Light
Committee (GLC). All TB patients infected with rifampicin resistant isolates detected
by this method are eligible to receive MDR-TB treatment regimen recommended by
WHO and drugs was provided by WHO and GLC. Since early 2011, fluorescence
LED microscope has been used as a routine diagnostic method at PNT hospital.
Aside from doing routine tests for TB diagnosis, PNT laboratory also participates in
international projects for evaluation of new TB diagnosis tests (eg. MODS assay with
OUCRU-Wellcome Trust, LAMP test with FIND and iLED microscope with FIND).
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2.1.2 Hospital for Tropical Diseases - Oxford University Clinical Research Unit
(OUCRU-HTD) - The OUCRU laboratory.
The Hospital for Tropical Diseases (HTD) was founded in 1862 and named "Cho
Quan" hospital at that time. From 1989, it was named as HTD and has functioned as
the tertiary referral hospital for patients with infectious diseases in southern Viet
Nam. This hospital has approximately 600 beds divided into paediatric, adult and Viet
Anh wards; and has laboratories for haematology, biochemistry, microbiology and
radiology which support diagnosis and treatment.
OUCRU laboratory is located at HTD. This laboratory was developed for doing
research on infectious diseases in collaboration with HTD, including tuberculosis,
malaria, dengue, influenza and other respiratory infection, enteric, central nervous
system infections, animal health and zoonoses, pharmacology and statistics,
bioinformatics, modeling and mapping. To date, almost 1000 research papers have
been published in the internationallitterature.
In the pilot phase evaluation of MODS in diagnosis of tuberculous meningitis
(chapter 3 - Section 2), samples were obtained from patients admitted to Viet-Anh
ward and processed in the OUCRU BSL3 laboratory.
2.1.3 Tuberculosis Units inHo Chi Minh City
Three district tuberculosis units (DTU) located within a radius of 8km from PNT
hospital participated in this study: DTUl, DTU5 and DTU8. The DTU is the primary
health care network of the NTP where almost all TB suspects come for TB screening
and diagnosis. Routinely, a patient with suspected TB is asked to submit 3 sputum
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samples (spot - morning - spot) to DTU for TB diagnosis by smear microscopy
method. The smear results are available in two days. If any of the three sputum
samples is positive, the patient is diagnosed with TB and will commence TB
treatment following the DOTS strategy. Further sputum samples will be collected if
results of the first three samples are not sufficient for determination. All smears done
at DTU are stored at the site according to NTP guidelines. At the end of each month,
all smears are sent to the microbiology laboratory at PNT hospital for blind
rechecking using LQAS rechecking method (Lot Quality Assurance System)
according to NTP guidelines.
The positive detection rates of the DTUs participating in LED study ranged from 10%
to 15%. The workload ofDTU5, DTU1 and DTU8 are approximately 10,20 - 40 and
more than 40 slides/person/day, respectively. DTUI and DTU5 have one technician
working full-time in the laboratory, whereas DTU8 has two technicians. These
technicians are responsible for sample collection, registration, smear preparation,
smear reading and reporting.
Patient recruitment, sputum collection and smear preparation, reading and reporting
were performed on site at the DTU. The study was supervised by Dang Thi Minh Ha.
2.2 STUDY TIMING AND DURATION
» The enrollment of TBM study - pilot phase was conducted from June 1st to
November 1st 2006.
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~ The enrollment of TBM study - implementation phase, paediatric TB, HIV-
associated study and MDR-TB study were carried out from May to November
2008.
~ The enrollment of the LED microscopy study was conducted from August
2008 to September 2009.
2.3 SCIENTIFIC AND ETHICAL APPROVAL
All protocols were approved by the Institutional Review Board (lRB) at Pham Ngoc
Thach hospital or Hospital for Tropical Diseases, as applicable, and the Health
Services of Ho Chi Minh City. Informed consent was not sought for the diagnostic
studies because the studies were conducted on routine samples only and did not
involve any intervention, additional samples or change in patient management. This
patient consent waiver was approved by the IRB of Pham Ngoc Thach hospital or
Hospital for Tropical Diseases in the protocol and is consistent with the guidelines on
informed consent provided by the University of Oxford Tropical Ethical Review
Board (OXTREC).
2.4 ENROLLMENT
2.4.1 Enrollment sites
MODS study
All patients with clinical symptoms suspected of tuberculosis meningitis presenting to
HTD were enrolled into the pilot study of evaluation of MODS in diagnosis of
tuberculous meningitis (TBM) - pilot phase (chapter 3 - section 2).
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Patients suspected of TBM and pulmonary TB presenting to Pham Ngoc Thach
hospital were enrolled into the study of evaluation of MODS in diagnosis of TBM -
implementation phase (chapter 3 - section 2), paediatric TB (chapter 3 - section 3),
HIV -associated TB (chapter 3 - section 4) and multidrug resistant TB (chapter 3 -
section 5) .
LED microscopy study
Adult patients suspected of pulmonary TB presenting to any of the three DTUs
(DTU1, DTUS and DTU8) were enrolled into the LED study (chapter 4).
2.4.2 Inclusion criteria
~ Suspected of tuberculosis (all studies)
~ 2: 16 years of age for all adult studies
~ Under 16 years of age for paediatric MODS study
~ HIV -infected for the HIVITB MODS study
~ Not on TB treatment (new cases) or on TB treatment less than or equal 7 days
(MODS study only).
2.4.3 Exclusion criteria
~ Receiving TB treatment for more than 7 days before sample collection
(MODS study only).
~ Under 16 years of age (LED microscopy study and adult MODS studies).
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2.4.4 Data collection
MODS STUDY
Data on socioeconomic and demographic features, TB history, TB contact history,
HIV status and presenting clinical features were prospectively collected on a standard
case report form (CRF). Samples were collected as per routine care as deemed
appropriate by the treating physician. No additional samples were collected as part of
this study. All specimen types from suspected cases were included in the study except
blood.
LED MICROSCOPY STUDY
Data on socioeconomic and demographic features, TB history, TB contact history,
HIV status and presenting clinical features were prospectively collected as part of
routine care for TB management of NTP but not for study evaluation. All sputum
samples collected for routine care at DTUs were used for evaluation of LED
microscopy. No additional samples were collected as part of this study.
2.5 SAMPLE COLLECTION AND TRANSFER
2.5.1 Sample collection
~ The number of samples collected from patients was determined by the treating
clinicians.
~ No additional samples were collected as part of this study.
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~ CSF samples were collected for TBM study and all other sample types (not
including blood) were collected for the paediatric study and HIV-associated
study. Only sputum samples were collected for the MDR study and the LED
study.
~ The samples were collected into sputum containers for sputum samples
provided by NTP or sterile tubes for other body fluids provided by the study.
2.5.2 Sample transfer
MODS studies
~ If the samples were collected during working hours, they were transferred
immediately to the microbiology laboratory for processing.
~ If the samples were collected after 4:00pm, they were kept in refrigerator
overnight at the wards or they were sent to be stored at 4°C at the
microbiology laboratory immediately.
~ If samples were collected during the weekend (Saturday and Sunday), they
were sent immediately to the microbiology laboratory and stored at 4°C until
processed.
LED microscopy study
For the LED study, no samples were collected at DTUs after 4:00pm or during the
weekend because the official hours of these units are from 7:00 to 16:00, from
Monday to Friday.
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2.6 LABORATORY METHODS
2.6.1 Sample processing
» Cerebral spinal fluid (CSF): If CSF samples were collected from patients
admitted to PNT hospital, CSF (sterile sample) was processed in the MODS
culture room which is separated from the sample preparation room and the
culture room to minimize the risk of contamination with unsterile samples.
» CSF samples collected at HTD were processed in OUCRU BSL3 laboratory
where smear microscopy, MGIT culture and LJ culture were also performed.
Techniques involving culture manipulation were performed in a separate
cabinet to sample inoculation to reduce the risk of cross-contamination.
» Other samples (not including blood) collected from PNT hospital were
manipulated in the sample preparation room and the culture room because
these samples require decontamination.
2.6.1.1 Cerebrospinal fluid (CSF)
The sterilin tubes containing CSF samples were centrifuged at 3000g, 4°C for 20
minutes (Eppendorf-5810R, Germany). After discarding the supernatant, 2ml pellet
was used for smear, MGIT and MODS culture. Technicians responsible for each test
were blinded to the other microbiological results and clinical data on the patient
records.
Chapter 2 - Materials and Methods Page 96
2.6.1.2 Samples other than CSF
All samples, except for blood, were homogenised and decontaminated by Sputaprep
(NaOH-NALC 2%) manufactured by Nam Khoa Company-Viet Nam prior to testing.
The kit contains Mucoprep (NaOH O.SMand Na3Citrate 0.05M, NALC (N-Acetyl-L-
Cysteine) and Phosphate buffer (P04 lOX - 0.67M). Homogenization and
decontamination buffer (HDB) were prepared from Mucoprep and Phosphate buffer
IX was diluted from the provided concentration. In brief, 3 - Sml sample was added
to 3 - Sml HDB contained in a SOmlfalcon tube. The tube was shaken slightly by
automated shaker and left at room temperature for 20minutes. After that, 35 - 39ml
phosphate buffer IX was added into the mixture. The mixture was shaken by hand
and then centrifuged at 3000g, 4°C for 30 minutes. The supernatant was then
discarded and O.Smlpellet at the bottom was re-suspended with 2ml distilled water.
The pH of 2.5ml pellet was 11.0. The deposit was then aliquoted into 3 parts for
smear, MGIT culture and MODS. If the sample was from MQDSIDST group, the
deposit was divided into 3 aliquots for DST-MODS, MGIT culture and LJ culture;
any growth from MGIT or LJ was used for indirect DST on LJ media (1%
proportional method).
2.6.2 Microbiological tests for diagnosis of tuberculosis
2.6.2.1 MODS culture
Principle: MODS detects the living Mycobacterium based on the two well-known
characteristics of M tuberculosis; that is the rate of growth in liquid medium is
considerably quicker than that on solid medium, and the morphology of
Chapter 2 - Materials and Methods Page97
M tuberculosis in liquid culture as cording factors, strings or tangles observed under
an inverted microscope.
Figure 2.1 Scheme of MODS culture/drug susceptibility testing
Procedure:
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2.6.2.1.1 MODS culture with 25041 processed sample
The MODS culture was conducted in a biosafety cabinet class I which was placed in a
separate room from the sample processing room, smear preparation room and MGIT
culture room. The MODS method was performed as described in Park et al. (151)
using the modification described by Caws et al. (34). Briefly, MODS media was
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prepared with 7.9 g Middlebrook 7H9 broth (Difco, Sparks, MD), 4.13 ml glycerol
and 1.67 g bactocasitone (Difco, USA) in 880 mls sterile distilled water. The media
was autoclaved and stored in 22 ml aliquots at 4°C. Each new batch was tested for
sterility by incubating one aliquot at 37°C for 1 week. Before use, OADC and
PANTA (Becton Dickinson, USA) were added into each tube to final concentrations
of 5.5% and 0.22% to make working MODS media. The pH of this working solution
is 6.5. One 48-well MODS plate (Becton Dickinson, USA) was set up each day.
Seven hundred and fifty uls of working MODS media was aliquoted to each well and
250 J.11processed sample was added. The pH of each well after adding processed
sample was 7.0. One positive control (H37Rv) and one negative·control well (sterile
distilled water) were inoculated to each plate. Samples were inoculated into alternate
wells to reduce potential for cross-contamination. 'Blank' wells contained MODS
media only. To prevent cross-contamination from evaporation, plate seals (optical
flims, Biorad) were used. The plate was incubated at 37°C, and the result was
recorded every alternate day after five days of inoculation for evidence of growth.
Any cord formation including long cords or comma-shaped cords was recorded as
positive and no cord was recorded as negative. The negative results were confirmed at
day 30. Contamination was recorded if there was any non-mycobacteria growth
(based on microscopy and color) and/or turbidity in any negative control well.
2.6.2.1.2 MODS culture with 100ul processed sample
The MODS media was prepared with 5.9 g Middlebrook 7H9 broth (Difco, Sparks,
MD), 3.lml glycerol and 1.25 g bactocasitone (Difco, USA). The procedure was
exactly the same as described in "MODS culture with 250J.11processed sample".
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Before each use, 2.5ml OADC and 500~1PANTA were added to 22ml aliquot of
MODS to maintain the concentrations of OADC and PANTA of 5.5% and 0.22%,
respectively. After that 900~1of working MODS media and 100~1processed samples
were added into each well. Setting up the MODS plates, incubation and reading were
followed the MODS culture procedure of 800~1samples.
2.6.2.2 Smear microscopy
Principle: Mtuberculosisis an Acid-fast bacilli (AFB) in terms of morphology and
staining color when observed under the microscope. However, microscopy cannot
distinguish Mtuberculosis from other AFBs such as Mycobacteria Other Than
Tuberculosis (MaTT). Since Mtuberculosis represents the overwhelming burden of
AFB disease in high burden settings it is assumed that smear positive cases are
infected with M.tuberculosis and a positive Acid-fast smear is considered sufficient
indication to initiate anti-tuberculosis chemotherapy in these countries. Resource
limitations do not permit the culture confirmation and mycobacterial speciation of all
sputum smear positive cases.
Procedures:
2.6.2.2.1 Smear preparation
a. Direct smear preparation:
A new, clean and unscratched slide was used for each sputum sample. A portion of
fresh specimen blood-speckled or yellowish cheesy mucus was transferred to the slide
using a bacteriological loop. The sample was smeared over an area of 1x2cm
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according to the guidelines of WHO (216). The smear was then dried at room
temperature and fixed over a Bunsen flame before staining.
b. Homogenous smear preparation
This procedure was done in a class I biological safety cabinet. Two drops
(approximately lOOIll)of processed sample were transferred onto the middle of a slide
by a Pasteur pipette. The drop was then smeared continuously and evenly over an area
of Ix2cm using a plastic bacteriology loop. Next, the smear was left at room
temperature for 15 - 30 minutes to air dry, followed by flame-fixing before staining
by either ZN or fluorescent method according to the requirement of each substudy and
WHO standard protocol (214, 216).
c. Panel slide preparation (NALC - NaOH - Formaldehyde):
Sputum samples with high volume (?:3ml),yellowish cheesy mucous and either smear
positive (2+ or 3+) or smear negative results were collected for panel slide
preparation. In brief, 3ml of each sample was transferred to a SOmlErlentube, and
lS01l1Formaldehyde 40% was added. After incubation at room temperature for 30
minutes, an equal volume of NALC - NaOH was poured into the Erlen. This Erlen
was then incubated on a stirring machine at 60°C for 30 minutes. The processed
sample was divided into 2 - 3 centrifuge tubes (SOml tubes)..Distilled water was
added into each tube to make a final volume of 40ml. This tube was centrifuged at
3,000 x g for 20 minutes at room temperature. After discarding the supernatant, 2-3ml
of deposit was used for dilution step. Smear negative processed deposit was used to
dilute smear positive processed samples to make a final positive solution with the
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required AFB number. Two drops of the final mixture were added to a new slide to
make a smear. After being dried at room temperature, the smear was then incubated at
37°C for two days for fixing. For each batch of panel slides, 15 - 20% of slides were
selected randomly for ZN staining and checking. If the reading result was not as
expected, the batch was discarded and the whole process for panel slide preparation
was repeated.
2.6.2.2.2 Staining methods
A maximum of 12 slides were placed onto a staining rack over the sink with a
distance of at least 1cm between each slide as recommended by WHO (216).
a. Ziehl-Neelsen staining(216)
} Reagents: The reagents for ZN methods were prepared according to WHO
guidelines
• Fuchsin 0.3%
• Decolourising solution: 3% acid-alcohol
• Counterstaining solution: 0.3% Methylene blue
} ZN staining procedure
First, smears were flooded with 0.3% Fuchsin It is mandatory that the smear area
is completely covered with Fuchsin so any AFB present on the slide will come into
contact with the Fuchsin. Second, these smears were heated until steaming to ensure
the lipid layer of the bacteria melts to allow intercalation of fuchsin. After this step,
all bacteria present on the slide will be stained with fuchsin color (pink-red). Third, all
Chapter 2 - Materials and Methods Page 102
free stain was washed away by a gentle stream of running water. To decolorize
fuchsin color of bacteria other than AFB, HCL 3 % was used. This step exploits the
Acid-fast property of Mtuberculosis, which will remain stained with fuchsin while
other non acid-fast bacteria are decolourised with acid. Next, other particles on the
smear (fiber, cells and other bacteria and fungi) were stained with 0.3% Methylen
(blue color) to enhance contrast with red AFB. Last, the slide was viewed under a
light microscope, AFB appear as a pink-red slightly curve rod shape against a blue
background (figure 2.2).
b. Fluorescence staining(2l6)
~ Reagents:
• Auramine 0, 0.1%
• Decolourising solution: 0.5% acid alcohol
• Quenching solution: 0.5% Potassium permanganate (KMn04)
~ FM staining procedure
Slides were placed on a staining rack as described above in the ZN staining section.
0.1% auramine solution was then flooded onto these slides without heating. After
incubating at room temperature for 20 minutes, auramine solution was gently washed
away under running water and decolorization solution was applied (0.5% acid-alcohol
for 3 minutes). Another running water wash step followed to make sure
macroscopically visible stain had been washed away. Background staining was then
carried out. Potassium permanganate 0.5% was flooded onto the slide for 1 minute.
Finally, all excess stain on the slide was washed away with running water. The slide
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was air-dried or dried on a hot plate. Critically, these slides must be kept away from
strong light to prevent colour fading. These slides were then placed in boxes ready for
reading. Under the microscope, AFB was recognized as bright-yellow slightly curved
rod-shapes which was predominant on the dark background. This observation can be
compared as stars on the night sky (figure 2.2).
2.6.2.2.3 Smear reading and recording
All smears were read under light microscope or fluorescence microscope according to
the study protocol. Semi-quantitative results were recorded and reported following
WHO guidelines (table 2.1) (216).
Figure 2.2 AFB observed under (a) light microscope (ZN staining) and (b)
fluorescence microscope (Auramine staining)
(a) ZN staining (b) Auramine staining
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Table 2.1 Reading and recording results according to WHO guidelines for ZN
staining and protocol of the LED study for fluorescence staining
MICROSCOPY SYSTEM USED
IUATLDIWHO BRIGHTFIELD
SCALE (lOOOx
FLUORESCENCE FLUORESCENCE
(1000x field=HPF) magnification; 1 (200-250x (400x magnification;
length = 2cm = 100
magnification; 1 1 length = 40 fields
Result HPF length = 30 fields = =200 HPF300HPF
Negative Zero AFBIl length Zero AFB/I length Zero AFB/llength
Scanty 1-9AFBIl length or
(actual count) 100HPF
1-29AFB/11ength 1-19AFBIl length
10-99AFBIl length 20-199 AFBIl
1+ or 100HPF (=1-9 30-299 AFBIl length length
AFB/10 fields)
2+
1-10 AFB/I HPF on 10-100 AFB/l field 5-50 AFB/l field
average on average on average
3+
2::10 AFBIl HPF on 2::100AFBIl field >50 AFB/l field
average on average on average
Source: Reference (216) and (64)
2.6.2.2.4 Slide storage at microscopy centers (peripheral laboratories) and transfer to
Pham Ngoc Thach laboratory.
After the smear preparation procedure, all smears were put into slide boxes provided
by FIND to prevent exposure to sunlight. After each reading, slides were put back into
the boxes. All positive and negative smears (without marking result on the slide) were
arranged in the boxes in the order of samples arriving to the laboratory according to
LQAS guidelines.
At the end of each calendar month, all slide boxes were transferred to PNT laboratory
for rechecking according to NTP standard operating procedures.
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2.6.2.2.5 Smear rechecking and classification of errors
All smears were blindly rechecked by the microbiological laboratory at PNT hospital.
The blind rechecking methods and numbers of slide to be rechecked depended on
study and phase detailed in chapter 4, section 4.3.1.
Classification of errors (254):
MAlOR ERRORS
Major errors may indicate gross technical deficiencies, and include both High False
Positive and High False Negative errors.
High False Positive: A negative smear that is misread as I+ to 3+ positive.
High False Negative: A 1+ to 3+ positive smear that is misread as negative.
MINOR ERRORS:
Quantification Error: Difference of more than one grade in reading a positive slide
between peripheral laboratory and reference laboratory.
Low False Positive: A negative smear that is misread as a low (1-9AFB/IOOfields)
positive between peripheral laboratory and reference laboratory.
Low False Negative: A low (1-9AFB/IOOfields) positive smear that is misread as
negative.
2.6.2.3 Bactec MGIT culture (Mycobacteria Growth Indicator Tube)
Principle: Mycobacteria are known to grow more rapidly in liquid than solid media
(155). This commercial automated method (Becton Dickinson, New Jersey, USA)
uses Middlebrook 7H9 broth for cultivation of mycobacteria. A fluorescent compound
coats the bottom of each MGIT tube. The fluorescence is quenched by dissolved
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oxygen in the media. Growth of micro-organisms in the tube will consume oxygen
and therefore lessen oxygen concentration, leading to fluorescent emission, which can
be detected by automatically by the MOlT machine or manually by observation under
a UV light. A positive MOlT culture was then used for ZN-smear preparation. The
observation of AFB by smear microscopy was considered confirmed positive MGIT
culture for Mtuberculosis. Speciation of mycobacteria was not done to confirm
M tuberculosis, due to resource limitations.
Procedure: Processed samples were subjected to MOlT culture following the protocol
of Becton Dickinson (13). In brief, O.1ml PANTA, O.5ml OADe and O.5ml of each
processed sample were added into a MOlT culture tube. The mixture was mixed by
inversion by hand and then incubated at 37°C in the MOlT machine. Positive results
were reported automatically by the MGIT system. Any positive MGIT culture was
then subjected to ZN smear to determine acid-fastness, to confirm positive
mycobacterial MGIT culture.
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Figure 2.3 MGIT culture tubes
MGIT culture tubes. From left to right: tube 1 and tube 2: MGIT culture positive, tube 3:
positive control of MGIT culture, tube 4: MGIT culture negative.
2.6.2.4 Lowenstein-Jensen (LJ) culture
Principle: LJ is the most widely used media for tuberculosis culture. It is an egg-
based media and contains glycerol/pyruvate which favors the growth of
Mtuberculosis complexIMOTT, respectively and malachite green which suppresses
the growth of non-mycobacterial organisms. The LJ media is prepared in slants.
Procedure: Two LJ slopes were used for each sample. Two to three drops (O.lml) of
specimen suspension were inoculated on each slope. It is important to spread
suspension evenly over the entire surface of the slope to ensure even distribution of
inoculums. Screw-cap was loosened for incubation. The tube was then incubated at
370C in a slanted position for 24- 48 hours and contamination was checked. After that,
the tube was placed uptight in racks for the remaining incubation time. The culture
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tube was examined weekly for bacterial growth. However, if any mycobacterial
growth was detected within 5 days of incubation, rapidly growing mycobacteria were
suspected. Positive culture of Mtuberculosis is rough, crumbly, waxy, non -
pigmented (cream coloured) and slow-growing. Colonies are detected from 3-5 weeks
after inoculation. If no growth is detected after eight weeks, culture is recorded as
negative. Quantitative results are recorded according WHO guidelines (214). The
reporting ofLJ cultures in this study is a qualitative result, ie.positive or negative.
Figure 2.4 LJ culture tubes
Colonies of Mycobacterium tuberculosis on Lowenstein-Jensen
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Table 2.2 Semi-quantitative result of LJ culture - Recording
Reading Report
No growth Negative
1-19 colonies Positive: Record the number of colonies
20 - 100 colonies Positive: 1+
100 - 200 colonies Positive: 2+
200 - 500 colonies Positive: 3+
>500 colonies Positive: 4+
Contamination Contamination
Note: Report the quantitative positive result based on the average colonies number of two
slopes.
2.6.2.5 Identification test
Identification tests were performed on isolates suspected of being MOTT based on
colony morphology of MODS culture, MOlT culture or LJ culture.
M tuberculosis is identified on the basis of acid-fastness, and 4 biochemical tests:
a. Niacin test
Principle: Niacin (also known as vitamin B3, nicotinic acid and vitamin PP) plays an
important role in the oxidation-reduction reactions that occur during metabolic
processes of all mycobacteria. Some species possess an enzyme that converts free
niacin to niacin ribonucleotide. However, M tuberculosis as well as some other
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species lack this enzyme and accumulate niacin as a water soluble byproduct in the
culture medium Detection of accumulated niacin in egg-based media/liquid media is
useful for identification. Niacin negative M tuberculosis strains are very rare (214)
and very few other mycobacterial species yield positive niacin tests.
Procedure: All cultures or subcultures of mycobacteria at 3-4 weeks in age on egg-
based medium were used for this test. The test was performed with paper strip
provided by BD (BD BBL Taxo TB Niacin Tests Reagents) or Nam Khoa Company
(Nam Khoa TB Niacin Tests Reagents). In brief, 1ml of distilled water was added into
a positive culture slant and make sure it covers the entire surface of the tube in 30
minutes. O.Smlof the broth was then transferred to a sterile screw capped tube and a
niacin paper was placed into the tube. Place the tube with tighten cap in
approximately 30 minutes. The result was interpreted based on color change. If no
color was observed, the negative result was record. If the strip turned yellow, the
positive result was recorded.
Figure 2.5 Niacin reaction
COLOR PLATE 12. Niacin paper strip test.
Source: Reference (40)
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b. Nitrate reductase assay
Principle: M tuberculosis is classified as an obligate aerobe. However, in granulomas
or culture tubes which may limit the availability of oxygen, M tuberculosis enters a
non-replicating persistent state I and state 2 (257). During this state, the reduction of
nitrate to nitrite by the nitrate reductase enzyme encoded by narGHJI (258) occurs.
The nitrate reduction test, which measures the enzyme activity, is used to differentiate
M.tuberculosis from other tubercle bacilli. The conversion of nitrate to nitrite is
detected by nitrate reductase assay. M.tuberculosis exhibits strong nitrate reduction
activity while M.bovis and M.africanum are usually negative. Only 20% of
M africanum and very rare strains ofMbovis give a positive test reaction.
Procedure: All cultures or subcultures of mycobacterium at 3-4 weeks in age on egg-
based medium were used for this test. In brief, 0.2ml of distilled water was added to a
screw-cap tube. After that, 2 loopfuls of colonies were transferred into the tube and
emulsified in distilled water. The tube was then incubated at 37°C for 2 hours after
adding 2ml NaN03 substrate and mixing well. Finally, 1 drop of Hydrochloric acid
solution, 2 drops of Sulfanilamide solution (0.2%) and 2 drops of N-
naphthylethylenediamine solution (0.1%) were added to the tube before reading the
results.
If the pink color developed, a positive reaction was recorded. Otherwise, no nitrite
was detected and a negative result was recorded. In some cases, the reduction has
proceeded beyond nitrite and therefore the test resulted in negative. To determine if it
is a true negative reaction (nitrate was not converted to nitrite), a small amount of
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Zinc powder was added to negative tests. If nitrate is still present it will be reduced by
the zinc powder and color will turn to red (true negative). If no color develops (no
more nitrate present in the tube), nitrate was reduced beyond the nitrite and therefore
the original reaction was positive.
Figure 2.6 Nitrate reductase reaction
+ 1+ 2+ 4+
COLOR PLATE 15. Nitrate color standards.
Source: Reference (40)
c. Inhibition of growth by 500mg/l p-nitrobenzoic acid (PNB)
Principle: Inability to grow on medium containing p-Nitrobenzoic acid - 500mglml
(PNB) is one of the key factors to differentiate M tuberculosis from Mycobacterium
other than tuberculosis (MOTT).
Procedure: All cultures or subcultures of mycobacterium at 3-4 weeks in age on egg-
based medium were used for this test. In brief, bacterial suspension adjusted to
McFarland turbidity standard No.1 was inoculated on to PNB-free LJ medium
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(control) and PNB-containing LJ medium and the slopes were then incubated at 37°C
in 28 days.
If confluent growth was found on both slopes, this isolate was MOTT. If abundant
growth on the control tube but little or no growth on PNB medium, this isolate was
Mtuberculosis complex strain. However, if no growth was detected on either slant,
the test was repeated.
d. Growth in the presence ofthiopen-2-carboxylic acid hydrazine (TCH)
Principle: Mtuberculosis is naturally resistant to Thiophen-2-Carboxylic acid
hydrazide (TCH 2 Ilg/ ml). This test is valuable for differentiation M.tuberculosis
from M bovis.
Procedure: Performance of this test is similar to 1% proportional DST method
2.6.3 Microbiology tests for diagnosis of MDR- TB
2.6.3.1 Indirect drug-susceptibility testing - 1% proportional DST method
Principle: Drug susceptibility testing determines the susceptibility of a microbe to a
certain microbial drug at a specific concentration.
Procedure: Phenotype indirect DST method was done at the Reference TB laboratory
at PNT Hospital, which is accredited for DST by the reference TB laboratory of
Western Pacific region. Drug-free LJ slants (control tubes) and drug-containing LJ
slants (Isoniazid O.21lg/ml, Streptomycin 41lg/ml, Rifampicin 40Ilg/ml and
Ethambutol 21lg/ml) for traditional DST were prepared locally. The All positive LJ
cultures with no less than 4 weeks old were prepared for indirect DST method and
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H37Rv and Mtuberculosis complex strains with well characterised drug susceptibility
profile were used as control strains. In brief, several loops of positive culture were
transferred into a sterile flask containing 8-10 glass beads at Irnm size. It is important
to have representatives of all colony types present in the culture tube. The flask
containing M tuberculosis colonies were vortexed for 30 seconds and then 2-4ml 7H9
Middlebrook were added. The mixture was shaken well to make a suspension. One to
two mls of supernatant from a suspension were transferred to a 16.5 x 128mm sterile
screw-capped tube to adjust for a density of McFarland # 1 (called the P
concentration) with sterile distilled water. A serial dilution of a suspension to the
concentrations of 10-2 and 10-4 was made. Finally, suspensions with diluted
concentrations of P, 10-2 and 10-4 were transferred to drug-free slants and drug-
containing slants for traditional DST. Two hundred microlitres of each diluted
concentration was transferred into two control tubes and drug-containing tubes. All of
these tubes were placed in a slanted position with slightly loosened screw caps and
incubated at 37°C for 24 - 48 hours. After that, all screw caps were tightened and all
tubes were placed upright. They were continuously incubated at 37°C until checking.
The DST results were read on the 28th day and the 42nd day after inoculation.
Resistance was determined based on the percentage of colonies observed on drug-
containing slants over the number of colonies observed on control slants. If the
percentage of resistance was less than I%, the strain was recorded as a susceptible
strain; otherwise it was recorded as a resistant strain. The DST was repeated when the
colony count in the control tube was less than 200 or the percentage of resistance
organisms appeared to approach 1%, by subjective assessment.
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2.6.3.2 MODS for diagnosis ofMDR-TB
Principle: The principle of drug susceptibility by MODS is similar to MODS culture.
However, this procedure includes drug-free wells (control wells) and wells containing
the drug of interest. The results of drug-containing wells are read on the same day that
the drug-free control well becomes positive. If cording growth is observed in the
control wells but not in the drug-containing well, a susceptible isolate is deemed to be
present in this sample. If cording growth is observed in both the control wells and the
drug-containing wells, a resistant isolate is present in the investigated sample.
Procedure: For each processed sample, 2 drug-free wells (control wells), I INH
containing well and 1 RIF containing well were set up. In brief, the MODS media was
prepared with 5.9g middle brook 7H9 broth (Difco, Sparks, MD), 3.1ml glycerol and
1.25g batocasitione (Difco, USA) in 880ml distilled water. This media was
autoclaved, filtered and stored in 4.5ml tubes at 4°C. Each new batch was tested for
sterility by incubating one aliquot at 37°C for 1 week. Before use, O.Sml OADe,
O.5ml processed samples and 100j.l1PANTA antibiotic were added into each 4.Sml
tube to have a working MODS media. 900111of the working MODS media was then
transferred to each of four wells in a 48 well-plate as described above. Next, 100j.l1
distilled water was added into the control wells. Finally, 100j.l1INH 4ug/ml (Sigma)
or 100j.l1 RIF IOpg/ml (Sigma) was added to the INH-containing well and RIF-
containing well, respectively. The final concentrations of OADC and PANT A in each
well were 10% and 20j.ll/ml, respectively. The drug concentrations in each well were
O.4j.lg/ml for INH and l ug/ml for RIF. Daily, one susceptible clinical isolate
(H37Rv), one INH- resistant clinical isolate and one RIF-resistant clinical isolate were
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used as the control. A suspension of each isolate was made and its turbidity was
measured against Me Farland 0.5 (approximately 104CFU/mi - Pasteur Insitute,
HCMC standard). After that, a 100 fold dilution (102 CFU/ml) was used.
The plate was incubated at 37°C, and the results were recorded on alternate days from
day 5 to day 15 and twice a week from day 16 to 1 month. If there was any cord
formation in both control wells, the drug containing wells were read. If cords were
detected in only one control well, MODS-DST was recorded as uninterpretable for
technical analysis. Any growth in the control and drug-containing wells was recorded
as resistant. If growth was observed in control wells but not in the drug-containing
wells, a susceptible result was recorded.
2.6.4 Subculture
Procedure: All positive cultures were subcultured on LJ media (Becton Dickinson) in
duplicate for further investigation and incubated at 37°C for several weeks. These
isolates were then used for standard biochemical identification tests, indirect
susceptibility testing, DNA extraction and archiving.
2.6.5 Archiving
Procedure: Positive-LJ subculture was archived in 7H9 media supplemented with
20% glycerol (7H9A). One or two loops of isolates collected from LJ subculture
were transferred into a cryotube containing 7H9A medium. These tubes were stored at
-20°C for archiving.
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2.6.6 Molecular tests
2.6.6.1 DNA extraction
Procedure: DNA extraction was carried out for all positive cultures using the CTAB
method (210). Mycobacteria were harvested from Lowenstein-Jensen slopes, placed
into 400lli of IX Tris-HCl EDTA (TE), and incubated at 80°C for 20 minutes to kill
the mycobacteria. After that, 50III of IOmg/ml lysozyme was added and the tube was
incubated at 37°C overnight. Next, 75111 of IO%SDS/proteinase K solution was added
and the tube was incubated at 55°C in 30 minutes. Then, IOOlll of5M NaCl and IOOlll
of prewarmed CTABlNaCI solution (N-cetyl-N,N,N,-trimethylammoniumbromide
and NaCI) were added and the tube was vortexed until opaque and incubated at 65°C
for 15 minutes. DNA was extracted by the standard ethanol-chloroform extraction
method. Seven hundred and fifty microlitres (7S01ll) of chloroform/isoamyl alcohol
(24:1) was added to the tube and vortexed for 10 seconds, centrifuged at II,OOOg for 8
minutes. The supernatant (aqueous phase) was transferred to a microcentrifuge tube
and 0.6 volume of isopropanol was added. The mixture was incubated on ice for 10
minutes and centrifuged at room temperature for 15 minutes. After discarding the
supernatant, the pellet was washed with 70% ethanol and centrifuged at room
temperature for 5 minutes. The pellet was dried at room temperature and dissolved in
20111of IX TE buffer. The DNA was stored at 4°C for further use.
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2.6.6.2 peR for detection of mutations
a. Multiplex allele specific polymerase chain reaction (MAS-peR) for detection of
RIF resistance mutations.
This technique was performed following the method developed by Tho et al (190).
Three separate peR reactions were performed with the same outer primers (Proligo,
Singapore) to amplify the 350bp fragment of rifampicin resistance determining region
(RRDR) of rpoB gene, and one of three inner primers (Proligo, Singapore) targeted to
wild type at hot spot codons 516, 526 and 531. The RRDR region was detected in all
isolates, both wild type and rifampicin resistant isolates. Amplification of the second
band occurred only in wild-type isolates with no mutation at the site targeted by the
inner primer. Each peR reaction contained 0.75 U Taq DNA polymerase (Bioline,
Taunton, MA, USA), 0.2 mM of each dNTP (Roche, Basel, Switzerland), 125-400
nM of primers and 2 mM Mgel2. Fifteen nanograms of genomic DNA was added. All
of the reactions were amplified under the same thermo cycling programme: 95°C for 1
min, followed by 35 cycles of 95°e for 10 s, 68°C for 20 s, 72°C for 20 s and a final
step of 72°e for 5 min. A negative control (water) and a positive control for each of
the three target codons were included with each batch processed. PCR products were
analyzed by electrophoresis on 1% agarose gel at 150V for 30 minutes.
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Figure 2.7 MAS-peR for detection ofRIF resistance mutations in the rpoB gene
Amplicon profiles in MAS-PCR of isolates carrying mutations at each site.
* a, codon516; b, codon 526; c, codon 531.
Samples 1:mutation at codon 516.
Sample 2: mutation at codon 526.
Sample 3: mutation at codon 531.
Sample 4: codon 516 and 526 mutated.
Sample 5: wild type control sample.
Sample 6: negative control.
M = 100 bp ladder; MAS-PCR = multiplex allele specific polymerase chain reaction;bp=
base pair.
b. MAS-PCR for detection of INH resistance mutations (191): Three primer sets
(Proligo, Singapore) were used for multiplex PCR and sequencing. The first primer
set targets Hsp65 (HSP65FI and HSP65RI) which is specific for Mtuberculosis and
serves as control. The second primer pair targets the inhA promoter region (TB92 and
inhARmut), with the reverse primers designed to detect mutation e-15T in this
region. The third primer set (katg2F andP6) is located inside the katG gene where the
forward primer will yield a peR product if the isolate is wild type. Each peR reaction
contained buffer IX, IU Taq DNA polymerase (Bioline, Taunton, MA, USA), O.2mM
of each dNTP (Roche, Basel, Switzerland), O.ISIlM - O.3IlM of each primer and 2mM
Mgeh.
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Fifteen nanograms of genomic DNA were added. All of the reactions were amplified
under the same thermo cycling programme: 95°C for 2 min, followed by 10 cycles of
950C for 20 s, 62°C for 1 min, 72°C for 20 s, then 25 cycles of 95°C for 20 s, 62°C
for 20 s, 72°C for 40 s and a final step of 72°C for 5 min. A negative control (water)
and a positive control for each of the three target codons were included with each
batch processed. PCR products were analysed by electrophoresis on 1% agarose gel at
120V for 40 min.
2.6.6.3 Spoligotyping
Principle: This method is based on DNA polymorphism present at a certain
chromosomal locus, the "Direct Repeat" (DR) region, which is uniquely present in
Mycobacterium tuberculosis complex bacteria (104). In Mtuberculosis complex, the
DR region consists of repeated sequences of 36 base pairs, which are interrupted by
DNA spacers with each containing 35 to 41 base pairs in length. Forty-three spacers
of known sequence, in total, were investigated in the DR region. Spoligotyping
method is used to determine the presence or absence of 43 spacers by hybridization of
PCR-amplified spacer DNA to a set of immobilized oligonucleotides, representing
each of the unique spacer DNA sequences.
Procedure:
Spoligotyping was done according to the standard international Spoligotyping
protocol (103, 104).
a. Chromosomal DNA extraction: See section 2.6.6.1
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h. Amplification of spacer DNA by PCR (104)
Since spacers are interspersed in the DR region, it is important to amplify the whole
DR region by the primers DRa (5'-GGT TIT OGG TCT GAC GAC- 3', biotinylated
at 5' end) and DRb (5'-CCG AGA OGO GAC GGA AAC-3') to amplify copies of
spacers. The PCR reaction contained 20ng template DNA, 4111 primer DRa (20pmol-
biotinylated) (Ocimum Biosolutions, Hyderabad, India), 4111primer DRb (20pmol)
(Ocimum Biosolutions,), 4111dNTP mixture (2.SmM each dNTP)(Roche, Ho Chi
Minh City, Vietnam), Sill concentrated Super Tth buffer (IOX)(Bioline, London, UK),
0.11l1Super Tth polymerase (5U/IlI) (Bioline) and MQ water. The final volume of a
PCR tube was 50Ill.
c. Hybridization with PCR product and detection (104)
Biotin-labeled PCR products were hybridized with membrane bound immobilized
spacer-oligos (Ocimum Biosolutions). After incubation with streptavidin-peroxidase
(Roche) and ECL detection (Enhanced Chemo-Luminescence Detection solution) (OE
Healthcare, London, UK), the presence of spacer on film (GE Healthcare) is
visualized as black squares.
d. Result interpretation (104)
The presence of each spacer is indicated by the presence of black squares on the film;
if the spacer is absent from the strain, the relevant square remains blank. The result is
recorded as a binary readout indicating the presence (represented as 1) or absence
(represented as 0) of the 43 spacers in sequence. This 43-digit binary number can be
presented in a shorter format called the octal code, in which a 3-continuous-digit
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binary number can be converted to a single digit octal number. These formats
facilitate inter-laboraory comparison of genotypes (54). A shared-type (ST number) is
described as a spoligotyping pattern common to at least two isolates. There are 1939
shared-types described in the fourth international spoligotyping database (25).
Figure 2.S Spoligotyping
space'r oUgas
A typical spo/igotyping result of Mtuberculosis H37Rv, M bovis BCG P3 and 38 different
clinical isolates. A membrane with 43 spacer oligonucleotides was used (vertical lines).
Source: Reference (104)
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2.7 DEFINITION AND TB CLASSIFICATIONFOR THE MODS STUDIES
2.7.1 Pulmonary tuberculosis
The definition of pulmonary TB was based on microbiological confirmation by either
smear or MGIT, intention to treat, treatment management and outcome.
Tuberculosis was defined as "confirmed TB' if the patient had clinical symptoms
consistent with TB (221, 225) and either smear or MGIT was positive in any sample,
including samples which were collected before the enrollment started. These samples
were not included in the sensitivity comparison but patients with prior samples
positive in this illness episode by either smear or MGIT were classified in the
"confirmed TB" group. A positive MODS culture was not considered as part of the
definition of 'confirmed TB' because this was the test under evaluation.
The patient was defined as "probable TB" on 'intention to treat' if the patient had
clinical symptoms consistent with TB (221, 225) but had no microbiological
confirmation, received no alternative diagnosis and initiated TB treatment and
transferred to a District Tuberculosis Unit for treatment and follow-up. Patients who
satisfied the first two characteristics of "probable TB" but self-discharged prior to
treatment were also classified in this group if the clinician intended to treat for TB. It
was impossible to either rule-out or confirm TB in this group due to the lack of
microbiological confirmation.
Patients were defined as "TB unlikely" if they recovered without TB treatment, had
TB treatment but deteriorated or received an alternative diagnosis and treatment. It
was impossible to 'rule-out' TB in these patients completely because clinical
Chapter 2 - Materials and Methods Page 124
deterioration on therapy may have been due to undetected drug-resistant TB.HIV
screening is not a routine test for patients at PNT Hospital. HIV counseling and
testing was offered if HIV was clinically suspected by the treating clinician, according
to routine guidelines.
2.7.2 Tuberculous meningitis
The definition of TBM was based on microbiological confirmation by either smear or
MGIT, intention to treat, treatment management and outcome.
> "Confirmed TBM" was defined as: patients with clinical symptoms consistent with
TBM and either smear or MGIT positive from CSF collected in the study only. A
positive MODS culture was not considered as part of the definition of 'confirmed
TBM' because this was the test under evaluation.
> "Probable TBM" was defined as patients with clinical symptoms consistent with
TBM but: no microbiological confirmation by either smear or MGIT for CSF samples
collected in the study and at least one of the following characteristics, AFB found in
samples other than CSF which were collected before or after enrollment, or
radiological symptoms suspected of tuberculosis on chest X-ray or CTIMRI. In
addition, these patients had received no alternative diagnosis, initiated TB treatment
and were transferred to a District Tuberculosis Unit (DTU) for treatment and follow-
up. Patients who satisfied the above characteristics of "probable TB" but self-
discharged prior to treatment were also classified in this group if the clinician
intended to treat for TBM.
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> "Possible TBM" on intention to treat was defined as patients with a clinical
presentation suspected of TBM and satisfying at least 4 of the following
characteristics: TB history, more than 5 days of illness, increased CSF lymphocyte,
CSF blood/glucose ratio <0.5, altered consciousness, focal neurological signs or PCR
positive on any CSF sample collected before the study. Patients who satisfied the
above characteristics of "possible TBM" but self-discharged prior to treatment were
also classified in this group if the clinician intended to treat for TB.
> "Not TBM" was defined as patients who did not fulfill the characteristics of the above
groups, recovered without TB treatment or received an alternative diagnosis. This
group also included patients receiving TB treatment before an alternative diagnosis
was confirmed.
2.8 STATISTICS
The statistics of the MODS and iLED studies were performed under the supervision
of Dr. Marcel Wolbers, Head of Bioinformatics, ODCRD.
2.8.1 The MODS study
The MODS study at Hospital for Tropical Diseases (Evaluation of MODS in TBM
diagnosis - pilot phase)
The sensitivity, specificity, positive predictive value and negative predictive value for
MODS were determined and compared for homogenous ZN smear and MOlT and LJ
culture by Mc.Nemar's test for patient analysis and Marginal regression model for
sample analysis, using clinical diagnosis (instigation of anti-tuberculous
chemotherapy) as the gold standard. Time to positive result for the three culture
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methods was compared using Wilcoxon signed rank test. Samples were excluded
where patient medical records were not available for analysis.
The MODS study at Pham Ngoc Thach Hospital (Evaluation of MODS in
diagnosis of TBM - implementation phase, paediatric TB, HIVITB and MDR-TB)
In the "per patient" analysis, reported confidence intervals for accuracy measures
(sensitivities, specificities, positive and negative predictive values) were calculated
according to the method of Pearson and Clopper (153). Comparisons of accuracies
between tests were done using Mc.Nemar's test.
In the 'per sample' analysis, a binary marginal generalized linear regression (GLM)
models with an identity link function was used for all analyses. These models are very
flexible, allow for the inclusion of covariates and account for the fact that results of
multiple samples from the same patient or test results of different tests on the same
sample may be dependent (153). Specifically, marginal regression model was used to
calculate confidence intervals for accuracy measures, to compare the sensitivities of
smear, MGIT, and MODS and to assess the impact of the duration ofTB treatment on
the sensitivity of MODS.
For the 'per sample' analysis, time-dependent sensitivity curves for MGIT and MODS
were also calculated. A test result was considered as positive by time t if the
respective test was positive overall and reached the positive value at most t days after
sample collection. Time-dependent sensitivity curves were estimated with the Kaplan-
Meier method and samples without a positive test result were formally regarded as
censored on day "infinity". Time-dependent sensitivities of MOlT and MODS by
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days 7 and 14, respectively, were compared using a marginal regression model as
described above. In addition, the time to positive MGIT and MODS, respectively, was
compared in samples were both tests reached positivity with the Cox proportional
hazards regression model.
Comparison of demographic and clinical features of patients between TB diagnoses
(definite, probable, possible or unlikely) was done with Fisher's exact test for
categorical data and the Kruskal-Wallis test for continuous data.
2.8.2 The iLED study
Reported confidence intervals for detection rates, sensitivity, specificity, false positive
and false negative rates were calculated according to the method of Pearson and
Clopper. Comparisons of these measurements between different time points were
done using Fisher'S exact test.
The time to result of ZN-iLED and FM-iLED 40X were compared by using the
Wilcoxon Rank-sum test
For both studies, all reported confidence intervals are two-sided 95% confidence
intervals and p-values ~O.OS were regarded as statistically significant. All analyses
and graphs were performed with Stata version 9 (Statacorp, Texas, USA).
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Chapter 3
EVALUATION OF MODS
3.1 Section 1.
MODS INTRODUCTION
Microscopic Observation Drug Susceptibility Assay (MODS) is a non-commercial
direct liquid based culture method, developed by a group of scientists in Peru for early
detection of MDR- TB isolates (33). In this test, processed sample is inoculated into a
48-well plate containing 7H9 media with and without drug and then incubated at 37°C
for at least 5 days. The principle of the test is to observe the presence or absence of
serpentine cording in wells containing mycobacteria. It is a rapid, low cost and
adaptable method in comparison to LJ and MGIT cultures. Based on this principle,
MODS has been evaluated for early detection of TB. Previous studies have shown it
sensitive, specific, economical and easy to perform for early diagnosis of TB and
MDR-TB in adults and children in high burden countries (20, 33, 132, 133, 144). A
systematic review showed that the pooled sensitivity and specificity of MODS were
98% and 99.4%, respectively for detection of rifampicin resistance and 97.7% and
95.8%, respectively for detection of isoniazid resistance (124). In 2009, MODS has
been endorsed by WHO for rapid screening of patients suspected of MDR- TB in high
burden countries as an "interim" solution (238). Equipment requirements are minimal
with a level I Biological Safety Cabinet and an inverted microscope required, making
it ideal for use in high TB burden settings.
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In this thesis, MODS is evaluated in chapters 3.2,3.3,3.4 and 3.5 for the diagnosis
of TB in 3 patient groups, which are difficult to confirm by smear microscopy due to
paucibacillary specimens: tuberculous meningitis, peadiatric TB, HIV associated TB;
and also for MDR-TB identification.
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3.2 Section 2.
MODS IN DIAGNOSIS OF TUBERCULOUS MENINGITIS
3.2.1 INTRODUCTION
Tuberculosis meningitis (TBM) is the most severe form of tuberculosis disease caused
by Mycobacterium tuberculosis. TBM causes death or severe long-term disability in
as many as two thirds of treated TBM patients (197). Early diagnosis and appropriate
TB treatment regimen improves treatment outcomes and reduces neurological
sequelae in survivors.
Three options are currently available for the rapid diagnosis of TBM: diagnostic
algorithms, nucleic acid amplification tests (NAAT) and microbiological tests (smear,
culture). Diagnostic algorithms based on simple clinical and laboratory features can
be sensitive and specific (196) but require further evaluation, especially in HIV-
infected patients and children and may not be generalisable outside the setting in
which they are developed since the spectrum of differential diagnoses will vary.
Nucleic acid amplification techniques require highly trained technicians, capital
equipment purchase and maintenance, specialized consumable supply chains,
alongside rigorous quality control to guard against contamination. Rapid commercial
NAAT tests are relatively expensive and are not more sensitive than smear
microscopy (149, 194). Therefore, microbiological tests are commonly used for TB
diagnosis, especially in resource-limited high burden countries. Among
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microbiological tests, smear microscopy is widely used because of its simplicity,
reproducibility, speed, low cost, high specificity, and the theoretical ability to delimit
contagiousness if a standardised protocol of smear preparation is followed strictly.
However, sensitivity of smear microscopy is rather low; detecting approximately 50%
of active pulmonary TB cases and largely varies depending on bacterial load of
clinical samples.
Microbiological diagnosis is more challenging in TBM cases because of the low
number of bacilli in cerebrospinal fluid (CSF) samples. Larger CSF volumes (>6mls)
and meticulous examination of slides (at least 30 minutes) increases the sensitivity of
CSF smear up to 60% (98, 195). However, large volumes of CSF are rarely submitted
to the laboratory, particularly from paediatric patients. In addition, it is often not
feasible to devote enough time to examine a single slide in high-throughput routine
laboratories. Although culture methods gain higher sensitivity than smear microscopy,
the prolonged time to positive (about two weeks for liquid culture and approximately
one month for solid culture) and high cost has limited their use in low income
countries. Therefore, early diagnosis of TBM remains a challenging problem.
Direct susceptibility testing from CSF samples is unlikely to yield high sensitivity due
to low numbers of bacilli in the specimens. Furthermore, it is often seen that CSF
samples divided and tested by more than one method can be positive by one method
but negative by another; this is thought to be due to the clumping of bacilli in aliquots
of a sample (194). In the case of smear positive/culture negative samples, the smear
technique may be detecting dead bacilli present in the sample, especially in patients
already on TB therapy. In these cases, the patient will have shown clinical
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improvement however the inability to differentiate viable bacilli remains a limitation
of smear microscopy familiar to TB clinicians. Low bacterial load and clumping of
bacilli are likely to lead to many uninterpretable and false negative results in direct
susceptibility testing. This study has therefore evaluated MODS as a technique for
rapid identification of Mtuberculosis in the CSF in comparison with smear, MGIT
and LJ culture against a clinical gold standard.
3.2.2 METHOS
3.2.2.1 Enrollment
3.2.2.1.1 The pilot phase
Routine diagnostic CSF samples were collected from consecutive patients (age ~18
years) with clinically suspected TBM presenting to HTD during the study period. All
newly presenting patients were enrolled into this phase. Patients on TB treatment for
at least one day were excluded from analysis. All patients were tested for antibodies
to human immunodeficiency virus (HIV) as part of routine care at HTD. In some
cases, more than one CSF was collected for diagnosis, as deemed appropriate by the
treating physician. All samples included in this phase were taken as part of routine
clinical care and the study did not involve any change to routine patient care and
therefore specific informed consent was not sought for the laboratory evaluation. This
is consistent with Oxtrec guidelines for patient consent waiver. In addition to routine
biochemistry tests, all CSF samples were also examined by Gram-stain, and culture
on blood, chocolate and sabouraud dextrose agar, to exclude bacterial meningitis and
India ink stain to exclude cryptococcal meningitis.
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This phase collected laboratory data and clinical diagnosis of enrolled patients.
3.2.2.1.2 The implementation phase
The implementation phase was conducted at PNT hospital. All eligible patients
(chapter 2, section 2.4) presenting at the PNT hospital were enrolled into the study.
Data on socioeconomic and demographic features, TB history, TB contact history,
HIV status and presenting clinical features were prospectively collected on a standard
case report form. HIV screening test is not routine at PNT hospital and is usually only
performed if clinical suspicion of HIV is high. As for the pilot study, one routine
diagnostic CSF sample was collected as per routine care as deemed appropriate by the
treating physician and no additional samples were collected as part of this study.
3.2.2.2 Definition of TBM classification
The definition of TBM classification is described in chapter 2, section 2.7
3.2.2.3 Sample collection, sample processing and tests
The sample collection, sample processing and tests are described in materials and
methods (chapter 2, section 2.S and section 2.6)
The volume of CSF deposit used was different in the pilot and implementation phases.
IOO~1 deposit of CSF was used for the pilot phase according to Park et al (151) and
2S0~1 was used for the implementation phase. The CSF volume was increased in the
implementation phase in an effort to increase the detection rate of the MODS
technique because the detection rate has been shown to be related to CSF volume
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(195) and the sensitivity of MODS in the pilot phase was slightly lower than MGIT
with one difference between the techniques being the volume of innoculum. For
paucibacillary samples, such as CSF, larger sample volumes have a higher probability
of containing sufficient viable bacilli for detection.
Spoligotyping was done in the implementation phase for all cultures positive by
MODS (n=37). CSF samples processed on the same day and inoculated on the same
MODS plate were investigated for probable cross-contamination.
3.2.3 STATISTICAL METHODS
The statistical methods were described in chapter 2, section 2.8
In both the pilot and implementation phases of this study, the detection rates of
MODS were also evaluated stratified by the HIV status of the patient.
Of note, in the implementation phase (study at PNT hospital), there were only 8/165
patients classified in the "Not TBM" group which is a small proportion of the study
population. This was due to the fact that PNT hospital is a referral centre and patients
being evaluated by lumbar puncture for TBM had a high clinical index of suspicion. It
was possible to 'rule-out' TBM in only a small number of patients in whom another
diagnosis was confirmed or who recovered without TB therapy. As we did not have a
sufficient number in the 'non-TBM' population to make a valid comparison, the
accuracy of smear, MGIT and MODS were compared in the "definite TBM" group
and the "clinical diagnosis" group (definite, probable or possible TBM).
Chapter 3 - Section 2 - TBM-MODS Page 135
3.2.4 RESULTS
3.2.4.1 The pilot phase (at Hospital for Tropical Diseases)
3.2.4.1.1 Enrollment and TBM classification
177 TBM suspects were enrolled into this phase. There were 6 patients for whom
clinical data was not available and 7 patients with an unclear diagnosis, usually due to
early self-discharge, who were excluded from the analysis. Finally, data of 137 newly
presenting patients and 27 patients (61 CSF samples) who were on TB treatment at
least one day were analysed separately (figure 3.1).
All CSF samples were sent to the OUCRU laboratory immediately or stored in the
fridge until processing. The median (IQR) CSF volume of newly presenting patients
and follow-up patients were 4ml (3-5ml) and 3ml (24ml), respectively. The
characteristics of CSF samples from newly presenting patients are described in table
3.6
Among 137 newly presenting patients, 41.6% (n=57/137) patients were deemed to
have TBM by clinical diagnosis, of which, 78.9% (n=45157) were classified as
definite TBM, 3.50% (n=2/57) as probable TBM and 17.56% (n=10/57) as possible
TBM. The remaining newly presenting patients (58.4%, n=80/137) were in "not
TBM" group.
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Figure 3.1 Study flow chart of MODS evaluation for TBM diagnosis - the pilot
phase atHTD
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Seventy-nine percent (n=108/137) of the newly presenting patients were male with a
median age of 30 years. All newly TBM suspects were screened for HIV infection
and 64.2% (n=88/137) were HIV-infected.
3.2.4.1.2 Accuracy of MODS in newly presenting patients
By patient analysis
Forty-five newly presenting patients with CSF samples positive by either smear,
MGIT or LJ were classified in the "definite TB" group. This definition includes only
those patients who had microbiological confirmation of TBM by a reference method
and is the most specific but least sensitive gold standard definition for TBM. The
sensitivity, specificity, positive predictive value (PPV), and negative predictive value
(NPV) of MODS were 77.79% (n=35/45, 95%CI: [62.9, 88.8]), 97.83% (n=90/92,
95%CI: [92.4, 99.7]), 94.59% (n=35/37, 95%CI:[81.8, 99.3]) and 90.0% (=90/100,
95%CI:[82.4, 95.0]), respectively.
Clinical gold standard was defined as all patients who satisfied the definition of
"Definite TBM", "Probable TBM" or "Possible TBM". It is likely that this definition
includes some patients who did not have true TBM, but in whom it is impossible to
exclude TBM. This is the most sensitive but least specific gold standard measure for
defining TBM patients. In 'by patient' analysis, the sensitivity of MODS was 64.9%
against clinical gold standard. The specificity and PPV of smear, MODS, MGIT and
LJ were 100%. The sensitivity and NPV of all four methods are described in table
3.1. No significant difference was observed between methods. The sensitivity of
MODS against smear, MGIT and LJ culture as the gold standard were 90.0%
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(n=27/30, 95%CI:[79.2, 100]), 82.5% (n=33/40, 95%CI:[65.2, 92.7]) and 77.5%
(n=31140, 95%CI:[61.5, 89.2]), respectively.
Table 3.1 Sensitivity and negative predictive value of smear, MODS, MGIT and
LJ against clinical gold standard in the pilot study of MODS evaluation for TBM
diagnosis.
Smear MODS MGIT LT
Sensitivity Pl=0.49 P2=0.79 P3=1.00 P4=0.34
0/0 52.6 64.9 70.2 70.2
n=xJy 30/57 37/57 40/57 40/57
95%CI [40.1,65.9] [52.7, 77.3] [58.0, 82.0] [58.0, 82.0]
Negative predictive value Pl=0.74 P2=0.88 P3=0.69 P4=0.64
% 74.8 80 82.5 82.47
n=xJy 801107 80/100 80/97 80/97
95%CI [65.4, 82.6] [70.8,87.33] [73.4, 89.4] [73.4,89.4]
Summary measure is n (DA)for these two measurements.
P values (by Mc.Nemar's test) were used for comparison of all four methods.
PI: for comparison between Smear and MODS.
P2: for between MODS and MOlT.
P3:for between MOlT and U.
P4:for between U and Smear.
Chapter 3 - Section 2 - TBM-MODS Page 139
By sample analysis
Data from ISO CSF samples collected from 137 newly presenting patients were
available for analysis. The sensitivity of MODS against clinical gold standard was
6S.1% (n=41/63, 9S%CI:[S3.2, 76.8]), which was comparable to smear (S2.4%,
n=33/63, 9S%CI:[39.7, 64.3], P=O.4),MGIT (73.0%, n=46/63, ·9S%CI:[62.0, 84.0],
P=0.6) and LJ (68.3%, n=43/63, 9S%CI:[S6.4, 76.6]). The specificity and PPV of all
four methods was 100%. The NPV of smear, MODS, MGIT and LJ was 74.4%
(n=87/117), 79.8% (n=87/109), 83.7% (n=87/104) and 81.3% (n=87/107),
respectively.
The agreements between MODS and MGIT, MODS and LJ and LJ and MGIT were
91.33% (kappa=0.789), 89.33% (kappa=0.73S) and 90.0% (kappa=0.760),
respectively.
By HIV status
Eighty-eight newly presenting patients were HIV infected, 40 of whom (45.45%,
n=40/88) were clinically diagnosed with TBM. Although MODS, MOlT and LJ
detected more positive samples or patients in the HIV- infected group than the HIV
un-infected group, the difference did not reach statistical significance (table 3.2). The
specificity of MODS, MOlT and LJ were 100% in both groups. Details of sensitivity
of all 3 culture methods in relation to HIV status are shown in table 3.2
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Table 3.2 Sensitivity of MODS, MGIT and LJ against clinical gold standard,
stratified by HIV status, in the pilot study of MODS evaluation for TBM
diagnosis.
By patient analysis By sample analysis
P value! P value'
Sensitivity HIV (+) HIV(-) HIV (+) HIV(-)[95% Cl] 95% Cl
MODS culture
% 67.5 58.8 0.82 68.9 55.6 0.82
n=xfy (27/40) (10/17) [-0.18,0.24] (31J4S) (10118)
[-0.15,0.25]
9S%CI [53.5, 82.5] [35.7,82.3] [55.5, 82.5] [42.7,69.3]
MGIT culture
0/0 75.0 58.8 0.65 77.8 61.1 0.66
n=x/y (30/40) (10/17) [-0.15, 0.27] (35/45)
(11/18) [-0.14, 0.26]
95%CI [58.8, 87.3] [32.9, 81.5] [62.9, 88.8]
[35.7, 82.7]
LJ culture
% 72.5 64.7 0.82 71.1 61.1
0.82
n...x/y (29/40) (11117) [-0.18, 0.241 (32/45) (11118) [-0.17,0.24]
95%CI [56.1,85.4] [38.3, 85.8] [55.7,83.6]
[35,1,82.7]
Summary measure is n (%) jar these three methods
Time to positive
Time to positive or turnaround time was defined as the duration of time from sample
inoculation to the presence of evidence of M tuberculosis growth determined by each
method. The time to positive of MODS was 6 days (IQR: 5 -7days), which was faster
than MGlT (15days, IQR: 13-24 days, P«O.OOl) and LJ (24 days, lQR: 18-35 days,
1 P values were calculated by Mc.Nemar's test
2 P values were calculated by Marginal regression model
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P<O.OOI). Interestingly, 90% (n=37/41) of the samples positive by MODS had a result
available in 10 days after inoculation while this was true of only 10% (n=5/46) for
MGIT.
3.2.4.1.3 Accuracy of MODS in diagnosis of "TBM patients already on TB
treatment"
Of 61 CSF samples from 27 patients on TBM therapy for between 2 days and 9
months, 16 samples were positive by one of the four methods. The detection rate of
MODS, smear, MGIT and LJ were 11.5% (n=7/61), 13.1% (n=8/61), 16.4%
(n=10/61) and 14.8% (n=9/61), respectively.
The median time from starting TB treatment to sampling date was 28 days (7 - 56
days). The turnaround time of MODS, MGIT and LJ were 8 days (7-10 days), 15 days
(14-17 days) and 21 days (21-23 days), respectively. In samples positive by both
MODS and MGIT, MODS was faster than MGIT (P=0.04).
3.2.4.1.4 Diagnosis of patients without TBM diagnosis
Among 80 patients not diagnosed with TBM, 35 had a final diagnosis of fungal
meningitis, 3 viral meningitis, 16 bacterial meningitis, 3 toxoplasmosis, 2 herpes
Simplex encephalitis, 7 viral encephalitis, 3 eosinophilic meningitis, 4 meningo
encephalitis, 6 meningitis of indeterminate cause and 1 alcohol poisoning.
3.2.4.2 The implementation phase (at Pham Ngoc Thach hospital)
3.2.4.2.1 Enrollment and TBM classification
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165 newly TB suspects were screened for TBM and all of them were eligible for the
analysis (Figure 3.2). Of these, 30.9% (n=511165)were classified as definite TBM,
39.4% (n=65/165) were probable TBM, 24.8% (n=411165)were possible TBM and
4.9% (n=8/165) were in "not TBM" group. The probable group included 8 patients
with positive sputum smears on samples collected before or during the study period
and the possible group included 1 patient with peR on eSF positive for tuberculosis
done at PNT hospital. The validity of the peR was not established and therefore the
patient was classified as 'possible'.
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Figure 3.2 Flowchart of patient recruitment in the implementation phase of
MODS evaluation for TBM diagnosis at PNT hospital.
165 TBM suspects
51 patients
Definite TBM
65 patients 41 patients 8 patients
Probable TBM Possible TBM NotTBM
,
49 patients 02 patients
TB treatment No TB treatment
(Death/unknown) 02 patients
39 patients No TB treatment
TB treatment (unchanged/home
to clie)
l 1
63 patients 02 patients
TB treatment No TB treatment
(FlU atDTU)
4 patients
TB treatment +-(cryptomeningitis/treated bacterial meningitis)
04 patients
No TB treatment I+-
(FlU at DTU/recoveredlcrypto or bacterial meningitis)
Patients were grouped based on micro-confirmation (Smear or MGIT), TB treatment and
outcome.
TBM' Tuberculous meningitis
FlU Follow-up
DTU: District Tuberculosis Unit
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3.2.4.2.2 Demographics and clinical features
Eighty percent (n=132/165) of the study population was male with a median age of
35. Over 53% (n=88/165) patients had evidence of BCG vaccination determined by
BCG scar. HIV testing was conducted for 73% (n=121/165) of patients. Forty-six
percent (46%, n=76/165) of patients in this study had a positive HIV test. Almost
thirty percent (n=29/165) of patients had previously been diagnosed with TB once in
their medical history. Table 3.3 shows demographic characteristics of the study
population and comparisons of the four final diagnostic groups. Table 3.4 shows
clinical features of all 165 TBM suspects. Among 24 patients who underwent a
computed tomography (CT) scan for TBM diagnosis, 62.5% (n=lS/24) had
radiological signs suspected of TBM. Table 3.5 describes radiological symptoms of
all patients in the study stratified by final diagnostic group for comparison.
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Table 3.3 Demographic characteristics of patients recruited in the
implementation phase of MODS evaluation for TBM diagnosis at PNT hospital.
Characteristic Total Definite Probable Possible NotTBM
population . TBM TBM TBM
N=165 N=51 N=65 N=41 N=8
Gender P=0.53
Male 132 (80.0) 44 (86.3) 51 (78.5) 31 (75.6) 6 (75,0)
Age P=O.O] 83
Median (year) 35 31 40 35 31.5
(IQR) (27 - 50) (27-41) (32 - 59) (24 - 49) (28 - 43)
BCG P=0.77
vaccination(')
Yes 88 (53.3) 31 (60.8) 35 (53.9) 19 (46.3) 3 (37.5)
No SO (30.3) 13 (25.5) 19(29.2) 15(36.6) 3 (37.5)
Unknown 27 (16.4) 7 (13.7) 11 (16.9) 7(17.1) 2 (25.0)
TB history P=0.98
Yes 29 (17.6) 9 (17.7) 11 (16.9) 8(19.5) 1 (12.5)
No 132 (80.0) 40 (78.4) 53 (81.5) 32 (78.1) 7 (87.5)
Unknown 4 (2.4) 2 (3.9) 1 (1.5) 1 (2.4) 0(0.0)
HIV testing P::::O.O rr
Positive 76 (46.0) 33 (64.7) 24 (36.9) IS (36.6) 4 (50.0)
Negative 45 (27.3) 10 (19.6) 18(27.7) 13 (31.7) 4 (50.0)
Unknown 44 (26.7) 8 (15.7) 23 (35.4) 13 (31.7) 0(0.0)
Summary measure is n(%) for all categorical characteristics. P value: Comparison for all
four groups. (*)Presence of BCG scar
P values were calculated by Kruskal-Wallis test for continuous variables and Fisher's exact
test for categorical variables.for comparison of allfour groups. If P<O:05, P 1, P2, P3 and
P4 will be calculated.
P1:for comparison between definite TBM and probable TBM - P2: for between probable
TBM and possible TBM. P3: for between possible TBM and not TBM. P4: for between not
TBM and definite TBM. P5:for between probable TBM vs not TBM and P6: for definite TBM
vs possible TBM
3 For Age: Pl=0.002, P2=O.04, P3=O.88, P4=O.77, P5=O.20 and P6=O.84
4 For HIV testing: Pl=O.08, P2=0.14, P3=O.64, P4=O.69, P5=O.63 and P6=O.22
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Table 3.4 Clinical features of 165 TBM suspects recruited in the implementation
phase of MODS evaluation for TBM diagnosis at PNT hospital.
Characteristic Total Definite Probable Possible NotTBM
population TBM TBM TBM
N= 165 N=51 N=65 N=41 N=8
History of illness P=O.97
Median days (lQR) 14 (7-30) 14 (7-30) 14 (7-30) 14 (7-30) 14.5 (10-23)
Glasgow comma scale P=0.26
Median score (IQR) 14 (12-15) 13(10-15) 13(11-15) 15 (13-15) 14.5(12.5-15)
Fever P=0.24
Yes 140 (84.9) 39 (76.5) 57 (87.7) 37 (90.2) 7 (87.5)
No 25 (15.1) 12(23.5) 8 (12.3) 4 (9.8) ) (12.5)
Headache P=0.75
Yes 148 (89.7) 44 (86.3) 60 (92.2) 36 (87.8) 8 (100.0)
No 15 (9.1) 6 (11.8) 4 (6.2) 5 (12.2) 0(0.0)
Unknown 2 (1.2) 1 (1.9) 1 (5.6) 0(0.0) 0(0,0)
Nuchal regidity P=0.26
Yes 145 (87.9) 48 (94.1) 54 (83.1) 36 (87.8) 7 (87.5)
No 19 (11.5) 3 (S.9) 11 (16.9) 4 (9.8) 1 (12.5)
Unknown 1 (0.6) 0(0.0) 0(0.0) 1 (2.4) 0(0.0)
Cranial nervous P=0.70
palsy
Yes 29 (17.6) 9 (17.7) 13 (20.0) 7(17.1) 0(0.0)
No 136 (82.4) 42 (82.3) 52 (80.0) 34 (82.9) 8 (100.0)
Hemiplegia P=OJ
Yes 20 (12.1) 5 (9.8) 12 (18.5) 3 (7.3) 0(0.0)
No 144 (87.3) 45 (88.2) S3 (81.5) 38 (92.7) 8 (l00.0)
Unknown 1 (0.6) 1 (2.0) 0(0.0) 0(0.0) 0(0.0)
Paraplegia P=0.85
Yes 7 (4.3) 3 (5.9) 2 (3.1) 2 (4.9) 0(0.0)
No 158 (95.7) 48 (94.1) 63 (96.9) 39 (95.1) 8 (100.0)
Summary measure is n (%) for all categorical characteristics
P values were calculated by Kruskal- Wallis test for continuous variables and Fisher's exact
test for categorical variables, for comparison of all four groups. If P<O. 05, P1, P2, P3 and
P4 will be calculated. P 1:for comparison between definite TBM and probable TBM -P2: for
between probable TBM and possible TBM, P3: for between possible TBM and not TBM, P4:
for between not TBM and definite TBM, P5:for between probable TBMvs not TBM and V6:
for definite TBM vs possible TBM
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Table 3.5 Radiological diagnosis of 165 TBM suspects recruited in the
implementation phase of MODS evaluation for TBM diagnosis at PNT hospital.
Total Definite Probable Possible NotTB
Radiological tests population TB TB TB
N=165 N=51 N=65 N=41 N=8
ChestX.ray
suspected of TB P<0.00)5
Yes 109 (66.1) 34 (66.7) 64 (98.5) 10(24.4) 1 (12.5)
No 46 (27.9) 13 (25.5) 1 (1.5) 26 (63.4) 6 (75.0)
Unknown 10 (6.0) 4 (7.8) 0(0.0) 5 (12.2) 1 (12.5)
CT scan done P=0.02
b
Yes 24 (14.6) 7 (13.7) 14 (21.5) 1 (2.4) 2 (25.0)
No 141 (85.5) 44 (86.3) 51 (78.5) 40 (97.6) 6 (75.0)
CT scan suspected
ofTBM P""0.06
Yes 15(62.5) 6 (85.7) 9 (64.3) 0(0.0) 0(0.0)
No 9 (37.5) 1 (14.3) 5 (35.7) I (100.0) 2 (100.0)
MRIdone P=0.74
Yes 4 (2.4) 1 (2.0) 1 (1.5) 2 (4.9) 0(0.0)
No 161 (97.6) 51 (98.0) 64 (98.5) 39 (95.1) 8 (100.0)
MRI suspected of
TBM P=l.OO
Yes 2 (50.0) 1 (100.0) 0(0.0) 1 (50.0) -
No 2 (50.0) 0(0.0) 1 (100.0) 1 (50.0) -
Summary measure is n (%) for all categorical characteristics.
P values were calculated by Kruskal-Wallis test for continuous variables and Fisher's exact
test for categorical variables, for comparison of all four groups. If P<O.05, PI, P2, P3 and
P4 will be calculated. PI: for comparison between definite TBM and probable TBM - P2: for
between probable TBM and possible TBM, P3: for between possible TBM and not TBM, P4:
for between not TBM and definite TBM, P5: for between probable TBM vs not TBM and V6:
for between definite vs possible TBM
5 For chest X-ray suspected ofTB: ~1=O.16, P2<O.Ol, P3=O.54, P4=O.08, P5=O.03 and P6=O.014
6 For CT scan done: Pl=O.36, P2=O.Ol, P3=O.03, P4=0.49, P5=l.OO and P6=O.l3
Chapter 3 - Section 2 - TBM-MODS Page 148
3.2.4.3 Detection rates of MODS, MGIT and Smear.
In patients with "definite TBM diagnosis"
Of fifty-one patients with CSF samples positive by either smear or MGIT, thirty
patients (58.8%, 95%CI [41.2, 72.4]) were positive by MODS. MGIT detected 92.2%
(n=47/51, 95%CI [81.1, 97.8]) of definite cases while smear only detected 37.3%
(n=19/51, 95%CI [24.1, 51.9]).
In patients with "Clinical TBM diagnosis"
a. Detection rates
The "clinical diagnosis" group consisted of "definite TBM", "probable TBM" and
"possible TBM" patients combined. One hundred and fifty-seven patients were
diagnosed with TBM by either microbiological confirmation or clinical symptoms and
intention to treat. The detection rates of smear, MGIT and MODS were 12.1%
(n=19/157, 95%CI [7.4, 18.3]), 29.9% (n=47/157, 95%CI [22.~, 37.8]) and 23.6%
(n=37/1S7, 95%CI [17.2, 31.0]), respectively. The detection rate of MODS was
higher than smear (P=0.0012, 9S%CI of difference: [0.04, 0.20]) and comparable to
MGIT (P=0.18, 95%CI ofdifference:[-0.12, 0.02]).
b. Time to positive
In samples positive by either MODS or MGIT (n=55/157), MODS detected
mycobacterial growth after a median of7 days (IQR: 7 - 10 days, n=37) while it took
18 days for MGIT (IQR: 14- 22 days, n=47).
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In samples positive by both MODS and MGIT, the turnaround time of MODS was
faster than MGIT; median (IQR) times were 7 days (6 - 9days) vs 15 days (IQR: 13 -
18 days), respectively, P<O.OOI. Figure 3.3 shows time dependent detection rates of
smear, MGIT and MODS in patients with clinical TBM diagnosis. MODS provided
higher time dependent detection than MGIT unti121 days after inoculation.
Figure 3.3 Time dependent detection rate of Smear, MODS and MGIT in
patients with clinical TBM diagnosis in the implementation phase at PNT
hospital.
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MODS had a higher time dependent detection than MGIT until21 days after inoculation, by
Kaplan-Meier graph.
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The time to positive of MODS and MGIT were compared at 7 days and 14 days after
inoculation. By day 7, no CSF sample was positive by MGIT while MODS detected
mycobacteria in 54.1% (n=20/37) of all CSF samples positive by MODS. The shortest
time to detection of MGIT and MODS were 9 days and 5 days, respectively. By day
14, MGIT only detected 29.8% (n=14/47) of all CSF samples positive by MGIT while
86.5% of all (n=32/37) MODS positive cases were diagnosed by MODS at that time.
MODS (86.49%, n=32/37) provided higher detection rate than MGIT (29.79%,
n=14/47) by day 14 (P<O.OOI, 95%CI of difference:[-O.l7, -0.05]).
c. TBM patients with microbiological confirmation by MODS only
Among 106 smear negative and MGIT negative TBM patients ("probable TBM" and
"possible TBM"), MODS detected 7 cases/samples (6.6%). Cross-contamination was
excluded for 6 samples because they were the only samples positive by MODS on the
corresponding culture date and were not H37Rv (the positive control strain) by
spoligotyping. One MODS positive sample was determined to be cross-contamination
with H37Rv by spoligotyping. Therefore, the true positive rate of MODS in detection
of smear negative and MGIT negative samples was 5.7% (n=6/106). The median time
to detection of MODS in these samples was 10 days (IQR: 7 -13days).
~ Detection rate by HIV status
When the detection rates of MODS and MGIT by HIV status were compared, we
found that among 76 HIV infected-TBM suspects, MGIT detected 40.8% (n=31/76)
and MODS detected 32.9% (n=25/76) of cases (P=0.18). In 45 HIV uninfected TBM
suspects, MGIT detected 22.2% (n=10/45) and MODS detected 13.3% (n=6/45) of
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cases (p=0.21). Our data also showed that MGIT and MODS detected significantly
more cases in HIV infected TBM suspects than in HIV uninfected TBM suspects,
(P=0.0015, 95%CI [0.19, 0.70] for MGIT and P=0.009, 95%CI [0.24, 0.78] for
MODS).
In "Not TBM patients"
Eight out of 165 patients were classified in "not TBM" group and MODS was
negative for all of these patients. The final diagnosis of these patients were
Cryptococcus meningitis (n=4) and bacterial meningitis (n=2).The other two patients
were suspected to suffer from unconfirmed viral infection. One patient recovered
without TB treatment and the other had unknown diagnosis.
3.2.4.4 TB treatment-dependent detection
One hundred and fifty seven CSF samples from 157 patients with clinical TB
diagnosis were analyzed. Thirty-six percent (35.7%, n=56/157) samples were from
patients with no TB treatment before the lumbar puncture and 64.3% (1011157) of
samples were collected from patients who were on TB treatment for a maximum of 7
days. Seventy-two samples (n=72/101, 71.3%) were collected from patients on TB
treatment less than or equal to 3 days and 29/101 (28.7%) samples were from patients
on TB treatment from 4 to 7 days (figure 3.4). In 'no prior TB treatment' group,
although the detection rate of MODS was comparable to MGIT, 39.3% vs 35.7%,
respectively, P=0.85, the turnaround time of MODS was shorter than that ofMGIT (7
days vs 15 days, respectively). The findings were similar in the "on treatment" group.
The detection rate of MODS was significantly decreased in samples from patients
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already on treatment compared to no prior TB treatment; 14.9% (15/101) vs 39.3%
(n=22/56), P=O.009, respectively. The detection rate of MGIT also tended to be lower
in samples from patients receiving TB treatment prior to lumbar puncture but the
result did not achieve statistical significance (26.7% vs 35.7%, P=O.39).
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Figure 3.4 Detection rates of smear, MGIT and MODS in relation to TB
treatment during the implementation phase of MODS evaluation for TBM
diagnosis.
NoTB treatment
_ 56 samples
Smear(+)
6 sample (10.7%)
MGIT(+)
20 sample (35.7%)
TAT*: 15 days
(IQR: 13-20days)
P=0.85
MODS(+)
22samples (39.3%)
TAT: 7 days
(IQR: 6-9days)
DiagnosisofTBM
157 samples
1 daygB treatment ~ days
72 samples
4days ~ TB treatment ~ 7days
29 samples
The positive rates of MGIT and MODS were similar and they were not related to treatment
time. The positive rates were compared by Mc.Nemar 's test.
• TAT: Turnaround time
Smear(+)
1 (3.5%) samples
Smear (+) P=0.17
12 (16.7%) samples I"_~
MGIT(+)
19 (26.4%) samples
TAT: 19 days
(IQR: 14-22 days)
P=0.15
MODS(+)
10 (13.9%) samples
TAT: 9.5 days
(IQR: 8-20 days)
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3.2.4.5 Cerebrospinal fluid characteristics
The characteristics of 165 CSF samples from the implementation phase (PNT
hospital) were analysed. Sixty percent of (n=99/165) samples were not stored in the
fridge because a fridge was not available at the time these sample were collected,
31.5% (n=52/165) were stored in the fridge and the remaining 14 samples had
unknown storage condition. Among 52 samples stored in the fridge, 14 samples were
stored for less than 3 hours, 31 samples were stored from 3-5 hours and 7 samples
were stored overnight (>16 hours). The detection rates of MODS in "no fridge
storage" and "fridge storage" were not significantly different (20% vs 26.9%, P=0.5).
The same figure was observed for MGIT culture (27.3% vs 30.8%, P=0.7). The
median storage time before sample processing was 2.5 hours.
Refrigeration principally reduces bacterial overgrowth in sputum samples and is
therefore likely to be less important for 'sterile' CSF samples. This data provides
reassuring evidence that, despite the tropical setting, the lack of a fridge for short-term
storage of CSF samples prior to processing may not substantially decrease
mycobacterial yield.
The median volume taken from a patient was 10ml but only approximately 3ml
(median) was sent to the microbiological laboratory for M tuberculosis testing. CSF
appearance was clear for over 60% of samples. Characteristics of CSF collected in the
implementation phase are detailed in table 3.6.
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Table 3.6 Characteristics of CSF samples collected from newly presenting
patients from the pilot and implementation phases of MODS evaluation for TBM
diagnosis.
Pilot phase
Implementation
CSF characteristics phaseN=137 N=165
CSF volume (ml) recorded in the lab
Median (IQR) 4 (3..5) 3 (2-5)
Mean (SD) 4.6 (±2.7) 3.7 (±1.9)
CSF appearance, n(%)
Clear NA 100 (60.6)
Bloody NA 9 (5.5)
Turbid NA 30 (18.2)
Yellow NA 26 (15.7)
CSF/blood glucose ratio (n=111)
Median (IQR) 0.42 (0.29-0.54) 0.4 (0.2 ..0.5)
Mean (SD) 0.45 (±O.S) 0.4 (0.2)
CSF protein (gIl) (n=1l8)
Median (IQR) 1.2 (0.8-1.6) 0.4 (0.2-0.6)
Mean (SD) 1.89 (±S.33) 0.4 (0.3)
Cell count, (cells/,...1) (n=113)
Median (lQR) 160 (38..510) 31 (5..98)
Mean (SD) 474 (±996) 89 (173)
Lymphocyte (%) (n=10S)
Median (IQR) 52 (23-80) 100 (90-100)
Mean (SD) 52 (±31) 92 (15)
HIV status, n(%)
HIV positive 88 (64.23) 76 (46)
Characteristics of CSF samples collected in 2 phases. Summary measure is n (%) for all
categorical characteristics. CSF collected in the pilot phase was more typical for rBM than
in the implementation phase, in terms ofCSF protein level and cell count.
Chapter 3 - Section 2 - TBM-MODS Page 156
3.2.4.6 Contamination and Spoligotyping in the implementation phase
The evaluation of contamination and cross-contamination were attempted for the
implementation phase only due to resource limitation.
One hundred and sixty-five CSF samples were cultured by both MODS and MGIT.
There were 55 samples positive by either MODS or MGIT. Of which, 29 samples
were positive by both MODS and MGIT, 8 samples positive by MODS only and 18
samples positive by MGIT only. DNA extracts were available from 37 MODS
positive cultures and were used for spoligotyping and evaluation of cross-
contamination. Contamination was assessed in terms of fungi or other bacteria and
Mtuberculosis cross contamination for the MODS assay.
In terms of fungal or bacterial contamination, there was 1.2% (n=2/l65) samples
contaminated with fungi in MODS culture. No fungallbacterial contamination in
MGIT was observed.
Cross-contamination was investigated for 29 samples positive by both MODS and
MGIT and 8 samples positive by MODS only using spoligotyping. When
investigating all samples cultured on identical days, on which 29 samples positive by
both MODS and MGIT were inoculated, no sample cultured in the same plate or on
the same day had the same spoligotype, so cross-contamination by MODS was
excluded in this group. In 8 samples positive by MODS only, one sample was
identified as H37Rv, and therefore was a false positive, cross-contaminated by the
positive control strain. This patient had been classified in "possible TBM" group. The
other 7 MODS positive isolates had genotypes different from those cultured in the
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same plate or on the same day. Therefore, the cross-contamination rate of MODS was
0.6% (n=I/165).
The cross-contamination rate of MOlT was not addressed in this study due to limited
resources.
3.2.5 DISCUSSION
MODS is a sensitive and rapid technique for the diagnosis of TBM, especially in HIV
infected individuals suspected of TBM. Our data from both study phases (pilot phase
at HTD and implementation phase at PNT) showed similar results:
First, although MOlT showed a slightly higher detection rate than MODS. the
differences were not significant (71% vs 65%, p=0.79 from pilot data and 30% vs
24%, p=0.18 from implementation data). Interestingly, detection rates of both MODS
and MOlT were significantly higher in the pilot study than in the implementation
study (65% vs 24%, p=0.0002 for MODS and 71% vs 30%, p=O.OOII for MOlT).
Second, both MODS and MOlT detected more TBM cases among HIV positive cases
than HIV negative cases; and this observation was significant in the implementation
data (33% vs 13%, p=0.009 for MODS and 41% vs 22%, p=O.OOI5 for MOlT). The
percentage of HlV positivelTBM patients detected by MODS and MOlT was
comparable (p=O.761 for pilot study and p=0.492 for implementation study).
Third, MODS had a faster turnaround time than MOlT (7 days vs 15 days. p<O.OOl)
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Fourth, the fungal contamination and cross-contamination rates of MODS were
negligible in the implementation phase (1.2% and 0.6%, respectively).
Last, the detection rates of MODS and MGIT were reduced by TB treatment. Both
MODS and MGIT detected more cases in non-TB treatment group compared to
patients already receiving TB treatment. However, only MODS showed a significant
difference (40% vs 15%, p=0.009).
A slightly lower sensitivity of MODS compared to MGIT in the pilot study may be
due to a smaller volume of deposit inoculated into MODS culture than MOlT culture
(100J.lIversus 500J.lI,respectively). However, when the volume of CSF deposit was
increased to 250J.lIfor MODS culture in the implementation phase, the detection rate
of MODS was still slightly lower than MGIT even though the difference did not reach
statistical significance. Interestingly, the detection rates of smear, MODS and MGIT
in the implementation phase were much lower than the sensitivity rates in the pilot
study, even though both studies focused on investigation of TBM suspects and CSF
samples were evaluated. Some differences were observed between the two study
settings related to patient population, characteristics of CSF and technicians
responsible for the tests. First, most patients presenting to HTD were naive to TB
treatment or antibiotic treatment. Therefore, diagnosis based on clinical presentation
or microbiological confirmation was not much different; smear detected about half of
TBM cases and MOlT and MODS detected around 65-70% of cases. In contrast,
64.3% (n=101l157) patients admitting to PNT hospital were on TB treatment for at
least one day. Our data showed that detection rate of MODS significantly decreased in
the "on treatment" group in comparison to "no TB treatment", as would be expected.
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The finding of a previous study by Thwaites et al. also demonstrated the same
phenomena (198). In this study, the sensitivity of direct CSF smear examination
dropped from 52% to 2% in patients on 5-15 days of TB therapy. Therefore,
unsurprisingly, TB treatment reduces the sensitivity/ detection rate of microbiological
diagnostic tests for TBM. Since the majority of cases in the implementation phase
were on TB therapy, clinical diagnosis was more challenging. It is possible the"
probable" and "possible" TBM groups in the implementation phase were over
diagnosed compared with the pilot phase, leading to lower detection rates of all
techniques. However, clinicians at both sites are highly experienced in diagnosis of
TBM and clinical TBM trials have been conducted involving both sites, leading to
broad standardization of diagnostic criteria. A more restrictive classification for TBM
would have improved comparability between sites but by definition would have only
included patients with classical presentation and therefore probably overestimated
sensitivity of the tests. This conundrum applies to any evaluation of novel TBM
diagnostics. Second, characteristics of CSF collected from the pilot and
implementation phases were different (table 3.6). CSF protein (gil) and number of
cells (cells/ml) recorded from CSF in the pilot study were higher and more typical for
TBM than in the implementation phase. A retrospective study. in Rio De Janeiro,
Brazil, reviewing 13,000 medical records of patients whose CSF samples were sent to
the laboratory by doctors for diagnosis of TBM reported that CSF culture is more
likely to be positive in patients with a high level of CSF protein (I.5g11 in culture
positive samples compared to 0.63g/1in culture negative samples) which suggests that
the positive culture found in these patients may be associated with the presence of
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high bacillary load in the CSF (156). In addition, this study also stated that more cases
were detected in patients infected with HIV (73%) and this conclusion is similar to
our findings. In the pilot phase, MODS and MGIT detected more TBM cases in the
HIV positive population than in the HIV negative group but the data did not reach
significance because of small sample size (40 HIV positive patients and 17 HIV
negative cases). However, in the implementation phase, significant difference of
detection rates of MGIT and MODS was observed. MODS and MGIT detected more
TBM cases in HIV positive cases than in HIV negative cases (33% versa 13%,
p=0.009 for MODS and 41% versus 22% for MGIT). This also demonstrates the
difference between two study phases in terms of study population. This finding is
inverse to pulmonary TB, where HIV positive cases are more likely to be sputum
smear negative. Third, only three staff performed microbiological testing in the
laboratory for the pilot study conducted at HTD. One staff member performed
MODS, one MGIT culture and the third smear microscopy. Therefore, inter-
technician variation related to technical issues due to many staff doing the same
technique was controlled. This situation was totally different from the high-burden
PNT laboratory, where staff work in groups as standard practice. Groups are
responsible for a certain process such as registration, sample processing and culture.
Although PNT staffs have a high proficiency level, many staff responsible for a chain
of work may introduce errors. Last, in the pilot phase, 4ml CSF was sent for
microbiological testing while only 3ml was tested in the implementation phase. The
improvement of detection rate of microbiological tests correlated with CSF volume
was demonstrated by Thwaites et al. (195).
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Time to detection of M tuberculosis by MODS was significantly faster than MGIT.
While the median time for MODS was 7 days, the time to culture positive of MGIT
was about 15 days. Theoretically, all cultures positive by MGIT are detected at
approximately 105 - 106 CFU/ml of Mycobacteria (13). Therefore, it takes time for
Mtuberculosis to achieve sufficient concentration to be detected by MGIT. In
contrast, MODS was developed to detect the presence of Mycobacteria by
observation of cord formation under the inverted-microscope after several days of
incubation. Since the cord morphology is magnified 400 times under the microscope,
one can observe the cord formation from a small number of bacilli present in each
well after a short time of culture. Therefore, MGIT has a longer tum-around time than
MODS but MODS is more laborious than MGIT. Interestingly, median time to
detection of Mycobacteria in sputa by MODS was 9 days (33), which is slower than
that of Mycobacteria in CSF (7 days). Sample processing may be the cause of this
observation. Since all sputa were digested and decontaminated before inoculation in
MODS, digestion and decontamination solution will affect the viability of
Mycoabcteria and residual decontaminant may impact the growth of bacteria. In
contrast, CSF samples are sterile so CSF pellets are inoculated directly for culture
without decontamination.
MODS is a reproducible and robust technique which is easily adopted by experienced
microscopy technicians. The MODS technique in the pilot phase was the
responsibility of a single staff member (Dang Thi Minh Ha) and in the
implementation phase by two staff members. All three had a common background in
smear microscopy technique and were well-trained on MODS. Although working in
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different working environments, the results were accurate (comparison between
MODS and MOlT) and contamination was controlled «2%). Therefore, this
technique can be scaled-up for use in TB laboratories which are equipped for doing
TB culture.
We have shown MODS a promising method for early diagnosis of tuberculosis
meningitis, because of these advantages. First, MODS can provide a comparable
detection rate to MOlT which has been approved as a gold standard for TB diagnosis
by WHO in 2007 (230). Second, MODS can detect the presence ofMycobacteria in a
short time after incubation. In this study, the median time of MODS was 7 days,
which is significantly faster than MGIT (15 days). Third, contamination is currently
not a serious issue if the sample used in MODS is CSF and if care in manipulation is
applied. The cross-contamination rate detected in this study was very low (0.6%).
Finally, MODS is easy to set up and technicians with high experience on microscopy
only need to participate in a training course in a short time (approximately 3 to 4
weeks) to reliably differentiate earlyMtuberculosis cording.
Chapter 3 - Section 2 - TBM-MODS Page 163
3.3 Section 3
MODS IN DIAGNOSIS OF PAEDIATRIC TB
3.3.1 INTRODUCTION
It is estimated that 9.27 million new tuberculosis (TB) cases occurred worldwide in
2000, of which approximately 11% were in children. Importantly, 75% of these
paediatric cases occur in 22 high-burden countries, including Viet Nam (225). It is
estimated by WHO that 35% of paediatric TB is pulmonary TB and 65% are
extrapulmonary TB and the ratio of pulmonary to extrapulmonary TB varies
depending on age, genetic factors and immune response (220). Most of
extrapulmonary TB patients are from infants and young children. The most severe
forms are milliary TB and tuberculous meningitis (TBM).
PNT hospital admits approximately 500 children with suspected TB each year. In
2007, only 14.9% (59/395) of treated pediatric TB cases had microbiological
confirmation (PNT hospital routine unpublished data). Almost 90% of confirmed
cases had pulmonary TB. Confirmation of extrapulmonary TB in children is more
challenging than pulmonary TB, as is the case for adults. This is consistent with
reports from other settings (22, 160).
The confirmation of TB is based on demonstration of Mtuberculosis in a clinical
sample. Culture and smear microscopy have been considered the gold standards for
the diagnosis of TB in adults and children. Sputum microscopy and culture for TB
diagnosis are widely used. However, young children and infants are usually unable to
produce sputum, as the sputum is swallowed. When sputum samples cannot be
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obtained, gastric aspirate samples or bronchial lavage samples are collected instead.
Even though smear microscopy can achieve 50% - 60% sensitivity and culture can
reach 70% - 80% sensitivity in diagnosis of TB in adults, less than 15% of pediatric
cases are sputum smear positive and cultures yield 30% - 40% sensitivity (185). The
sensitivity of microbiological diagnostic tests varies between settings. Factors
affecting the sensitivity of the tests include sample type, sample volume, sample
quality, sampling method and.diagnostic method. A study from South Africa showed
that in children aged from one month to 5 years, the bacterial confirmation
(smear/culture) rate was 25%; smear and culture from induced sputum or gastric
aspirate samples were positive in 87% and 65%, respectively (263). Similarity, in
Peruvian children with a mean age of 5 years (ranging from 1 month to 16 years), LJ
culture detected 54% of cases and smear microscopy detected 39% and 42% of cases,
respectively for ZN staining alone and ZN and auramine staining in combination
(129). Nucleic acid amplification tests have not proved sensitive for the diagnosis of
TB in children (75). Diagnostic confirmation may be difficult because of non-specific
clinical symptoms, coexisting malnutrition, atypical chest X-ray and paucibacillary or
disseminated diseases in addition to low rates of bacterial confirmation. As result, the
TB diagnosis relies mainly on case definition, chest X-ray and tuberculin skin test
(225).
In 2007, there were approximately 60 suspected cases of TBM in children admitted to
PNT Hospital. However, only 3/60 (5%) of these cases had microbiological
confirmation. Overall, the problems of TB diagnosis in adults are exacerbated in
children due to the difficulty of obtaining sufficient volumes of appropriate samples.
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Available techniques are time consuming, have low sensitivity or require expensive
capital equipment or reagents. Therefore, it is necessary to develop new diagnostic
methods that can eliminate the disadvantages of the established techniques.
The previous study described in chapter 3 - section 1 - pilot phase of TBM MODS
study has shown that MODS can diagnose approximately 65% of all clinically
diagnosed adult TBM in 6 days (34) with a higher sensitivity than smear (50%) and a
faster turnaround time than MGIT culture (12 days). A similar trend was shown in the
implementation phase of the TBM-MODS study. The diagnosis of tuberculosis in
children is frustrated by similar challenges as those experienced in adult TBM patients
due to the paucibacillary samples and difficulty obtaining suitable sample volumes for
testing. In this study, the effectiveness of MODS in diagnosis of tuberculosis in
children presenting to PNT hospital was assessed.
3.3.2 METHOD
3.3.2.1 Enrollment
All children :::;16years of age ful-filling the enrollment criteria (chapter 2, section
2.4) and presenting to the paediatric ward at PNT hospital during the study period
were enrolled into the study.
Data on socioeconomic and demographic features, TB history, TB contact history,
HIV status and presenting clinical features were prospectively collected on a standard
case report form (CRF). Samples were collected as per routine care as deemed
appropriate by the treating physician. No additional samples were collected as part of
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this study. All specimen types from suspected cases were included in the study except
blood.
3.3.2.2 Definition and TB classification
The definition and TB classification were described in chapter 2, section 2.7.
3.3.2.3 Sample collection, sample processing and tests
» As described in materials and methods (chapter 2, section 2.5 and 2.6).
» All samples except blood including sputum, cerebrospinal fluid (CSF), gastric
fluid and pleural fluid were collected for this study.
» All processed samples were tested by homogenous smear, MOlT and MODS
culture.
3.3.3 STATISTICAL METHODS
» Accuracy measures of the 3 tests were calculated for two different definitions
of the 'gold standard' reference test: (1) microbiological confirmation
(confirmed group) or (2) 'clinical diagnosis' (clinical gold standard including
the confirmed and the probable group). In addition, data was analyzed on a
'per patient' or a 'per sample' basis.
~ Details of statistical methods are described in chapter 2, section 2.S.
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3.3.4 RESULTS
3.3.4.1 Patient recruitment and classification.
One hundred children suspected of TB were enrolled into the study. Data for 96
(96%) children were included in the analysis. Four patients were excluded from the
study as they exceeded the age limit for the study population (equal or older than 16
years of age) (Figure 3.5). A total of 217 samples were collected including sputum
(n=132), gastric fluid (n=50), CSF (n=32), and pleural fluid (n=3). Thirty five patients
(36.5%, n=35/96) had microbiological confirmation by a method other than MODS.
43 patients (44.8%, n=43/96) were classified as 'probable TB' and 18 patients
(18.8%, n=18/96) were classified as 'TB unlikely'. There were three out of96 patients
who self-discharged before a final treatment decision was made. Samples were
collected within 4 days after admission and approximately 73% (70/96) of patients
provided samples within the first two days.
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3.3.4.2 Demographic characteristics and clinical presentation
General demographic characteristics of the study population are shown in Table 3.7.
In brief, the male: female ratio was 1:1.3 and the median age was 9 (IQR=3-13).
Almost 80% of suspects had evidence of BCG vaccination (neonatal BCG vaccination
is routine in Viet Nam), only 5% had undergone previous TB treatment. Over 90%
(n=88/96) of suspects were not screened for HIV infection. Only patients suspected of
HIV were counseled for HIV testing, under routine practice on the ward. Seven out of
eight (87.5%) of those tested were positive. A quarter (24/96) of the study population
had a known TB contact according to parent interview and of those contacts 21/24
(87.5%) were a direct household member.
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Table 3.7 Demographic characteristics of paediatric patients
Characteristic Total Confirmed Probable TB TB unlikely
population TB N=43 N= 18
N=96 N=35
Gender P=O.04 Pl=0.002 P2:=0.83 P3=0.50
Male 41 (42.7) 11 (31.4) 22 (51.2) 8 (44.4)
Age P=O.OOS Pl=0.004 P2=0.34 P3=0.07
(year) Median (IQR) 9 13 6 8.5
(3 - 13) (5-14) (2 - 11) (4-12) .
BCG v8ccination(") P=0.31
Yes 74 (77.1) 27 (77.1) 32 (74.4) 15 (83.3)
No 21 (21.9) 8 (22.9) 11 (25.6) 2(11.1)
Unknown 1(1.0) 0 0 1 (5.56)
TB treatment history P=0.86
Yes 5 (5.2) 2 (5.7) 2 (4.7) 1 (5.6)
No 89 (92.7) 33 (94.3) 39 (90.70) 17 (94.4)
Unknown 2 (2.1) 0 2 (4.6) 0
HIY status P=O,34
Positive 7 (7.3) 2 (5.7) 3 (7.0) 2(11.1)
Negative 1 (1.0) 0 0 1 (5.6)
Unknown 88 (91.7) 33 (94.3) 40 (93.0) IS (8.3)
ARV therapy (HIV + P=0.85
only)
Yes 2 (28.6) 0 2 (66.7) 0
No 5 (71.4) 2 (100) 1 (33.3) 2 (100)
TB contact P=1.0
(Parent report)
Yes 24 (25.00) 9 (25.7) 11 (25.6) 4 (22.2)
Contact family member 21/24 (87.5) 7/9 (77.7) 10/11(90.9) 4/4 (lOO)
No 72 (75.00) 26 (74.3) 32 (74.4) 14 (77.8)
Summary measure is n (%) for all categorical characteristics.
(*) Scar or parent report
P values were calculated by Kruskal- Wallis test for continuous variables and Fisher's exact
test for categorical variables, for comparison of all three groups. IjP<O.05, Pi, P2, P3 was
calculated.
Pi: for comparison between confirmed TB and probable TB; P2: for between probable TB
and TB unlikely and P3: for between TB unlikely and confirmed TB
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Clinical symptoms of TB in this referral study population included cough (67.7%),
fever (80.2%), weight loss (45.8%) and chest X-ray consistent with TB (75%) (Table
3.8). Other symptoms were haemoptysis, convulsion, unconsciousness, difficulty
breathing and vomiting. The median history of illness was 20 days. The 'confirmed
TB' patient group reported cough more frequently than 'probable' TB patients
(P=0.03) and had a chest X-ray consistent with TB more often (P=0.005) than
probable TB patients, probably representing more advanced disease in those with
microbiological confirmation.
Chapter 3 - Section 3 - Paediatric TB Page 172
Table 3.8 Clinical features of 96 pediatric TB suspects
Characteristic Total population Confirmed TB Probable TB TB unlikely
N=96 N=35 N=43 N=18
History of illness P=0.89
Median days (IQR) 20 (14 - 30) 15 (12-30) 20 (14,-30) 24.5 (10-
--e-- --------- 1---------- -----lQ)-----
Cough P=0.025 Pl=O.03 P2=0.03 P3=0.59
-_ 65 ~67.7) 21JI?.:!L ____~!i?}..:~l-__t~(~21_
Fever P=0.36
77 (80.2) -- 27 {77.1}
__1-__n_~·I) __gl?2.~_
Nightsweat P=0.63
33 (34.4) 11 (31.4)_ __J1_Q9.~)__ ~~J_27·~_L_
Weightloss P=0.37
- 44 (45.8) 1) {42.~ __ ~--!!_(!!.:~-
_11 _(~_L!l_
Failure to thrive P=0.48
18Q!_7) 5 (l4.~_ 1i18·~1 _ __.2._(~7 .8L_
Lymphadenopathy P=0.38
_!_i_D4.6) 7_pO.Q)__ _~Jl. _ __ Ulii·7L-
Chest X-ray P=0.025 Pl=0.005 P2=0.08
P3=0.59
suspected of TB
Yes 72 (75.0) 31 (88.6) 26 (60.5) 15 (83.3)
No 20 (20.8) 3 (8.6) 15 (34.9) 2(11.1)
Unknown 4 ~4.2) ~_-- 1--_l_~_..§J----- --~-
Radiological
description (for
chest X-ray
suspected of TB
only)
Cavity 13 (18.1) 10 (32.3) 1 (3.9)
2 (13.3)
Miliary 3 (4.2) 1 (3.2) 1 (3.9)
1 (6.7)
Infiltrate 28 (38.9) 7 (22.6) 14 (53.9)
7 (46.7)
Nodular lesion 9 (12.5) 5 (16.1) 2 (7.7)
2 (13.3)
Instertitial infiltration 1 (l.4) 1 (3.2) 0 0
Shadowing 12 (16.7) 5 (16.1) 4 (15.4)
3 (20.0)
Hillar enlargement 4 (5.6) 2 (6.5) 2 (7.7) 0
No description 2 (2.8) 0 2 (7.7) 0
Summary measure is n ('l~)for all categorical characteristics.
P values were calculated by Kruskal- Wallis test for continuous variables and Fisher's exact
testfor categorical variables, for comparison of all three groups. ljP<O.05, PI, P2, P3 will
be calculated.
PI: for comparison between confirmed TB and probable TB; P2: for between probable TB
and TB unlikely and P3: for between TB unlikely and confirmed TB.
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3.3.4.3 Accuracy of MODS
3.3.4.3.1 Clinically diagnosed TB as the gold standard
The clinical gold standard was defined as patients who satisfied characteristics of
either "confirmed TB" group or "probable TB" group combined. Seventy-eight
patients were diagnosed with TB by clinical features and/or microbiological
confirmation and 18 patients were classified as 'TB unlikely'.
When analysed by patient, the sensitivity of smear, MGIT and MODS were 28.2%,
[95%CI: 18.6, 39.5] (n=22178), 42.3%, [95%CI: 31.1, 54.0] (n=33178) and 39.7%,
[95%Cl: 28.8, 51.4] (n=31178), respectively. MODS was more sensitive than smear
(P=O.OII) [95%Cl of difference: 2.3%, 20.7%] but comparable to MGIT (P=0.50;
95%Cl of difference [-2.2%, 7.3%]). Specificity and positive predictive value (PPV)
of smear and MGIT was nominally 100% because these tests were part of the
definition for confirmed TB and therefore a true assessment of specificity of these
tests was not part of this study. However, all patients with a positive smear or MGIT
result had clinical symptoms consistent with TB and were considered to have TB by
the treating clinician. Specificity and PPV of MODS were 94.4%, [95%CI: 72.7,99.8]
(n=17/18) and 96.8%, [95%Cl: 83.7, 99.9], (n=31132), respectively. Negative
predictive value (NPV) of smear, MGIT and MODS was 24.3%, [95%CI: 15.0,35.6]
(n=18174]; 28.6%, [95%CI: 17.8, 41.3] (n=18/63) and 26.6%, [95%CI: 16.2, 39.0]
(n=17/64), respectively.
When analysed by sample, the sensitivity of MODS, MGIT and smear was 43.8%
[95%CI: 32.8, 54.7] (n=74/169), 48.5% [95%CI: 36.9, 60.0] (n=82/169) and 27.2%
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[95%CI: 17.0, 37.4] (n=46/169), respectively. MODS was more sensitive than smear
(P<O.OOl; 95% Cl for difference [8.5%, 24.6%]) but less sensitive than MOlT
(P=0.027; 95%CI of difference [-8.9%, -0.5%]). Table 3.9 shows the sensitivity of
the three methods against clinical diagnosis as the gold standard in terms of patient
and sample.
Table 3.9 Sensitivity of MODS, smear and MGIT against clinical gold standard
in 78 paediatric patients
Comparison: Pwalue',
MODS SMEAR MGIT r9S%CI of difference]
N(%) N(%) N(%)
[9S%CI] [9S%CI] [9S%CI] MODS vs MODS vs
SMEAR MGIT
By patient 31 (39.7) 22 (28.2) 33 (42.3) 0.011 0.5
(N=78) [28.8,51.4] [18.6,39.5] [31.1,54.0] [2.3%,20.7%] [-2.2%,7.3%)
By sample 74 (43.8) 46 (27.2) 82 (48.5) <0.001 0.027
(N=169) [32.8,54.7] [17.0,37.4] [36.9,60.0] [-2.5%,-8.5%] [-8.9%,-0.5%]
Sputum 63 (62.4) 42 (41.6) 68 (67.3) <0.001 0.051
By (N=101) [48.1, 76.5 [26.5, 56.6] [52.8,81.8] [9.6%,31.9%] [-0.9%,0.03%]
Sample
type Gastric
fluid 10 (28.6)
3 (8.6) 10 (28.6) 0.045 1
(N=35) [5.1,52.1]
[0.0,20.5] [6.1,51.0] [-39.5%,-0.4%] [-8.2%,8.2%]
7 P values were calculated by Mac.Nemar's test for patient analysis and by Marginal regression model
for sample analysis.
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3.3.4.3.2 Microbiological confirmation as the gold standard
Of 35 patients with confirmed TB, 31 (88.6%) had at least one sample positive by
MODS (Figure 3.6). When analysed by patient, the sensitivity, specificity, PPV and
NPV of MODS were 88.6% [95%CI: 73.0, 96.0] (n=31135), 98.4% [95%CI: 91.0,
99.0] (60/61), 96.88% [95%CI: 83.0,99.0] (n=31/32) and 93.8% [95%CI: 84.0,98.0]
(n=60/64), respectively against microbiological confirmation by MOlT/smear as the
gold standard. The specificity of MODS was not 100%because there was one patient
positive by MODS but negative by both smear and MOlT. Spoligotyping of the
MODS positive isolate of this patient, showed it to be H37Rv, which was used as the
positive control in the MODS technique and this result was therefore classified as
false positive by cross-contamination. The final diagnosis of this patient was
microbiologically confirmed Staphylococcus aureus infection.
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Figure 3.6 MODS positive in relation to smear and MGIT, for 96 paediatric
patients.
96 patients
Available for analysis
o I
1
3S patients
With confirmed TB by either
Smear (n=22) or MGIT
61 patients
Without confirmed TB
1
I
31 patients
MODS positive
l
01 patient"
MODS positive
60 patients
MODS negative
1
21 patients
Smear positive
31 patients
MGIT positive
*This patient was deemed a false positive due to H37Rv (the positive control strain)
identification by spoligotyping.
When analysed by sample, MODS yielded a sensitivity of 81.3% [95%CI: 73.3, 89.2]
(n=74/91), specificity of 99.2% [95%CI: 97.7, 100] (n=125/126), PPV of 98.6%
[95%CI: 96.0, 100] (n=74175)and NPV of 88.0% [95%CI: 81.7, 94.4] (n=125/142).
Using stored aliquots of the original processed sample we recultured 8 samples by
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MODS which had been positive by MGIT but negative by MODS. These samples
remained culture negative by the MODS technique.
3.3.4.4 Effect of sample type
To investigate whether sample type had a strong impact on the sensitivity of the three
methods, we investigated the number of each sample type collected from 78 patients
with clinical picture of TB and analyzed the sensitivity of these methods in terms of
sputum sample (n = 101), gastric fluid (n = 35), CSF (n=30) and pleural fluid (n=l)
(table 4.4.3.1.1). Our data showed that in sputum, the sensitivity of MODS (62.4%,
n=63/101) was significantly higher than smear (41.6%, n=42/101), P<O.OOl; 95% Cl
for difference [9.6%, 31.9%]; and marginally lower than MGIT (67.3%, n=68/101)
with P=O.051; 95%CI of difference [-9.92%, 0.03%]. In gastric fluid, MODS and
MGIT had the same sensitivity (28.6%, n=10/35); and they were more sensitive than
smear (P=0.045; 95% Cl [0.4%, 39.5%]). In CSF samples, no positive result was
detected by smear. MODS detected Mtuberculosis in one CSF sample and MGIT was
positive with 4 CSF samples. There were insufficient samples to analyze the
sensitivity of these methods in CSF (n=30) and pleural fluid (n=I).
3.3.4.5 Effect of anti-tuberculosis treatment
One hundred and seventy-five samples of all types from patients receiving TB
treatment in this admission were collected on the day of TB treatment or within seven
days of starting TB therapy. TB treatment for more than 1 day reduced the sensitivity
of all 3 microbiological tests, but this difference did not reach significance; (P=0.054;
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95%CI of difference [-31.1%- 0.2%]) for smear, (P=0.154; 95%CI [-32.1%, 5.0%])
for MGIT and (P=0.154; 95%CI [-31.9%, 5.0%]) for MODS (figure 3.7).
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Figure 3.7 Detection rates of Smear, MGIT and MODS in diagnosis of paediatric
TB in relation to TB treatment.
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3.3.4.6 Time to detection
Time to detection was defined as the number of days from sample processing (day 1)
to positive result available. Smear results were available one day after sample
processing in accordance with routine practice due to the high volume of samples in
this laboratory. The median time to detection by MODS was faster than MOlT, 8 days
(IQR: 6 - 12) vs 13 days (IQR: 9 - 19), respectively, in samples positive by either
MODS or MOlT. In the 73 samples which were both MOlT and MODS positive,
MODS was faster for 64 (88%) samples and the median (lQR) time difference was 3
(1 to 6) days in favor of MODS (p<O.OOI).
"Time-dependent sensitivity" analysis included only samples positive by both MOlT
and MODS which reached positivity by day 7 or 14, respectively. The time-dependent
sensitivity against clinical gold standard was significantly higher for MODS
compared to MOlT on both day 7 (18.34% vs. 7.10% P<O.OOI), and on day 14
(36.09% vs. 29.59%, P=0.04) (figure 3.8).
Four CSF samples positive by MOlT had a median time to positive of 25 days (IQR:
23 - 25). One CSF sample was positive by MODS 6 days after inoculation.
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Figure 3.8 Time-dependent sensitivity of smear, MODS and MGIT in diagnosis
of paediatric TB.
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In the 73 samples which were both MGIT and MODSpositive, the time dependent sensitivities
of MODS were higher than MGIT on both day 7 (P<O.OOJ) and day 14 (P = 0.04), by
Marginal regression model.
3.3.4.7 Detection of smear negative TB
To evaluate if MODS is useful for the detection of smear negative cases, we evaluated
the sensitivity of MOlT and MODS among 56 smear negative TB cases (confirmed
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and probable) and 123 smear negative TB samples including either MODS or MGIT
positive.
The sensitivity of MGIT and MODS by patient were comparable, (P = 0.5; 95% Cl
for difference [-3.1%, 10.2%]), which were 21.4% (n = 12/56) and 17.9 (n = 10/56),
respectively. The sensitivities were 30.1%, [95%CI: 18.5, 41.6] (n = 37/123) and
25.2% [95%CI: 14.9, 35.5](n = 311123)for MGIT and MODS, respectively, in terms
of sample with P=0.053, 95% Cl for difference [-0.05%, 9.80%]. The median time to
positive of MODS for smear negative samples was considerably faster than MGIT,
which was 12 days (IQR: 8 - 17 days) compared to 19 days (IQR: IS - 22 days). In
the 30 samples where both MGIT and MODS were positive, the median time
difference was 6 days (IQR: 3 - 11days) in favor of MODS (p=0.005). Therefore,
MODS appeared to have an advantage over MGIT in terms of time to detection.
3.3.4.8 Time to positive in relation to smear result
To investigate whether time to positive of MGIT and MODS is related to smear
positive grading, we analyzed the association of time to detection of MGIT and
MODS with smear grade. Figure 3.9 demonstrates a negative correlation of the time
to a positive test for both MGIT and MODS, respectively, compared to smear with
both P s 0.001.
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Figure 3.9 Time to MGIT positive and MODS positive in diagnosis of paediatric
TB, in relation to smear grade.
A B
• 0 •(")
0 • • •
C"'1
Lt) •N
t.() (J)~ N
(5 00 ..
:E :; 0 - •Ool N
~ ~
Ool
~ •
(I)
0
(I)
0.
0 • •0. II) •.9 .s ,..
(I)
It') •
~
.... (Jl ••iU' ••
0 0 0
0
....
-e--
t.()
It')
neg. scenty 1+ 2+ 3+ neg. scanty 1+ 2+ 3+
Smear result . Smear result
Filled dots are samples positive by either (A) MGIT or (B) MODS, lines are scatter plot
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3.3.4.9 Cerebrospinal fluid
One CSF was collected from each patient with suspected TBM. Thirty-two out of
ninety-six patients (33.4%) were suspected of TBM and had a lumbar puncture
performed. Of these, 4 patients were classified as confirmed TBM. Among these 4
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confirmed TBM patients, three of these patients had CSF positive by MGIT alone,
one patient had CSF positive by both MODS and MGIT. Twenty six patients were
defined as probable TBM (see chapter 2, section 2.7) and 2 patients were defined as
'not TBM' (see chapter 2, section 2.7).
CSF appearance was usually clear (68.8%), the median CSF:blood glucose ratio was
0.33, median CSF protein was 0.46g11(IQR: 0.26 - 0.63), median cell count was
47cells/mm3 (IQR: 13 - 110) and 100%were lymphocytic. CSF parameters were not
significantly different among groups (data not shown).
The CSF volume available for testing varied with a median value of 3ml (IQR: 2.5ml
_ Sml). The median CSF volume of children in the younger age group (under five
years of age) (n=19) was 3ml (IQR: 2ml- 3ml) and it was Sml (IQR: 5ml- Sml) in
the older group (over 12 years old) (n=4).
3.3.4.10 Assessment of contamination
In terms of contamination with fungi, the original contamination rate of MGIT and
MODS were 1.39% (n = 3/217) and 0.9% (n = 2/217), respectively. All MGIT
contaminated samples were decontaminated again and reinoculated in MGIT medium.
No contamination was observed after the second decontamination. Reprocessing for
sample contaminated by MODS was not attempted because of the low total volume
(lml for each well).
Spoligotyping was done for all cultures positive by MODS (n=73). If MODS was
contaminated while subculturing from MODS to LJ for DNA extraction (n=2) or
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MODS was negative but MGIT positive (n=8), cultures positive by MGIT were used
for spoligotyping.
In terms of cross-contamination with Mtuberculosis, one sample and four negative
control wells on 4 different plates were contaminated with the positive control isolate
(H37Rv) at the wells closest to the positive control well. Figure 3.10 shows the
positions of contamination observed in the MODS experiment. The average number
of samples processed on each day having contamination was 8, ranging from 3
samples to 21 samples.
Figure 3.10 Position of contamination observed in MODS plates of MODS
evaluation for diagnosis of paediatric TB
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F:Well was contaminated with fungi.
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Rv(4}. Four plates were contaminated with H37Rv at this position.
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One isolate that was culture positive by MGIT but negative by MODS was not
transferred for genotyping because of contamination during archiving. Serial isolates
or isolates from different samples from the same patient had identical spoligotypes
except in 2 cases. One patient had different genotypes isolated from MGIT and
MODS cultures. Spoligotyping was used to investigate the possibility of cross-
contamination of the MODS culture. No other samples with the same spoligotype
were processed for MODS on that day, therefore this may have been a cross-
contamination in MGIT culture or a patient with dual infection. The patient had
symptoms consistent with TB and was considered to have TB by the treating clinician
and received TB treatment.
In another patient, a single MGIT culture was contaminated with Mycobacterium
fortuitum on subculture. However, 3 MODS positive cultures and 2 MGIT cultures
from this patient isolated Mtuberculosis with identical genotypes.
3.3.5 DISCUSSION
This study demonstrates that MODS is a suitable, rapid, sensitive and specific test for
the diagnosis of paediatric TB.
With clinical diagnosis as the gold standard, MODS was more sensitive than smear
(P=O.Oll) and the sensitivity was comparable to MOlT (P=O.5) on per patient
analysis (n=78). However, on per sample analysis (n=169), MODS was more
sensitive than smear (P<O.OOl) but less sensitive than MOlT (P=O.027). Larger
sample size (169 samples compared to 78 patients) may account for this difference.
Chapter 3 - Section 3 - Paediatric TB Page 187
With microbiological diagnosis by MGIT/smear as the gold standard, MODS
diagnosed 88% of TB cases, similar to a report from Peru in 2006 in which MODS
detected 87% of pediatric TB cases (144). Although sensitivity of MODS was not
statistically different from MGIT in terms of patient analysis, MGIT detected
marginally more pediatric TB patients than MODS (33/35 patients vs 31133 patients).
One explanation for this difference may be the volume of sample inoculated in each
well. It is known that sample volume is important in TB diagnosis for paucibacillary
samples; an increased volume increases the likelihood of bacilli in the sample
(l95).We applied 0.5ml of decontaminated sample for MGIT culture while only
0.25ml (half volume) was used for MODS. In another study in adults, O.Smlwas used
for MBBacT (Organon Teknika) and O.72mlof decontaminated ~putumwas used for
MODS, almost three times higher than our volume, although comparison between
studies are difficult because the relative proportion of sample will depend on the
resuspension volume of the processed deposit (132). In that study, the sensitivity of
MODS was higher than MBBacT (97.8% vs 89.0%) and this may be due to a larger
proportion of deposit being inoculated to MODS than MBBacT. In our laboratory, 48
well-plates are used instead of the 24 well-plates described in the standard MODS
operating procedure (SOP of MODS)(90). This allows for faster plate reading, an
important consideration in high-burden laboratories however this lowers the deposit
volume inoculated which may have an impact on sensitivity. Combining a more
concentrated deposit with a 24-well plate may potentially improve sensitivity without
compromising speed.
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Pediatric TB samples are paucibacillary and it is therefore important to consider
which sample types yield highest sensitivity from the limited sample volumes that are
inevitably available from children. Our study found that sputum and gastric fluid were
appropriate for use to diagnose pediatric TB, in agreement with other groups who
have also found gastric fluid to improve confirmed TB rates in sputum-negative
pediatric TB (144). An alternative method of sampling, such as the string test (211,
212) may further improve diagnostic yield and should be considered for evaluation in
this setting.
For patient samples for which both MODS and MOlT tests reached positivity, the
time to positive of MODS was shorter than MOlT with a median time difference of 6
days. Technical issues affect the turnaround time of each method. In MOlT culture,
lOS to 106 bacteria/ml are required for the machine to signal a positive result. In
MODS culture, the result was read under an inverse microscope with 400x
magnification. Therefore, a few bacteria in each well can be detected by MODS
several days before MOlT. From this study, we also observed that the time to positive
is inversely related to the number of bacilli in each sample as determined by the
observed smear result classified as scanty, 1+, 2+ or 3+. Since the sensitivity of
MODS and MOlT were similar in smear negative samples and MODS has a faster
time to positive than MOlT, MODS is a candidate method for routine use in diagnosis
of smear negative pediatric TB.
The specificity of MODS (98.4%) was slightly lower than smear (100%) and MOlT
(100%) because we had one false positive sample due to cross-contamination with
H37Rv. However, our analysis was biased against MODS since MOlT cultures were
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not investigated for cross-contamination and may have occurred without detection.
Our results were similar to the results of a study conducted in 2006 which recorded a
specificity of 99.6% due to cross-contamination between samples (132). All MODS
positive samples in this present study were identified as Mtuberculosis by
spoligotying and no sample with cross-sample contamination was detected. No mis-
identification of Non-tuberculous mycobacteria (NTM) was recorded in this study but
this needs further evaluation in populations with higher rates ofNTM, such as patients
co-infected with HIV.
Contamination is a common problem with all liquid culture and MODS is not an
exception; careful manipulation and rigorous aseptic technique must be maintained to
minimize contamination. Contamination with fungi was rare at only 1.4%. We have
not detected any cross-contamination between samples. All cross-contaminated wells
were sited at the positions closest to the positive control wells. A high concentration
ofH37Rv is inoculated into positive control wells (>105 bacteriaJIOOul),and therefore
cross-contamination was more likely from the positive control than from
paucibacillary samples.
Overall, MODS is a sensitive, quick and reliable culture test for use in the diagnosis
of pediatric TB, allowing these vulnerable individuals to start TB treatment earlier.
Costs of each test were not formally evaluated but MODS has lower reagent costs
than the alternative rapid culture or molecular methods currently available. Further
cost-effectiveness studies should be done to evaluate the specificity, cross-
contamination, and feasibility of MODS in National TB Programs
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Due to the lack of child-friendly diagnostic tools, it is difficult to confirm TB
diagnosis in children and therefore it is challenging to determine the epidemiology
and the efficacy of TB control strategies for this population. In the report of the 2011
STOP TB Childhood Tuberculosis subgroup meeting (50), Cuevas summarized that
among 6699 publications on evaluations of diagnostic tests including fine needle
aspiration, fluorescence microscopy, LED-fluorescence microscopy, MODS,
BACTEC 960, fully automated BACTEC, line probe assays, LAM and gene Xpert,
only 144 (2%) publications reported study results on children. Especially, only 4/144
(2.7%) studies evaluate the efficiency of fluorescence microscope, MODS and line
probe assays in children. Aside from diagnostic tools as the major challenge in
management of childhood TB, there are barriers to integration of childhood TB
healthcare into public health programmes, implementation of WHO guidelines on
childhood management and financial constraints. To overcome this problem, a call for
action for childhood TB has been launched in 2011 (72) to appeal to national TB
programmes, healthcare providers, policy makers, scientific organizations, social
communities to include pediatric TB in their strategic plan development.
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3.4 Section 4
MODS IN DIAGNOSIS OF HIV ASSOCIATED TUBERCULOSIS
3.4.1 INTRODUCTION
Of9.4 million new cases of tuberculosis (TB) in 2008 1.4million (15%) were in HIV-
positive patients and 23% of all HIV deaths are attributable to TB according to WHO
estimates (236, 237).
Viet Nam is a high TB burden country with steeply rising rates of HIV-TB co-
infection (202); 8.1% of newly diagnosed TB patients are now HIV infected (236).
These cases are the most urgently in need of diagnosis because they have the highest
morbidity and mortality yet the diagnosis of TB among HIV infected individuals is
difficult. Screening algorithms based on clinical symptoms alone show high
sensitivity but low specificity (28, 29, 226). Microscopy smear while simple, specific
and widely available in high burden settings, has particularly low sensitivity in HIV
patients and cannot be used to rule out a diagnosis of TB (128, 182).Microbiological
confirmation remains desirable and allows investigation of drug susceptibility
profiles. Commercial rapid liquid culture techniques have been endorsed by WHO
(230), show higher sensitivity and are more rapid than traditional solid media-based
techniques such as Lowenstein-Jensen culture. However, their high cost and biosafety
infrastructure requirements limit their applicability in many high burden settings.
Rapid molecular line-probe assays, also endorsed for use in low-resource settings by
WHO (233), allow simultaneous identification of M tuberculosis and resistance to
rifampicin or isoniazid but are currently only recommended for smear-positive
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samples and positive cultures. In addition, they are expensive and require molecular
expertise which is often not available in low-resource settings. Recently, GeneXpert
has been approved by WHO for early diagnosis of TB and MDR-TB at peripheral
levels (248). WHO also recommended that GeneXpert should be prioritized to detect
TB and MDR-TB in high risk groups, including HIV infected individuals and patients
suspected of infection with MDR-TB (246). However, rolling out this test may
encounter challenges in terms of a low positive predictive value .for MDR TB, costs,
sustainability, monitoring during treatment, storage condition, maintenance, shelf-life
of the cartridge, delivery and technical issues to prevent cross-contamination.
MODS has been shown effective in identification ofTB in HIV patients (7, 161). The
increasing number of HIV-positive pulmonary TB suspects presenting to PNT
hospital has led to an urgent need for a rapid and sensitive test to detect TB for this
population.
Here, we evaluated the MODS assay for TB diagnosis in HIV-infected patients
presenting to PNT. As in the previous studies, we assessed the sensitivity, specificity,
negative predictive value, positive predictive value, contamination rate and
turnaround time of MODS against clinical gold standard and microbiological gold
standard.
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3.4.2 METHODS
3.4.2.1 Enrollment
» All HIV -positive individuals suspected of tuberculosis, who fulfilled
enrollment criteria (chapter 2, section 2.4) and presented to the HIV ITB ward
at PNT Hospital were enrolled into the study.
» Data on socioeconomic and demographic features, TB history, TB contact
history, HIV status and presenting clinical features were prospectively
collected on a standard case report form.
3.4.2.2 Definition and TB classification
» The definition and TB classification were described in chapter 2, section 2.7
3.4.2.3 Sample collection, sample processing and laboratory tests
» As described in materials and methods (chapter 2, section 2.5 and 2.6).
» Sputum samples were collected for this study.
» All processed samples were tested by homogenous smear, MGIT and MODS
culture.
3.4.3 STATISTICAL METHODS
» Accuracy measures of the 3 tests were calculated for two different definitions
of the 'gold standard' reference test: (1) microbiological confirmation
(confirmed group) or (2) 'clinical diagnosis' (clinical gold standard including
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the confirmed and the probable group). In addition, we analyzed data on a 'per
patient' or a 'per sample' basis.
» Details of statistical methods were described in chapter 2, section 2.S.
Comparisons between MODS, smear and MOlT in terms of accuracy, time to
positive, TB treatment- dependent sensitivity and contamination were
performed.
3.4.4 RESULTS
3.4.4.1 Enrollment
Three hundred and forty-one HIV positive individuals were screened for pulmonary
tuberculosis (Figure 3.11). Of these, 8.2% (n=28/341) patients were excluded because
they subsequently tested HIV negative (3 cases), no samples were collected (24 cases)
or they had already received TB treatment for more than eight days (1 case). Thus,
313 patients were eligible for the analysis. However, six additional patients were
excluded after clinical and laboratory analysis because insufficient information was
collected prior to self-discharge of the patient (4 cases) and inappropriate sample
(gastric fluid) was collected (2 cases). Thus, data from 307 patients were analyzed
and reported in this study.
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II
A total of 738 sputum samples were collected from these 307 patients. Two hundred
and twenty-two (72%, n=222/307) patients had microbiological confirmation by a
method other than MODS. This group also included 6 patients with microbiological
confirmation by smear or MGIT based on samples collected prior to study enrolment.
61 patients (20%, n=61/307) were classified as 'probable TB' and 24 patients (8%,
n=24/307) as 'TB unlikely'.
3.4.4.2 Demographics and clinical features
Over 90% (n=301l307) of the study population was male with a median age of 29.
Almost 60% (n=182/307) of patients had evidence ofBCG vaccination determined by
BeG scar. Only 13% (n=42/307) were on antiretroviral therapy (ART). Twenty
percent (n=611307) of patients had previously been diagnosed with TB once in their
medical history. Table 3.10 shows demographic characteristics of the study
population and comparisons of the three groups. Table3.11 shows clinical features of
the 307 HIV-associated TB suspects. Cough, fever and weight loss were the most
frequent symptoms with the majority of patients having a history of illness between
30-59 days. Lymphadenopathy was present in 43% of patients.
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Table 3.10 Demographic characteristics of HIV positive patients enrolled into the
study.
Characteristic Total Micro- Probable TB
population confirmation TB TB unlikely
N=222
N=307 N=61 N=24
Gender P=1.000
Male 301 (98.1) 217(97.8) 60 (98.4) 24(100.0)
Age (year) P=0.801
Median 29 29 30 30
(IQR) (26 - 33) (26 - 33) (26 - 33) (27 - 35)
BCG P=0.S58
vRccinationCO)
Yes 182 (59.3) 130 (58.7) 39 (63.9) 13 (54.2)
No 117 (38.1) 85 (38.3) 21 (34.4) 11 (45.8)
Unknown 8 (2.6) 7 (3.2) 1 (1.7) 0
TB history P<O.OOl P1=0.52 P2=O.OOl P3<O.OI
Yes 61 (19.9) 36 (16.2) 12 (19.7) 13 (54.2)
No 245 (79.8) 186 (83.8) 48 (78.7) ] 1 (45.8)
Unknown 1 (0.3) 0 1 (1.7) 0
ARV therapy P=0.116
Yes 42 (13.7) 29 (13.1) 10(16.4) 3 (12.5)
No 261 (85.0) . 192 (86.5) 49 (80.3) 20 (83.3)
Unknown 4 (1.3) 1 (0.5) :2 (3.3) 1 (4.2)
TB contact P=0.758
Yes 12 (3.9) 10 (4.5) 1 (1.6) 1 (4.2)
No 281 (91.5) 203 (91.4) 56 (91.8) 22 (91.7)
Unknown 14 (4.6) 9 (40.l) 4 (6.6) 1 (4.1)
Summary measure is n(%) for all categorical characteristics.
(*)Presence of BCG scar
P refers to the p-value of a (global) comparison of all three groups. P values were calculated
by Kruskal-Wallis test for continuous variables and by Fisher's exact test for categorical
variables. If P<O.05, the pairwise comparisons PI, P2, P3 were also performed.
PI: confirmed TB vs probable TB.
P2: probable TB vs TB unlikely.
P3: TB unlikely vs confirmed TB.
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Table 3.11 Clinical features of307 TBIHIV suspects
Characteristic Total Micro- Probable TB unlikely
population confirmation TB TB
N=307 N=222 N=61 N=24
History of illness
~29 days 74 (24.1) 52 (23.4) 12 (19.7) 10 (41.7)
30-59 days 185 (60.3) 130 (58.6) 42 (68.8) 13 (54.2)
~ 60 days 48 (15.6) 40 (IS.0) 7 (11.5) 1 (4.2)
P=O.107
Cough 297 (96.7) 216 (97.3) 58 (95.1) 23 (95.8)
P=0.465
Fever 294 (95.8) 2t6 (97.3) 60 (98.4) 18 (75.0)
P<O.OOI Pl=0.63 P2<0.OOl P3<0.OOl
Nightsweat 245 (79.8) 174 (78.4) 54 (88.5) 17 (70.8)
P=O.106
Weightloss 292 (95.1) 212 (95.5) 59 (96.7) 21 (87.5)
P;;:O.201
Lymphadenopathy 138 (44.9) 106 (47.8) 24 (39.3) 8 (33.3)
P:::::O.031 Pl:::::O.08 P2:::::0.89 P3=0.25
Summary measure is n (O/ll) for all categorical characteristics.
P refers to the p-value of a (global) comparison of all three groups. P values were calculated
by Kruskal-Wallis test for continuous variables and by Fisher's exact test for categorical
variables. If P<O.05, the pairwise comparisons P1, P2, P3 were also performed.
P1: confirmed TB vs probable TB.
P2: probable TB vs TB unlikely.
P3: TB unlikely vs confirmed TB.
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3.4.4.3 Accuracy of MODS
3.4.4.3.1 Accuracy against microbiological gold standard
Microbiological gold standard was defined as patients whose samples were Accuracy
against microbiological confirmation as the gold standard positive by either smear or
MOlT. MODS detected 87.4% of these cases with a specificity of93%. The accuracy
of MODS against microbiological gold standard, by patient and sample analysis, is
detailed in table 3.12.
Table 3.12 Accuracy of MODS versus microbiological confirmation as the gold
standard in 307 HIV ffB suspects.
By patients By samples
Sensitivity
% (n=xly) 87.4 (194/222) 81.0 (431/523)
95%CI [82.3 - 95.1] [76.3 - 85.7]
Specificity
% (n=xly) 92.9 (79/85) 97.1 (2001206)
95%CI [85.3 - 97.4] [94.8 - 99.3]
Positive predictive
value
% (n=xly) 97.0 (194/200) 98.6 (431/437)
95%CI [93.6 - 98.9] [97.5 - 99.7]
Negative predictive
value
% (n=xly)
95%CI
73.8 (79/107)
[64.5 - 81.9]
66.4 (200/301)
[58.5 - 74.4]
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3.4.4.3.2 Accuracy against clinical gold standard.
Clinical gold standard was defined as patients satisfying the definition of
"microbiological confirmation" group (n=222 patients) or "Probable TB" group (n=61
patients). In total, 283 patients and 684 samples were classified as TB using the
clinical gold standard. Table 3.13 describes the sensitivity and negative predictive
value of MODS, smear and MGIT against clinical gold standard by patient and by
sample analysis. MODS was significantly more sensitive than smear (71% vs 57%,
p<O.OOl by patient analysis and 64% vs 54%, p<O.OOl by sample analysis) but less
sensitive than MGIT (75%, p=0.03 by patient analysis and 70%, p<O.OOl by sample
analysis). The specificity and positive predictive value of all methods were 100%.
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Table 3.13 Sensitivities and negative predictive values of MODS, smear and
MGIT methods versus the clinical gold standard in diagnosis ofHIVrrB.
Comparison: Pwalue",
MODS SMEAR MGIT [95%CI of difference]
% (n=xly) % (n=xly) % (n=xly) MODSvs MODSvs
[95%CI] [95%CI] [95%CI] SMEAR MGIT
All subjects
B~ Qatient 70.7 56.9 74.9 <0.001 0.03
(n=283) (200/283) (1611283) (212/283) [8.6%,18.9% [-8.1%,-0.4%]
[64.9, 75.9] [50.9,62.7] [69.4, 79.8] ]
B~ samQle 63.8 53.9 69.2 <0.00] <0.001.c (n=684) (437/684) (369/684) (473/684) 6.9%,12.9%] [-7.7%,-2.8%].,.
~ [58.5,69.2] [48.2,59.7] [63.9, 74.4].,......,.~= Smear negative subjects~
VJ
B~ Patient
(n=122) 37.7 N/A 45.1 N/A 0.078
(46/122) (55/122) [-15.4%,0.7%]
[29.1, 46.9] [36.1,54.3]
B~ samnle 29.2 N/A 36.2 N/A 0.003
(n=315) (92/315) (114/315) [-11.5%,-2.4%]
[22.4,36.0] [28.8,43.6]
All subjects
B~ Qatient 22.4 16.4 25.3 0.323 0.711
(n=283) (24/107) (241146) (24/95) [-12.7%,4.2%] [-7.9%,11.6%]
[14.9,31.5] [10.8,23.5] [16.9,35.2]
~:s B~ samQle 17.9 14.6 20.37 <0.001 0.002-a;;> (n=684) (54/301) (54/369) (54/265) [1.6%,5.1%] [0.9,3.9%]
~ [11.3,24.6] [9.1,20.2] [12.9,27.8]~
Col
._
-= Smear negative subjects~
~
~ B~ Qatient 24.0 N/A 26.4 N/A 0.770.~ (n=122) (241100) (24/91) [-8.6%, 11.7%]~
bJ) [16.0,33.6] [17.7,36.7]~
Z
B~ samQle 19.5 N/A 21.2 'N/A 0.009
(n=315) (54/277) (54/255) [0.42,2.9%]
f12.3,26.7] [13.5,28.9]
8 P values were calculated by Mc.Nemar's test for patient analysis and by Marginal regression model
for patient analysis
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3.4.4.4 MODS in diagnosis of smear-negative, HIV-associated TB
One hundred and twenty-two patients with 315 samples were diagnosed with
confirmed or probable TB but all their smear samples were negative. Of which,
15/122 (12%) patients were positive by MOlT only, 40/122 (33%) patients were
positive by both MODS and MOlT, 6/122 (5%) patients were positive by MODS
only, 6 patients were positive by either smear or culture in only samples collected
before the enrollment and 55 patients were neative by all microbiology methods,
including MODS, in samples collected before and after the study enrollement. MODS
detected 75.4% (n=46/61) of culture positive-smear negative TB cases. Comparisons
of the sensitivity and negative predictive value of MODS and MOlT are detailed in
table 3.13. The sensitivity of MODS tended to be lower than MOlT in the 'by patient'
analysis (38% vs 45%, p=0.078). Conversely, MOlT was significantly more sensitive
than MODS (36% vs. 29%, p=0.003) in the "by sample" analysis. The specificity and
positive predictive value of these tests in smear negative patients/samples were 100%.
Of 122 smear negative TB cases, 30 cases did not have TB therapy at Pham Ngoc
Thach Hospital because of death, self-discharge or referral to District Tuberculosis
Units to start TB treatment and follow-up. Ten out of these 30 cases (33%) did not
receive TB treatment because the patient was discharged following a negative smear
before the culture results were available.
3.4.4.5 TB treatment-dependent sensitivity
Six hundred and eighty four samples from 283 patients with a clinical TB diagnosis
were analyzed. Fourteen percent (14%, n=97/684) of samples were from patients not
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on TB therapy. Five-hundred and forty (n=540/587, 92%) samples were collected
from patients on TB treatment ~ 3 days and 47/587 (8%) samples were from patients
on TB treatment >4 days. The sensitivity of MODS, Smear and MOlT against clinical
gold standard in patients receiving TB treatment ~ 3 days or 2: 4 days was compared.
The sensitivity of MODS and smear were significantly decreased among samples
collected after 4 days of TB treatment compared to earlier samples (53% vs 70%,
p=O.035 for MODS and 45% vs 61%, p=O.034for Smear); The sensitivity of MOlT
also tended to be lower for longer TB treatment duration but the result did not achieve
statistical significance (60% vs 74%, P=O.053).
3.4.4.6 Time to positive
Time to positive was defined as the number of days from sample ,processing (day l) to
positive result available. The results of smear were available on day 2 (routine
procedure at PNT Hospital). In samples positive by either MODS (n=437/684) or
MOlT (n=473/684), the median time to detection of MODS and MOlT were 8 days
(IQR: 6 - 10days) and 11 days (IQR: 8 - ID days), respectively. Among smear
negative samples, the median time to detection of MODS and MOlT were II days
(IQR: 9 - 16 days) and 17 days (IQR: 13- 21 days).
3.4.4.7 Time-dependent sensitivity
Time-dependent sensitivity of MODS and MOlT are shown in Figure 3.12. In
samples positive by both MODS and MOlT, MODS was faster, than MOlT in 70%
(n=289/418) samples with a median time difference of 2 days (lQR: 0 - 5 days,
P<O.O1). In smear negative samples, of 79 samples positive by both MODS and
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MOlT, the MODS results were available 4 days earlier than MOlT (IQR: 0-7 days,
P<O.Ol). MODS also yielded a higher sensitivity than MOlT by day 7 (28% vs. 16%,
P<O.OOI) and day 14 (57% vs. 52%, P=0.009) after inoculation.
Figure 3.12 Time-dependent sensitivity of MODS, smear and MGIT in diagnosis
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3.4.4.8 Assessment of contamination
In total, 738 samples were cultured by both MODS and MOlT. We assessed the
contamination in terms of fungi or other bacteria and cross contamination between
samples for the MODS assay.
In terms of fungal contamination, the original contamination rate of MODS in
samples was 1.1% (n= 81738) while it was 2.6% (n= 191738) for MOlT. All MOlT
contaminated samples were decontaminated again and re-inoculated in MOlT
medium. The final fungal contamination rate of MOlT was 1.8% (131738).
Reprocessing for samples contaminated in MODS culture was not attempted because
of low volume (total of lml for each well). Contamination with fungi was also
observed in 8 negative control wells.
To assess cross-contamination of MODS with Mycobacterium tuberculosis, spacer
oligonucletide typing (spoligotyping) was applied to all available MODS isolates
(n=437/478). Serial positive cultures from individual patients were compared for
discrepancies in spoligotype. A positive MOlT culture (n=41) was used for
comparison if the MODS culture yielded a negative spoligotype (n=21) or subculture
was contaminated from MODS to LJ (n= 20). Among 21 MODS cultures with
negative spoligotype, 2 cultures were M kansasii and 19 cultures were M tuberculosis
complex identified by molecular line probe assay (INNO-LiPA Mycobacteria,
lnnogenetics, Ghent Belgium). 412/437 (94%) samples had defined spoligotypes
while the remaining 25/437 did not because of negative MGIT culture (n=3), negative
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spoligotype (n=3) and DNA not available (n=19). Spoligotypes were deemed
possible cross-contamination if serial isolates from an individual patient were
discrepant or an isolate was H37Rv (the positive control isolate).
Eight samples from 8 patients (1.1%, n=81738)were positive by MODS with H37Rv,
the positive control strain. An additional twenty-seven MODS isolates were identified
as probable MODS cross-contamination due to multiple strains isolated from one
patient. It is impossible to rule-out infection with multiple-strains in these patients, but
the maximum cross-contamination rate of MODS with Mtuberculosis was 4.7%
(n=351738). All false-positive MODS cultures were in 'confirmed' or 'probable' TB
groups.
3.4.5 DISCUSSION
We have shown MODS to be a sensitive and rapid method for diagnosis of TB in
HIV-infected patients. Although MODS was slightly less sensitive than MOlT (71%
vs 75%, P=0.03), MODS is faster than MOlT in samples positive by both methods
with a 2 day difference (P<O.OOI).In smear negative TB cases, although MODS
tended to be less sensitive than MOlT (38% vs 45%, P=0.078), MODS detected more
cases than MOlT by day 7 (4.4% vs 0.6%, P=0.027) and day 14 (21% vs 12%,
P<O.OOI).MODS detected 72.8% (40/55) culture-positive, smear-negative TB cases.
Therefore, MODS is an appropriate microbiological method for early detection of
HIV-associated TB.
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Delays in diagnosis result in poor outcomes, increased morbidity and ongoing
transmission (28). MODS detected significantly more TB cases at day 7 (4.4% vs
0.6%) and day 14 (21% vs. 12%) than commercial rapid liquid culture, similar to
findings comparing MODS and Lowenstein-Jensen in previous studies (7, 79, 132);
this is crucial for early diagnosis of TB in immuno-compromised patients. Over 30%
of the smear negative TB cases in our study did not receive TB treatment because the
MGIT culture result was not available at discharge time. This underlies the need for a
rapid diagnostic test in HIV/TB cases. Suspected TB cases who are smear negative
are generally prescribed 7 to 14 days broad spectrum antibiotics to exclude other
possible causes of community-acquired pneumonia before being re-tested for TB, in
accordance with WHO policy (232).
Contamination is an issue with all microbiological techniques and evaluation of
contamination is of importance for wide application of MODS'. As for the MODS
evaluations in pediatric and TBM, we have shown the fungal contamination rate to be
low in our hands; 1.1% in this study. Probable cross-contamination of MODS was 4.7
% which is within the expected contamination range of MOlT culture (3% to 8.5%)
(42, 43, 106, 175). Cross-contamination is difficult to evaluate effectively in TB
culture techniques because genotyping techniques have relatively low discriminatory
power in endemic settings and it is difficult to rule-out TB infection in symptomatic
patients in a high prevalence setting. The median cross contamination rate of TB
laboratories is around 3% (3), but it can be much higher (159). An alternative typing
technique, such as Restriction Fragment Length Polymorphism (RFLP) or
Mycobacterial Interspersed Repetitive Units (MIRU) may have yielded further
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resolution of suspected cross-contamination events, however, RFLP has low
discriminatory power for isolates with less than 5 IS6110 copies, which represent
around 40% of isolates in southern Vietnam (35) and MIRV was under assessment for
discriminatory power in local strains in our laboratory at the time of this study.
In this study, only 14% of HIV-infected individuals suspected of tuberculosis and
only 13% of TB confirmed-HIV patients were on ART at the time of TB diagnosis.
This suggests further efforts are required to enhance integration of the TB and HIV
programmes in HCMC. These efforts are ongoing. Since HIV fuels TB infection and
increases the risk of development TB disease; and active TB disease accelerates HIV
progression, this vicious circle increases the mortality rate of HIV-associated TB
patients. Therefore, early ART and implementation of effective TB screening for
HIV-infected individuals is crucial. It is known that early start of ART in combination
with intensified TB case finding, infection control and isoniazid preventive therapy
will reduce the burden of TB in HIV-infected people. Recently, WHO now
recommends ARV for all HIV-infected individuals, who were screened for exclusion
of active TB, as soon as possible, irrespective of CD4 cell count (degree of
immunosuppression) to reduce the risk of TB infection and progressive to active TB
(251). Monitoring and follow-up of patients after transfer to district tuberculosis units
was not part of this study and we did not have information on ART or TB treatment
outcome of these patients.
In conclusion, this study confirmed that MODS is an effective method for detecting
M tuberculosis in HIV infected patients, including sputum smear negative cases.
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3.S Section S
MODS IN DIAGNOSIS OF
MULTIDRUG-RESISTANT TUBERCULOSIS
3.5.1 INTRODUCTION
MDR-TB is caused by Mtuberculosis which is resistant to at least the two most
powerful TB drugs, INH and RIF. In addition to the high costs, long duration of
treatment and the lack of randomized controlled trials for optimal regimens, a major
barrier to control of MDR- TB is the lack of laboratory diagnostic capacity in high-TB
burden settings. Major initiatives are now under way to scale-up capacity for both
Mtuberculosis culture and DST (70). According to WHO, of 27 high MDR-TB
burden countries, only 22 settings had a National Reference Laboratory in 2008. Of
572 laboratories worldwide performing drug susceptibility testing (DST), only half
participated in external quality assurance (245).
Recently, the documentation in over 50 countries of extensively drug-resistant
tuberculosis (XDR-TB), defined as MDR-TB plus resistance to a fluoroquinolone and
at least one second-line injectable agent (amikacin, kanamycin or capreomycin) (245)
has further emphasized the need to scale up detection and treatment of MDR TB. In
HIV co-infected individuals the classical smear diagnostic test has very low
sensitivity and the need for enhanced culture has further urgency in settings with HIV
co-epidemics; late diagnosis and treatment contributes to high mortality rates and on-
going transmission in this population (226). Classical DST for Mtuberculosis on solid
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media requires 6-8 weeks as the sputum sample must first be cultured and then
regrown on drug-containing media. In 2007, WHO recommended the use of liquid
culture and DST in low and middle-income countries as a step-wise approach to scale
up TB and MDR-TB diagnosis and management (229, 234). Automated liquid
culture allows fast turn-around times of 10-14 days when direct DST is performed but
the automated equipment is expensive for most high-burden settings and cheaper
alternative methods may be easier to implement. Molecular line probe assays (LPA)
for rapid detection of MDR-TB, which are based on reverse hybridization technology
have been endorsed by WHO in 2009 (238). With sensitivity and specificity of over
90% and 99%, respectively, against conventional DST method (233), LPA are an
alternative rapid and accurate DST method but are only reliable in smear positive
cases. Unfortunately, the cost and the requirement of relatively complicated
technology and infrastructure in addition to well-trained staff have limited the use of
LPA in high TB burden countries where the need is greatest. GenXpert, a novel
molecular based technique, detects Mtuberculosis and M.tuberculosis carrying
rifampicin resistance mutations directly from sputum samples. The test provides
sensitivity and specificity of M tuberculosis detection of 98% and 99%, respectively
and correctly identifies 97.6% isolates with rifampicin resistance and 98% of
rifampicin susceptible isolates compared with phenotypic DST (17). However, the
cost remains relatively high for use in developing countries at the present time, with
FIND negotiated pricing of 18USD per test cartridge (246). Therefore, no single test
currently available provides all the characteristics of an ideal test for rapid diagnosis
of MDR-TB, including rapid, low-cost, easy to perform, sensitive and specific.
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Microscopic Observation Drug Susceptibility (MODS) assay is a direct rapid DST
test which has been evaluated for MDR screening from clinical specimens. Previous
studies have shown it an accurate, feasible and low-cost test thatis promising for use
in high burden countries for early diagnosis of MDR TB (61, 132, 133). Procedures
for quality assurance of the test are still in development (130) and the accuracy of the
test when adopted by non-expert groups needs to be confirmed (256). This technique
is now endorsed by WHO for use in resource-limited settings as an interim solution to
increase TB case detection (238). The MODS evaluation for early diagnosis ofMDR-
TB in new Vietnamese TB suspects was performed in this study.
3.5.2 METHODS
3.5.2.1 Enrollment
All patients suspected of tuberculosis, who were newly presenting to the Out Patient
Department (OPD) at Pham Ngoc Thach Hospital from August to November 2008
were enrolled into the study. Details of recruitment criteria are described in chapter
2, section 2.4.
Data on demographic features and HIV status (if available) were prospectively
collected on a CRF.
3.5.2.2 Sample processing, sample collection and tests
~ Only the first sputum samples were collected for this study.
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> Sample collection, transfer and testing are described in cbapter 2, section 2.5
and section 2.6. The samples were then sent for direct DST by MODS and
indirect DST by I% proportional method on LJ.
> All cultures positive by MOlT or LJ were subcultured on LJ (Becton
Dickinson) for indirect DST, standard biochemical identification and
archiving.
> All cultures positive by MODS (control wells) were subcultured on LJ in
duplicate for DNA extraction and archiving.
> If DNA extraction from MODS isolates failed due to contamination or failure
to grow on subculture, DNA extraction from MOlT or LJ was used.
Spoligotyping was performed for all cultures positive by MODS (n=329). If MODS
was contaminated during subculture from MODS to LJ for DNA extraction (n=24) or
MODS was negative but MOlT positive (n=36), cultures positive by MOlT were used
for spoligotyping. Spoligotyping was used to support the screening of cross-
contamination. Cross-contamination of MOlT was not addressed in this study due to
resource limitations.
3.5.2.3 Definitions
> For performing DST-MODS, each processed sample was inoculated into two
drug-free wells (control wells), one INH-containing well and one RIF-
containing well.
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~ Any sample positive with at least one control well was recorded as a positive
MODS culture.
~ If two control wells were positive, results from drug-containing wells were
recorded: If cording was detected in control wells but not in drug-containing
wells, the strain was recorded as susceptible. If cording was detected in control
wells and drug-containing wells, the strain was recorded as resistant.
~ In samples for which only one control well was positive, the DST test was
recorded as uninterpretable.
~ MOlT or LJ culture was used as the gold standard for determining sensitivity
and specificity of MODS culture; and DST -LJ was applied as the gold
standard for sensitivity and specificity of DST-MODS.
~ Cross-contamination was confirmed based on spoligotyping. Identification of
H37Rv from any well except the positive control well was considered as a
cross-contamination event.
~ Cross contamination was suspected if only one control well was positive by
DST -MODS and both MOlT and LJ culture were negative for that sample; or
DST -MODS was positive with two controls but both MOlT and LJ culture
negative. In these cases if spoligotyping showed the isolate was unique on the
MODS plate processed that day, contamination was discounted.
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3.5.3 STATISTICAL ANALYSIS
Detection rates for MODS, MGIT and LJ were summarized and compared between
methods using McNemar's test. The accuracy of MODS for diagnosis ofTB was then
assessed using MGIT and LJ as the gold-standard reference test, i.e. a sample was
defined as positive by the reference test if either MGIT or LJ (or both) was positive.
The accuracy of DST -MODS for drug-susceptibility testing was assessed in samples
with a valid drug susceptibility test result by both DST-MODS and DST-LJ. The
gold-standard reference test was the DST-LJ result. We also summarized agreement
between DST-MODS and DST-LJ as raw agreement and by Cohen's kappa.
Confidence intervals for accuracy measures (sensitivities, specificities, positive and
negative predictive values) were calculated according to the method of Pearson and
Clopper. Finally, we compared the time to a positive test for MGIT and MODS,
respectively, in samples positive by both methods using the Wilcoxon signed rank test
and visualized it using the empirical cumulative distribution.
Statistical analysis was done with Stata version 9 (Statacorp, Texas, USA).
3.5.4 RESULTS
3.5.4.1 Study population and demography
Seven-hundred and nine patients clinically suspected of tuberculosis were enrolled
into the study. The median age was 39 years (IQR: 27 - 53 years). The male:female
ratio was 1.7 (n=447/262). HIV status was unknown for the majority of the patients
(99.0%, n=7021709) and only one patient was recorded as HIV positive.
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3.5.4.2 Detection ofTB
Accuracy of MODS culture for Mtuberculosis detection against MGIT culture or LJ
culture as the gold standard.
In 709 sputum samples sent for TB diagnosis, the detection rate of MODS, MOlT and
LJ were 50.5% (n=3581709, 95%CI: 46.7, 54.2), 51.6% (n=3661709, 95%CI: 47.9,
55.3) and 44.4% (n=3151709, 95%CI: 40.7, 48.1), respectively. No significant
differences in detection rates were found between MODS and MOlT (P=0.80),
MODS and LJ (P=0.2) or MOlT and LJ (P=O.I).
There were 3731709 (52.6%) samples positive by either MOlT or LJ culture. The
sensitivity, specificity, positive predictive value and negative predictive value of
MODS against MOIT/ LJ positive as the gold standard were 89.0% (n=332/373,
95%CI: 85.4, 91.9), 92.3% (n=310/336, 95%CI: 88.9, 94.9), 92.7% (n=332/358,
95%CI: 89.5,95.2) and 88.3% (n=310/351, 95%CI: 84.5,91.5), respectively.
3.5.4.3 Detection of drug-resistance
3.5.4.3.1 Drug-resistant isolates detected by 1% proportion method (DST-LJ - the
gold standard method) (n=364)
Although there were 373 samples positive by either MOlT or LJ, 9 samples were
identified as Mfortuitum or M Chelonae which were identified by standard
biochemical tests and therefore DST-LJ was not done for these samples. Of these 9
samples, seven samples were positive by MODS and could not be differentiated from
M.tuberculosis complex by cording observation, one sample was -MODSnegative and
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the last one was contaminated with fungi. As a result, 364/373 samples with DST
results by 1% proportion method were available for analysis (table 3.14). The
multidrug resistant isolates (MDR-TB) account for 3.8% (n=14/364) of cases.
Isoniazid and rifampicin monoresistant isolates was detected in 3.8% (n=14/364) and
0.3% (n=1/364) of samples, respectively.
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Table 3.14 Drug-resistant profiles of364 samples witbDSTILJ results available
for analysis.
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(2Jlg/ml) and Z: Pyrazinamide (PZA - 200pg/m/). The MDR-TB rate (at least HR resistant)
was 3.8%. Isoniazid monoresistance and Rifampicin monoresistance were 3.8% and 0.3%.
respectively.
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3.5.4.3.2 Study population for the evaluation of DST-MODS
Of the 358 samples positive by MODS culture, 88.5% (n=317/358) had two control
wells (drug-free wells) positive by DST-MODS and 94.6% (n=300/3l7) of them were
eligible for final DST analysis between DST-MODS and DST-LJ (figure 3.13). Five
point four percent (5.4%, n=17/317) of samples were excluded from analysis because
of probable cross-contamination by MODS (n=1) and no DST-LJ results (n=16). The
remaining positive MODS samples (11.5%, n=41/358) only had one control well
positive by MODS and were analyzed separately.
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Figure 3.13 Recruitment flow chart of 709 TB suspects evaluation of MODS for
detection of MDR-TB.
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3.5.4.3.3 DST-MODS analysis
There were 300 isolates with DST results available by both MODS and traditional
DST method. Accuracy of DST-MODS were evaluated based on these isolates
DST results by MODS
For 300 isolates with DST-MODS and DST-LJ available for analysis, DST-MODS
detected INH, RIF and MDR resistant isolates at 16.7% (n=50/300), 3% (n=9/300)
and 2.7% (n=8/300), respectively. DST results of 300 isolates by MODS in
comparison to LJ for INH and RIF are described in figure 3.14.
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DST-MODS against DST-LJ as the gold standard
Direct drug susceptibility testing results on MODS were compared with indirect DST on
LJ as the gold standard for 300 samples. The sensitivity, specificity, positive predictive
value (PPV) and negative predictive value (NPV) of DST-MODS were 72.6% (n=45/62,
95%CI: 59.8, 83.1), 97.9% (n=233/238, 95%CI: 95.2, 99.3), 90.0% (n=45150, 95%CI:
78.2, 96.7) and 93.2% (n=233/250, 95%CI: 89.3, 95.9), respectively for detection of
INH resistant isolates; and 72.7% (n=8/11, 95%CI: 39.0, 93.9), 99.7% (n=288/289,
95%CI: 98.1, 99.9), 88.9% (n=8/9, 9S%CI: 51.8, 99.7) and 98.8% (n=288/291, 95%CI:
97.0,99.8), respectively for RIF resistant isolates. The agreement between DST-MODS
and DST-LJ were 92.7% (n=278/300, 95%CI: 89.1, 95.3, kappa: 0.8, P<O.OOI)for
detection of INH resistant isolates and 98.7% (n=296/300, 95%CI: 96.6, 99.6, kappa:
0.8, P<O.OOI)for RIF resistant isolates.
In terms of MDR-TB diagnosis, the sensitivity, specificity, PPV and NPV of DST-
MODS against DST-LJ as the gold standard were 77.8% (n=7/9, 95%CI: 39.9, 97.1),
99.7% (n=290/291, 95%CI: 98.1, 99.9), 87.5% (n=7/8, 95%CI: 47.3, 99.6) and 99.3%
(n=290/292, 95%CI: 97.5, 99.9%), respectively. The agreement between DST-MODS
and DST-LJ was 99% (n=297/300, 9S%CI: 97.1, 99.7, kappa: 0.8, P<O.OOI) for
detection of MDR isolates.
3.5.4.4 MAS-PCR
In this study, MAS-PCR was used to confirm INH and RIF resistance in isolates
classified as susceptible by MODS and resistant by LJ, or vice versa. MAS-PCR cannot
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be used to 'rule-out' true resistance because approximately 5% and 20% of RIF and INH
resistant isolates, respectively will not have mutations in the targeted gene sites (109).
Resolve discrepancy in resistant isolates detected by DST -MODS and DST -LJ
There was 25/300 isolates with discrepant DST results between MODS and LJ for INH,
RIF or both INH and RIF (table 3.15). Of which, 3 samples were discrepant for RIF
resistance, 22 samples were discrepant for INH resistance and 1 sample was discrepant
for both INH and RIF resistance.
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Table 3.15 Discrepant DST results between MODS and LJ resolved by MAS-peR
Isolate f----r----+----r-----I~===::..:;...r..::::.::.::.~-l
NO
2
3
4
5
6
9
10
Remark
DST-MODS DST-LJ MAs-peR
s
S
S
resistant
resistant
resistant
resistant
20
21
22
25/3 00 isolates (8.3%) had discrepant DST results between MODS and LJfor INH or RIF.
R: resistant, S: susceptible, blank (-): no PCRproduct. Blank in black: concordance results
between MODS and LJ therefore MAS-PCR was not attempted.
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Among 4 isolates with RIF results discrepant between DST-MODS and DST-LJ (table
3.15), repeated DST-MODS for RIF 1ug/ml, MAS-peR and ropE sequencing
confirmed RIF resistance for one isolate (isolate 4, table 3.15) and RIF susceptible for 3
isolates (isolate 1,2,3) (table 3.15).
The sensitivity of MODS against LJ in detection of MDR-TB was 77.8% (n=7/9). Two
MDR isolates determined by LJ but not by MODS (both isolates were INH resistant and
RIF susceptible by MODS, (table 3.15, isolate 2,4) were resolved by MAS-peR. Of
these two isolates, one isolate was INH susceptible and RIF resistant by MAS-peR. The
other isolate was INH resistant by MAS-peR. No RIF result by MAS-peR for this
isolate because of no hybridization.
The specificity of DST-MODS in detection ofMDR-TB was 99.7% (n=290/29I). There
was one MDR isolate determined by DST-MODS but this isolate was INH and RIF
susceptible by DST-LJ (table 3.15, isolate 1). MAS-peR detected INH resistance
mutation (katG) for this isolate but no mutation on ropE target gene was found.
Of 62 isolates with INH resistance by DST-LJ, 17 isolates were INH-susceptible by
MODS (table 3.15 and table 3.16). Of these 17 isolates, mutations on katG and inhA
promoter genes were detected in 35.3% (n=6/17) and 47.1% (n=8/17) of isolates,
respectively. Wild type was found by MAS-peR for 17.6% (n=3/17) of cases.
Therefore, we concluded that 14/17 isolates were truly INH resistant due to the
confirmed presence of resistance mutations. For the remaining 3 isolates we were unable
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to confirm/exclude resistance since INH resistance conferring mutations may be present
outside the MAS-peR target sites.
Table 3.16 Analysis ofMAS-PCR in 62 isolates with INH resistant by proportional
DST method, in relation to DSTIMODS results
MAs-peR
KatGand
KatG inhA inliA WT Indefinite Total
00 33
~ Resistant 03 01 07 01 45
0
~
Suscepti 06 08 00 03 00 17
00 ble
~ All
strains
39 11 01 10 01 62
Of 17 isolates with INH susceptible by DSTIMODS, 8 isolates (47.1%) had mutation on inhA
promoter gene and 6 isolates (35.3%) carried mutation on katG gene.
Twenty-two isolates with INH results discrepant between DST-MODS and DST-LJ
were repeated by DST-MODS for INH at a lower concentration (Glug/ml instead of
OAI!g/ml) because it was hypthesised the O.4I!g/ml concentration may be missing low-
level INH resistant isolates since a recent meta-anlysis (124)suggests better accuracy of
the O.Iug/ml INH concentration for MODS. Eighteen (81.8%,n=18/22) samples were
culture negative on MODS (recruited smear results were negative for 13 samples, scanty
for one sample and 1+ for 4 samples). Therefore, DST results for these samples were not
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available. The results of the remaining 4 isolates were completely accordant with those
of DST-LJ and MAS-peR; two of them converted from resistant to susceptible and the
other two converted from susceptible to resistant. The latter carries mutation on inhA
promoter gene detected by MAS-peR.
3.5.4.5 Analysis of samples with one positive control by DST-MODS (DST-MODS
results were recorded as uninterpretable).
Thirty-two DST -MODS samples with one positive control (figure 3.13) were analyzed
separately. Of which. 21.9% (n=7/32) were negative by both MGIT and LJ culture and
78.1 % (n=25/32) were positive by either MGIT or LJ culture. Data from routine testing
showed that 96% of these samples (n=24/25) were negative by direct smear and only
one sample had positive smear (scanty result).
3.5.4.6 Time to detection
Time to detection (positive) for TB diagnosis
Time to positive was recorded as the duration of time from sample inoculation to
positive result available in days. For 327 samples positive by both MODS and MOlT.
the tum-around time of MODS was 9 days (IQR: 7-11 days) while it was 11 days (IQR:
7-13 days) for MGIT. The time to positive of MODS was significantly faster than that of
MGIT (P<O.OOI) (figure 3.15).
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Figure 3.15 Time to positive of MODS culture and MGIT culture in DST·MODS
study.
••••••••• MODS
---MGIT
9 11 20 30 40
Time to positive results (in days)
n = 327
In 327 samples positive by both MODS and MGIT, the turnaround time of MODS and MGIT
were 9 days (IQR: 7-11 days) and 11 days (IQR: 7-13days), P<O.OOI by Cox proportional
hazards regression model.
Time to DST result available
Time to DST result available was defined as the period of time from sample inoculation
to DST result available in days. For DST-MODS, this duration was exactly the same as
the time to positive by MODS culture (median = 9 days). For DST-LJ, this time was the
sum of time to positive of MOlT or LJ culture (a median of 11 days) and doing DST-LJ
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(42 days). Therefore, the median total turn-around time of DST-LJ was 51 days which
was much slower than DST -MODS.
3.5.4.7 Contamination
Contamination with fungi and cross-contamination were analyzed for all 709 samples.
Contamination of MODS culture: The initial fungal contamination rate was 0.6%
(n=41709). No re-decontamination and re-culture on MODS were attempted for
contaminated MODS because of the limited volume of MODS culture (Iml). Three
samples were cross-contaminated with H37Rv, the positive control isolate used in this
study and seven samples were suspected of cross-contamination between samples,
generating a maximum possible cross-contamination rate of 1.4% (n=101709).
Contamination of MOlT and LJ: The final fungal contamination rate of MOlT and LJ
were 0.7% (n=51709) and 0.6% (n=41709), respectively. Four samples were
contaminated for both MOlT and LJ. Cross-contamination by MOlT and LJ was not
determined. However, there was one isolate found to be RIF susceptible by DST-MODS
and synonymous mutation on ropB gene by sequencing but resistant by DST-LJ (table
3.15, isolate 2).
3.5.5 DISCUSSION
Our data showed that MODS is a sensitive and rapid method for diagnosis of TB and
MDR-TB. Although TB detection rate of MODS (50.5%) was not different from MOlT
(51.6%, p=0.8) and LJ (44.4%, p=0.2), MODS was faster than MOIT at 9 days vs 11
days.
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For MDR detection, the turnaround time strongly favored DST-MODS (9 days) over
DST-LJ (53 days). In terms of detection of INH or RIF resistance, the agreement
between DST-MODS and DST-LJ were 92.7% for detection of INH resistant isolates
and 98.7% for RIF resistant isolates. The sensitivity and specificity of DST-MODS
against DST-LJ (the gold standard) were 72.6% and 97.9%, respectively for INH
resistance and 72.7% and 99.7%, respectively for RIF resistance. The agreement,
sensitivity and specificity of DST-MODS and DST-LJ for detection of MDR-TB
isolates were 99%, 78.7% and 99.7%, respectively.
The sensitivities in detection of INH and RIF resistance in our .study were lower than
those from the study of Moore at el (72.6% vs 84.6% for INH and 72.7% vs 100% for
RIF) (132) although both studies used the same INH concentration (O.4~glml)and RIF
concentration (1ug/ml). These concentrations have been recommended by the MODS
guidelines from the Peru group (90). However, a recent meta-analysis published after
completion of this study concluded that the sensitivity was higher with a concentration
of 0.1ug/ml without loss of specificity (124). To address this issue, we attempted to
repeat DST-MODS and performed MAS-peR for 26 isolates with discrepant results
between DST-MODS and DST-LJ for INH and RIF.
For INH discrepant isolates, we found that 8/17 (47%) isolates susceptible by DST-
MODS but resistant by DST-LJ carried mutation on inhA promoter gene (table 3.15 and
table 3.16). Previous study has shown that inhA promoter mutation was associated with
phenotypic INH resistance at low INH concentration (0.2~glml) (77). We attempted to
repeat DST-MODS for INH at O.Iug/ml concentration for all of these 8 processed
samples but only 2 samples were re-identified as INH resistant. The remaining samples
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were negative by MODS culture due to low bacterial load. This is a limitation of this
technique. Recently, Mello et al found that the sensitivity of DST-MODS for detection
of INH resistant isolates increased to 96.7% if INH 0.1 ug/ml was used for the MODS
assay (118); and similar conclusion was reported from a meta analysis (124). This
review supported the use of INH 0.1 ug/ml for DST -MODS and our data also supports
the conclusion that the use of O.4J.lglml reduces sensitivity in comparison with
conventional DST. The clinical applicability of these concentrations has not been
determined.
After resolving discrepant results between DST-MODS and DST-LJ for RIF for 4
isolates(table 3.15) by repeated DST-MODS, MAS-peR and ropB sequencing, the final
sensitivity of DST-MODS for detection of RIF was 77.8% (n=7/9). However, this
sensitivity is still lower than previous studies (118, 132) although the number of RIF
resistant isolates in this study was small leading to wide 95% confidence intervals on the
sensitivity estimate (39-93%) and the number of false negative results for RIF
resistance was only 3.
In 25 isolates with discrepant DST results between DST-MODS and DST-LJ for INH or
RIF (table 3.15), 20 isolates were susceptible by DST-MODS for either INH 0.4J.lg/ml
or RIF 1ug/ml but resistant by DST -LJ. One probable explanation is that the bacterial
load present in processed samples was not equally aliquoted into each of 4 wells of
DST-MODS due to the clumping characteristic of Msuberculosts. More bacteria may be
present in control wells than in drug-containing wells because processed samples were
aliquoted into control wells first and then the drug-containing wells; and therefore
cording formation was detected earlier in control wells than in drug-containing wells if
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there were resistant isolates present in that sample. As a result, at the reading time,
growth was seen in control wells but not in drug-containing wells and this isolate was
determined as a susceptible isolate by DST-MODS. Clumping may be the main factor
leading to one positive control of 32 samples in our study.
It is clear that INH O.4Ilg/ml is not appropriate for performing direct DST-MODS and
INH O.Iug/ml is a more appropriate concentration for implementation. In addition,
samples with low bacterial load (smear negative, smear scanty and smear 1+) are more
likely to result in inconsistent results by direct DST -MODS due to unequal aliquoting.
The only equipment needed to perform the MODS assay are an inverted microscope,
MODS plate and consumables, biological safety cabinet and incubator. The technical
competence required is aseptic technique and microscopy skills; NTPs applying smear
already have a workforce of experienced microscopists. A commercial MODS plate (TB
MODS kit™) has been developed by Hardy Diagnostics, USA in collaboration with
PATH and is under evaluation MODS is appropriate for screening for MDRTB in high
burden countries where such tests are urgently needed.
MODS meets many criteria for an MDR TB diagnostic test applicable for high-burden
settings such as rapid, low-cost, accurate and can be performed without the need for
biological safety level 3 laboratories (if the plate is not opened after inoculation).
Therefore, MODS is an alternative method for rapid MDR- TB detection in these
settings. Recently, wide application of MODS in resource-constrained settings has been
endorsed by WHO (238). However, an international standard operating procedure and a
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quality assurance system accredited by WHO should be developed to standardize and
maintain accuracy.
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3.6 Section 6
SAMPLE VOLUME FOR MODS ASSAY
3.6.1 INTRODUCTION
It has been known that sample volume affects the sensitivity and detection rate of a
microbiological test, especially volume of processed sample used for testing. The
importance of sample volume collected from patients has been confirmed in
bacteriological diagnosis for IBM by Thwaites et al (195). In previous MODS
studies, 100JlIof processed sputum sample was inoculated into each well of a 24 well-
plate and the sensitivity of MODS was higher than 90% (133, 151). In my project, the
sensitivity of MODS in diagnosis of IBM was evaluated. When 100111of CSF was
used for MODS culture (chapter 3 section 2, pilot study at HTD), although the
sensitivity of MODS was marginally lower than MGIT, the difference was not
significant (64.9% vs 70.2%, P=0.8). With the hope that increasing sample volume
would increase the sensitivity or detection rate of MODS, 250111processed sample
was used for the MODS study at PNI hospital (IBM-MODS, paediatric-MODS and
HIV-MODS). The results showed that the sensitivities of MODS against clinical gold
standard were comparable to those ofMGIT in IBM-MODS study (23.6% vs 29.9%,
respectively, P=0.18) and in paediatric-MODS study (39.7% vs 42.3%, respectively,
P=O.5). However, the sensitivity of MODS was lower than that of MGII in HIV-
MODS study (70.7% vs 74.9%, respectively, P=0.03). Interestingly, our DSI-MODS
data showed that with 100JlIprocessed sputum sample, the detection rates of MODS
Chapter 3 - Section 6 - Sample volume for MODS assay Page 235
and MOlT were comparable (50.5% vs 51.6%, respectively, P=0.8). From our data, it
is not clear if the concept that "increasing sample volume would increase the
sensitivity of MODS" is true for sputum samples. The aim of this chapter is to
compare the sensitivity of MODS in diagnosis of pulmonary TB using different
processed sample volumes (1OO~lvs 250~l).
3.6.2 METHOD
» One hundred smear positive routine sputum samples were consecutively
collected for this study. These samples were part of the DST-MODS study
conducted at PNT hospital at that time. Samples were collected at district
tuberculosis units for smear microscopy and then transferred to PNT hospital
for DST-MODS and volume evaluation. The average volume of each sputum
sample collected was 2ml. One mililitre of each processed sample was used
for DST-MODS. The remaining volume (lml) was used for volume
evaluation.
» 48-well plates were used for volume evaluation.
» Different processed sputum volumes were used. If 100~1 and 250~1 samples
were used, termed 100~1MODS and 250~1MODS, respectively.
» Detection rates, time to detection and contamination with fungi were
compared between methods.
» Details of laboratory methods were described in chapter 2, section 2.6.
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3.6.3 STATISTICAL ANALYSIS
~ The detection rates and reported confidence intervals were calculated
according to the method of Pearson and Clopper. Comparisons of accuracies
between tests were done using McNemar's test.
~ The time to positive of MODS between methods was compared in samples for
which both tests reached positivity with the Cox proportional hazards
regression model.
~ All analyses were done with Stata version 9 (Statacorp, Texas, USA).
3.6.4 RESULTS
3.6.4.1 Detection rate
In 100 smear positive sputum samples collected for this study, the detection rate of
250~1 MODS and 100~1MODS were 79% (n=79/100, 95%CI: 69.7%, 86.5%) and
91% (n=911100, 95%CI: 83.6%, 95.8%), respectively. The detection rate of
250~IMODS was comparable to 100~1MODS (P=0.49, 9S%CI:-0.l, 0.06).
3.6.4.2 Time to detection
Time to positive 250~1 MODS and 100~1MODS were 10 days (7-1Sdays) and 10
days (7-14 days), respectively.
3.6.4.3 Evaluation of contamination
No fungal contamination was observed in 250~1MODS and 100~1MODS.
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Evaluation of cross-contamination was not attempted due to resource limitation.
3.6.5 DISCUSSION
There was no evidence that increasing sample volume did not proportionally increase
the detection rate of MODS. Although the detection rate of 250111MODS and lOOll1
MODS were comparable (79% vs 91%, respectively, P=0.49), 'the higher detection
rate was in favour of IOOIlIMODS.
In this study, the total volume of sputum sample collected from a patient was
unchanged but the total volume of a processed sputum sample used for 3 MODS
experiments was increased (2ml compared to 1ml if one MODS experiment was
used). Performance of many experiments at the same time would increase the need of
processed sample volume; leading to over dilution of these processed samples. This
would result in a reduction in the number of bacilli aliquoted into each experiment
and therefore reduce the sensitivity and detection rate of the test. In addition,
clumping characteristic of M tuberculosis also increases the challenges in generating
equal aliquots for these experiments. Therefore, increasing total sample volume
collected from a patient is more important. WHO recommended that for culture, a
sputum specimen should have ideally a volume of 3-5ml with good quality (214).
Smaller quantity is acceptable but not less than 2ml and good quality.
The increase in processed sample:broth ratio will change pH of final MODS culture
and probably affect bacterial growth. With the sample:broth ratio of 1:10 (IOOIlI
MODS) and 1:3 (2501l1 MODS), the detection rates of MODS were comparable
although lOOll1MODS had a marginally higher detection rate. A recent study from
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India suggested that the sensitivity of MODS was proba~ly related to high
sample:broth ratio and at the ratio of 1:5, the sensitivity of MODS was improved
compared to that at 1:10 ratio (122). However, more studies should be conducted to
confirm this theory.
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3.7 Section 7
SUMMARY OF FINDINGS FROM THE MODS STUDY
3.7.1 MODS IN DIAGNOSIS OF TB
The accuracy of MODS in diagnosis of TB and MDR-TB has been evaluated in this
project.
Compared to homogenous smear microscopy, MODS had a higher sensitivity
against clinical gold standard in detection of TB for all patient groups (12.1% vs
23.6%, respectively, P=0.0012 for TBM; 28.2% vs 39.7%, respectively, P=O.OII for
paediatric TB and 57% vs 71%, respectively, P<O.OOI for HIV/TB). The pooled
sensitivity of MODS was 13% higher than that of smear microscopy (P=0.0092)
Compared to MGIT, MODS had a similar sensitivity against clinical gold standard
in detection ofTB in TUM (29.9% vs 23.6%, respectively, P=0.18 for data from PNT
hospital), paediatric TB (42.3% vs 39.7%, respectively, P=0.5) and in adults
pulmonary TB with unknown HIV status (DST-MODS) (51.6% vs 50.5%,
respectively, P=0.8). However, in HIV-infected patients suspected of pulmonary TB,
the sensitivity of MODS was lower than that of MGIT (70.7% vs 74.9%,
respectively, P=0.03). In patients suspected ofTBM, both MODS and MGIT detected
more cases in HIV positive group than in HIV negative group although no significant
difference was detected (67.5% vs 58.8%, respectively, P=0.8 for MODS culture and
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75% vs 58.8%, respectively, P=0.6). The pooled sensitivity across all studies of
MODS was comparable to MGIT (53.0% vs 57.8%, respectively, P=0.39).
In general, although the sensitivity of MODS and MOlT were not always significantly
different, the sensitivity of MODS was consistently marginally lower than that of
MOlT across all studies.
The specificity of MODS was 100% for TBM-MODS, 94.4% for paediatric-MODS
and 100% for HIV-MODS.
Time to positive of MODS was faster than MOlT in all sample types. For CSF
sample, the turnaround time of MODS and MOlT was 7 days and 18 days,
respectively. For other sample types, mainly sputum samples, the turnaround time of
MODS and MOlT was 8 days (IQR: 6-12 days) and 13 days (lQR:8-19 days),
respectively.
In smear negative TB patients, the sensitivity of MODS and MOlT was comparable
(17.8% vs 21.4%, respectively, P=0.5 for paediatric study and 38.0% vs 45.0%,
respectively, P=0.078 for HIV positive patients). However, median time to detection
of MODS was faster than MOlT, 12days (IQR: 8-17 days) vs 19 days (IQR: 5-22
days), respectively.
3.7.2 MODS IN DIAGNOSIS OF MDR-TB
The sensitivity and specificity of DST-MODS were 72.6% (n=4S/62) and 97.9%
(n=233/238), respectively for detection of INH resistant isolates, 72.7% (n=8/11) and
99.7% (n=288/289), respectively for RIF resistant isolates and 77.8% (n=7/9) and
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99.7% (n=290/291), respectively for MDR isolates. The agreement between DST-
MODS and DST-LJ was 92.7% (kappa: 0.8, P<O.OOl) for detection ofINH resistance,
98.7% (kappa: 0.8, P<O.OOI) for RIF resistance and 99.0% (kappa: 0.8, P<O.OOl) for
MDR. PPV and NPV were 90.0% and 93.2%, respectively, for detection of INH
resistance, 88.9% and 98.8%, respectively, for RIF resistance and 87.5% and 99.3%
for MDR-TB. The low sensitivity of DST-MODS in our study was probably due to
low bacterial load samples and high INH concentration (O.4Ilg/ml). The turnaround
time of DST-MODS was 9 days and it was 53 days for DST-LJ.
Overall, these studies showed that MODS is an accurate and reliable method for
diagnosis of TB and MDR-TB in high burden countries. Large scale operational
research should be conducted to evaluate the implementation of MODS.
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Chapter4
EVALUATION OF A NEW GENERATION OF FLUORESCENT
MICROSCOPE (LED-based fluorescence microscope) IN TB
DECTECTION
4.1 INTRODUCTION
4.1.1 Conventional smear microscopy
Global Millennium Health Development goals for TB are to reduce TB prevalence
and mortality by 50% relative to 1990 levels and to eliminate TB by 2050 (224). To
achieve these targets, early diagnosis and treatment of new cases are crucial. In most
countries, under National TB Programs, TB cases are primarily detected by acid-fast
bacilli identification in sputum by conventional light microscope because it is
specific, rapid, inexpensive and straightforward. However, the most important
disadvantage of smear microscopy is poor sensitivity (estimated to be around 50% of
active pulmonary cases) (234). Therefore, rapid, highly sensitive and inexpensive
tests are urgently needed to improve case detection under the Stop TB strategy (234).
Since smear microscopy has been implemented in national TB programs worldwide,
the easiest way to increase case detection in developing countries is to improve smear
microscopy. Collaborative global efforts have been established to address this issue.
According to a series of. systematic reviews by the UNICEFIUNDP/World
Bank/WHO Special Programme for Research and Training in Tropical Diseases
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(TOR) in 2005, there were three potential ways to improve sputum microscopy:
sputum processing methods, number and quality of sputum samples examined per
patient and fluorescence microscopy (223).
Sputum processing methods are used to concentrate the bacterial load in a sample to
gain higher detection rates. Detection rates can be increased by either applying
sputum processing in areas where only direct smear is currently performed, or by
developing improved and simpler sputum processing methodologies. However,
existing methods require laboratories equipped for safe sample processing and well-
trained staff. In addition, sample processing increases the workload for staff whose
workload may already exceeded the upper limit recommended by WHO. Therefore,
sputum processing methods may not be a feasible priority in high burden countries
which lack both financial and personnel resources.
Sputum smear microscopy utilising Ziehl-Neelsen (ZN) is currently the cornerstone of
diagnosis applied in the National TB Program in Viet Nam despite its well-known
disadvantages (121). The TB reference laboratory at PNT hospital receives about 900
to 1000 clinical samples of all types per day for TB detection; generating
overwhelming work for laboratory staff. Approximately 100 slides are read by each
technician daily, of which almost 30% are fluorescence smears. At peripheral sites
(District TB Units), according to an internal report from the TB Control Programme
in Ho Chi Minh City, 49,965 suspects were screened for TB in 2008, generating
207,590 slides for examination (80). This is a high burden of work for staff working
at laboratories, especially in peripheral TB units where smear microscopy is the only
microbiological method for use in TB diagnosis. To promote quality assurance of
smear microscopy, the National TB Programme has a programme including annually
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training and retraining for technicians, supervision and supply of high quality
microscopes. However, recommendations on daily work-load per technician should
be considered to prevent visual fatigue leading to a deterioration of reading quality.
WHO suggests that at least 2-3 smears need to be read by a microscopist per day to
maintain proficiency and each technician should examine a maximum of 20 smears
per day to avoid visual fatigue and deterioration of quality (215, 254). However, staff
at over 30% ofTB laboratory units in HCMC have to examine over 20 smears per day
due to a lack of or poor continuity of human resources. Furthermore, staff shortages
combined with increasing numbers of requests for sputum microscopy are creating
unmanageable workloads with negative effects on TB case finding. The poor
sensitivity of light microscopy even under optimal conditions further aggravates this
situation. Therefore, in the absence of a viable alternative diagnostic technique,
reducing workload and increasing the sensitivity of smear microscopy as well as
diminishing smear reading time are urgent priorities for the National TB Program.
Recently, replacing light microscopy with fluorescence microscopy has been
considered and may be one of the immediate options to improve the situation in high
burden countries (64).
4.1.2 Fluorescence microscopy
Fluorescence microscopy (FM) appears to have several advantages over light
microscopy (LM). First, the fluorescent staining procedure is simpler than that of ZN
staining because no heating step is required. Second, AFBs are stained with auramine
and appear as a bright yellow colour which is dominant on a dark background as
'stars on the night sky' and is easily recognized. Third, an increase in sensitivity has
been reported for FM. A meta-analysis has shown that FM is 10%more sensitive than
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LM in detection of AFB from specimens (180). Fourth, 40X objective can be used in
FM instead of 100X in LM leading to shorter reading time by reducing the number of
fields examined for a single slide. It has been estimated that using FM can save 75%
of reading time in comparison with LM (180).
Unfortunately, despite many apparent advantages against LM, FM has not been
widely implemented, especially in low resource settings with a high burden of TB.
The major obstacles are the high price for FM and the lack of robustness and
sustainability. Conventional FM use expensive and very fragile gas discharge lamps
(such as Xenon- or Mercury-lamps) with high power consumption and a short lifespan
of only 100-200 hours (6). The lifespan is further shortened by fluctuating power
supply or turning them on and off frequently. Furthermore, heat production and the
need to work in a dark room have prevented FM from being applied in many high TB
prevalence areas.
4.1.3 ILED microscope
In response to a call from WHO in 2005 in an expert consultation meeting (223),
progress has been made to develop a simpler FM which overcomes the disadvantages
of the conventional FM. Carl Zeiss, Inc company (www.zeiss.com) has developed
the Primo Star iLED (iLED) microscope, functioning as both light and fluorescence
microscope, in agreement with the Foundation for Innovative New Diagnostics
(FIND) (65) which has a high specification and lower price. The iLED microscope
refers to iLED fluorescence microscope, unless demonstration as ZN-iLED for iLED
light microscope, and was evaluated in this chapter.
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iLED is a fluorescence microscope using the ultra bright LED (light emitting diode)
technology as a light source to detect bacilli on a fluorescent smear (6). The lifespan
of LED is at least 10 years. After connection to a power source, the microscope is
ready to use immediately, without the warm-up and cool-down steps as required with
mercury vapour lamps. In addition, it consumes only one-tenth the power of a 50 watt
mercury-vapour lamp. The first generation of this microscope has undergone an initial
performance evaluation using conventional FM and LJ culture as the gold standard,
which showed promising results in the development phase: The sensitivity and
specificity of the Primo Star iLED prototype on direct smear was equivalent to the
results of standard FM, which is 71.6% vs 67.4%, respectively for sensitivity and
96.4% vs 96.1 %, respectively for specificity. Furthermore, feedback from 4 reference
laboratory settings revealed that in reading condition with or without a dark room, the
contrast and brightness of iLEO are still better than available standard FM.
Interestingly, the time saved using the Primo Star iLEO prototype was 45-75%
compared to LM and was at least equivalent to standard FM (64). This microscope is
therefore being evaluated and developed further. Data from FIND/WHO/TOR has
shown that compared to LM, Primostar iLEO is more sensitive and specific, faster in
reading time and more flexible (64) There is no need to work in the dark room, a
drawback of the conventional FM. Therefore, demonstration projects were initiated
for the iLED microscope.
In recent years, aside from ~rimo Star iLED microscope, some commercial LED
alternatives are available. CyScope® (Partee, Gorlitz, Germay), like Primo Star iLED,
uses a LED source for both light and fluorescence illumination. The other products
are attachments which are used to transform an existing light source from a light
microscope into a fluorescence illumination so that all lenses can be used with both
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light sources. These alternatives are Lumin™ (LW Scientific, Lawrenceville, GA,
USA), ParaLens™ (QBCTM Diagnostics, Philipsburg, PA, USA) and FluoLEDTM
(Fraen Corporation Srl, Settimo Milanese, Italy). All of these competitors are battery
powered but vary in weight and cost. Therefore, depending on purpose of use and
financial resources, users can choose the most appropriate product for their
application (126).
Pham Ngoc Thach hospital is one of the eight sites in the world (India, Viet Nam,
South Africa, Russia, Peru, Lesotho, Ethiopia and Tanzania) participating in the
FINDdemonstration phase evaluation of the iLED microscope led overall by
Catherina Boheme. The study aimed to determine the effectiveness of the iLED
microscope in TB detection at peripheral tuberculosis units and also evaluated the
performance and appraisal of the microscope by the operating laboratory technicians.
The work described here was conducted in collaboration with FIND diagnostics.
Dang Thi Minh Ha was a principal investigator for the Pham Ngoc Thach hospital site
and was responsible for the supervision, conduct and analysis of the work described
here.
4.2 AIMS
1. To assess the sensitivity and specificity of Primostar iLED in TB diagnosis at
microscopy centers with and without prior experience with fluorescence
microscopy.
2. To determine the false positive and false negative rate of LED fluorescence
reading compared to ZN baseline results and compared to results from the
supervisory site.
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3. To determine the development of false positivity and negativity rates of LED
fluorescence reading oyer time (with increasing experience).
4. To determine if AFB fading affects quantitative reading smear results and
factors leading to AFB fading.
5. To assess the impact of this implementation on daily workload and case
detection rates.
6. To evaluate the appraisal of Primos tar iLED by lab technicians.
4.3 METHODOLOGY
4.3.1 Enrollment
Phases involved in the enrollment period:
Phase I: Pilot study. Determination of sensitivity and specificity of Primostar iLED
using panel slides. This was done by one FM experienced technician at PNT
laboratory to compare conventional LM, conventional FM 40X, FM-iLED 40X
magnification and FM-iLED 20X magnification together.
Phase 2. Operational study. Programmatic implementation of Primostar iLED at three
District Tuberculosis Units (DTUI, DTU5 and DTU8) in Ho Chi Minh City
Phase 2.1. Establishing ZN baseline
Phase 2.2. FM and iLED training
Phase 2.3. Validation
Phase 2.4. Implementation
Phase 2.5. Continuation
Chapter 4 - iLED study Page 249
Phase 2.6. Reading assessment
4.3.1.1 Phase 1: Pilot study
Determination of sensitivity and specificity using Primostar iLED compared to
conventional light and fluorescence microscope using evaluation slide panels
prepared from real sputum. This phase was done by one FM-experienced
technician at PNT laboratory.
A slide set from real sputa was generated by Pham Ngoc Thach laboratory as
requested from FIND. A set included 110 ZN stained smears and 330 auramine
stained smears. All of these smears were read by conventional ZN microscope (110
slides), conventional fluorescent microscope 40X (110 slides), iLED 40X (110 slides)
and iLED 20X (110 slides). Of each 110 slide set, 35 slides were smear negative
(31.8%),15 slides were scanty (13.6%), 45 slides were 1+ (41.0%) and 15 slides were
high positive (2+ or 3+; 13.6%). Slides were put into standard slide boxes and stored
in an air conditioned room. All slides were labeled with ID numbers, for which smear
results were documented in a confidential Excel summary sheet which was stored at
FIND.
Prior to participating in this study laboratory technicians had to familiarize themselves
with the Primostar iLED using Auramine-stained slides that had been stored from
routine work at PNT hospital.
One FM-experienced technician conducted blinded reading for comparison between
Primostar iLED, standard light microsope and fluorescence microscope by
examination of the 110 slide set stained with ZN or Auramine/KMn04. Each day, this
technician read 15 - 16 ZN slides by light microscope (Olympus, model ex 21), 15 -
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16 auramine slides by conventional FM (Olympus, model BX 51) and 15 - 16
auramine slides by iLED 40X. The order of reading by conventional bright
microscope, conventional FM and iLED 40X were alternated every day to exclude
bias of fatigue at the end of the day. A set of auramine slides was also read by iLED
20X for comparison with the iLED 40X. The whole process was completed in 3
weeks. We assessed the sensitivity, specificity, positive predictive value, negative
predictive value, false positive and false negative rates, and identical rate and
corresponding rates (see section 4.3.2 for definition) of these methods in comparison
with phase 1 panel slide reference results. The time to result was also addressed in this
study; and the time to identical or corresponding results was evaluated.
4.3.1.2 Phase 2: Operational study
Programmatic implementation of Primos tar iLED in three routine microscopy
centers in Ho Chi Minh City without prior experience in fluorescence
microscopy, to determine operational performance and as well as laboratory
staff appraisal.
The scheme of phase 2 is shown in figure 4.1.
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Figure 4.1 Scheme of phase 2 - Operational study
Non FM-experienced staff
{ZN baseline (1 month) Read: conventional LMRecheck: conventional LM
FM training (5 working days) { Primostar iLED microscope
{Validation (1 month) Read: FM-iLED 40XRecheck: conventional FM 40X
Reading assessment { Read: FM-iLED 40XZN-LM Implementation (3 months) Recheck: FM-iLED 40X
FM-iLED40X
{ Read: FM-iLED 40XContinuation (6 months) Recheck: FM-iLED 40X
Fading assessment
FM-iLED 40X
LM· Light microscope
FM· Fluorescence microscope
ZN: Ziehl- Neelsen staining method
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4.3.1.2.1 Establishing ZN baseline phase (l month)
In order to be able to compare false positive and negative rates of LED fluorescence
to the respective rates of ZN reading, it was necessary to establish a baseline under
study conditions. Using data available from the routine quality assurance program
would possibly result in a bias because the performance is likely to be better under
study conditions. In this phase, all incoming sputum samples were examined by ZN
microscopy according to program normal operating procedures and kept in slide
boxes provided by FIND. All slides were rechecked by a ZN-experienced technician
at PNT laboratory and discrepant results were rechecked a second time by another
ZN-experienced technician from this laboratory according to the National TB
programme guidelines.
4.3.1.2.2 FM and iLED training (5 working days)
Pham Ngoc Thach Hospital was responsible for training laboratory staff from 3
microscopy centers. The training focused on smear preparation, auramine staining
method, FM reading and recording results. Slide storing and transfer to PNTH for
rechecking was also emphasized in the course. This training took place over 5 days
and all training materials were provided by FIND. All trainees passing the final test
(maximum 3 slides with major errors [see definition in chapter _2,section 2.6.2.2.5]
over 10 slides tested from the slide panel) had permission to start the validation phase
immediately after the course.
4.3.1.2.3 Validation phase (1 month)
The validation phase lasted for one month, during which auramme slides were
prepared from all incoming sputum samples at 3 participating sites and were
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examined by using Primostar iLED with 40X magnification for screening at the sites.
All slides were rechecked daily by the supervisory site using conventional
fluorescence microscopy 40X. Results were sent back to the microscopy center the
following day and treatment was started on the basis of the conventional fluorescence
microscopy result. At the end of this phase all staff at the sites participating to the
study underwent proficiency testing.
If the validation phase and proficiency panel met the following targets the sites were
ready to enter the implementation phase:
1) >95% accordance between results of the demonstration site and supervisory
site for fluorescence reading.
2) Quality of Auramine stains acceptable in 100%of slides.
3) ~ 2 false results in the proficiency testing panel.
Sites that failed to meet performance targets received additional training and
underwent proficiency testing until targets were met.
4.3.1.2.4 Implementation phase (3 months)
All routine sputum samples underwent routine microscopic examination with the
Primostar iLED according to program normal operating procedures, and patients were
managed based on Primostar iLED results for a period of 3 months. All slides were
stored in slide boxes which were provided by FIND. Quality control (QC) and
assurance (QA) followed the standards of the National TB Programme. All smears
were rechecked without re-staining at PNT laboratory by iLED 40X microscope. In
the first two months of this phase, all positive smears with scanty and 1+ results; and
20% of negative smears were rechecked. In the last month of this phase, rechecking
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followed the LQAS guidelines; generating 14 slides which were rechecked for DTUI
and 8 slides each for DTU5 and DTU8. The rechecking process allowed
determination of the sensitivity, specificity, false positive / false negative rates and
detection rates over time (with increasing experience). These rates were then
compared to the rates of the ZN baseline. Rechecking was performed by experienced
staffs only and all discrepant slides were re-examined by another experienced
technician at PNT laboratory. The prevalence of positive slides during
implementation was compared with preceding quarters.
4.3.1.2.5 Continuation phase (6 months)
All routine sputum samples were examined by iLED 40X and the rechecking
procedure followed the LQAS guideline. In addition, to examine if fading affected the
reading accuracy of technicians, AFB fading in relation to sample processing method
and storage conditions were also addressed during this phase. After staining and after
each reading, all slides were put into the standard storage boxes to prevent exposure
to sunlight. The average percentage of AFB faded in a reading field was recorded for
each slide. This assessment was subjective and dependent on the proficiency skill of
reference technicians to distinguish AFB colour of recent reading time to their
experience. Semi-quantitative results were also recorded in the fading assessment.
Results were recorded according to WHO scale and were compared with previous
scale.
4.3.1.2.6 Reading result in relation to AFB fading and storage time
Slide collection was carried out in June, July and August of 2009 and rechecking was
finished in November 2009.
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In brief, routine slides from peripheral sites were kept at the sites until the end of the
calendar month at room temperature (28°C - 32°C, approximately 70% - 80%
humidity and without any air-conditioning in the room). After that, all of these slides
were transferred to PNT hospital for LQAS procedure. These slides were stored in an
air-conditioned room (22°C - 25°C, approx. 60% humidity) during the working day
and at room temperature overnight (the normal storage conditions at PNT laboratory).
Slide collection and rechecking schedule was carried out as described in table 4.1.
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Table 4.1 Slide collection and rechecking schedule in fading assessment related to
storage time
June 2009 July 2009 August 2009
Total slides collected 15 smears+
ve 15 smears +ve 15 smears +ve
15 smears?" 15 smears?" 15 smears?"
Number of slides in the 1st
rechecking (after 1 month, 4 smears' " 5 smears'?" 6 smears?"
mainly slides from LQAS
system)
Number of slides in the
2nd rechecking 30 slides 30 slides 30 slides
(rechecked in October
2009)
Number of slides in the
3rd rechecking 30 slides 30 slides 30 slides
(rechecked in November
2009)
In total, 45 positive smears and 45 negative smears were collected for this assessment.
The first rechecking was done mainly for positive smears in the LQAS collection of
the continuation phase. The second rechecking and the third rechecking were done in
October and November, respectively for all 90 slides. Time difference (in days)
between the two reading times of the same slide, reading result and AFB colour were
recorded. The percentage of faded AFB on each slide was recorded at each time of
reading. The quantitative results were compared to those from the previous reading.
Chapter 4 - iLED study Page 257
4.3.1.2.7 AFB fading in relation to sample processing methods and storage condition.
One hundred and eighty smear positive sputum samples were' subjected to smear
preparation and Auramine staining and were divided into 3 groups:
Group 1: Sixty samples were processed with NALC-NaOH to generate
homogenous smears.
Group 2: Sixty samples were processed with NALC-NaOH and Formaldehyde
(method for panel slide preparation).
Group 3: Sixty samples were subjected to direct smear preparation (without
any processing method).
Thirty slides from each group were stored at room temperature and the remaining
slides were stored in an air conditioned room during the working day. All slides were
rechecked 3 times by iLED 40X at an average of one month intervals. The percentage
of faded AFB on each slide was recorded on each occasion of reading.
4.3.1.2.8 Reading assessment
This assessment was performed during the Implementation phase to compare reading
accuracy between ZN- light microscope (ZN-LM) and FM-iLED. This assessment
was applied to all six technicians participating in this study, including 4 technicians
from demonstration sites and 2 technicians from PNT laboratory. Each staff member
read 1 ZN panel slide set (25 slides) and 1 FM panel slide set '(25 slides) by using
conventional light microscope and FM-iLED40X, respectively, with time taken
recorded. Each ZN set consisted of 15 smear negative and 10 smear positive slides.
Each Auramine set included 15 - 16 smear negative and 9 - 10 smear positive slides.
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The sensitivity, specificity, false positive and false negative rates, reading time and
focusing time (median time, in seconds) for each technician were used for comparison
between technicians and between the two reading methods. Reading time, recorded by
a supervisor, was defined as the time from starting to examine the first field of a slide
to the time when the semi-quantitative result was available. If there was any
discrepancy between the first reading results and the reference results, time to the
results available of the second reading was recorded for evaluation. Focusing time
was defined as the time taken for adjusting the microscope to starting to read the slide.
4.3.2 Definitions
~ "Sensitivity" of a test is the number of slides read as positive by that test over
the total slides read as positive by a gold standard method.
~ "Specificity" of a test is the number of slides read as negative by that test over
the total slides read as negative by a gold standard method.
~ "Positive predictive value" is the number of slides read as positive by both
evaluated test and gold standard method over the total p~sitive slides read by
that evaluated test.
~ "Negative predictive value" is the number of slides read as negative by both
evaluated test and gold standard method over the total negative slides read by
that evaluated test.
~ "False positive rate" is the number of slides read as negative by a gold
standard method but positive by an evaluated test over the total number of
slides observed.
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> "False negative rate" is the number of slides read as positive by a gold
standard method but negative by an evaluated test over the total number of
slides observed.
> The 'identical rate' was defined as the number of slides having the same semi-
quantitative results (according to IUALTD/WHO scale) over the total number
of slides read.
> The 'corresponding rate' was defined as the number of slides with the same
binary result (positive or negative, ignoring the positive scale) over the total
slides examined.
~ Time to result was defined as the duration of time from the start of reading to
the result available.
~ Time to identical or corresponding results is the duration of time from the start
of reading to the results being available for slides with identical results or
slides with corresponding results. This time did not include the time for
microscope adjustment.
4.3.3 Quality assurance
Light microscopes (Olympus, CX21) with 3-4 years of use and conventional
fluorescent microscope (Olympus, BX 51) with 4 years of use were compared with
iLED microscope. All of these microscopes were still in good condition at the time of
the study (recorded from the latest quarterly supervision report).
All routine smears at the participating sites were read by TB technicians who have
never previously worked with FM microscope but had a median of 28.5 years (range
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8-29 years) experience with ZN microscopy. Smears were read/rechecked by one of
the three full-time PNT laboratory supervisors based on the requirements of each
phase, who have a median experience of 5 years with FM (range 1 - 5 years)and 9
years (range 5 - 29 years) with ZN microscopy.
A workshop was organized for all participants involved in the study, including both
supervision and demonstration sites. The training focused on knowledge and skills to
perform fluorescence-based smear microscopy using the Primo Star iLED. After the
training, a proficiency test was performed for all participants. The proficiency reading
results showed 100% sensitivity and specificity for all staff.
At the end of the validation phase, a proficiency slide panel of 10 ZN and 10
auramine slides were provided to all participating sites. If there was (1»95%
accordance between results of the demonstration site and supervisory site for
fluorescence readings and (2) Quality of auramine stains was acceptable in 100% and
(3) ~ 2 false results in the proficiency testing panel, the participating site was ready to
enter the implementation phase. Otherwise, further training was provided until the
above targets were met.
At the end of implementation and continuation phases, each technician from the
demonstration sites had to read a slide panel including 10 ZN slides and 10 auramine
slides by using iLED microscope (both smear positive and negative slides) to
determine the reading skill development over time. The sensitivity, specificity, false
positive and false negative rates, corresponding results and reading time were
recorded for comparison between phases.
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All staining reagents and solutions were prepared monthly by PNT laboratory for use
at PNT and all study sites. For each preparation batch, quality testing was done by
preparation of control slides to ensure all working solutions/reagents met standard
requirements (in terms of AFB colour, decolourization, background staining and
contamination).
All staining solutions were stored in a place away from heat, humidity, sunlight and
explosivelflammable agents. Fuchsine and auramine were filtered twice a week before
use. All redundant staining solutions were discarded after a month.
During the study, site visits from supervision site to participation sites were organized
according to protocol guidelines for quality assurance; at least one supervisory visit
was conducted for each site monthly.
An appraisal form was also completed by staff at each site by the end of each phase to
determine end-user assessment at the sites.
4.3.4 Microbiology methods
~ Panel slide preparation (phase 1 and fading assessment phase): see chapter 2,
section 2.6.2.2.1.c
~ Sample collection at District Tuberculosis Units (phase 2): see chapter 2,
section 2.4
~ Smear preparation, staining, reading and recording: see chapter 2, section
2.6.2.2
4.3.5 Statistical analysis
~ The statistical analysis is described in chapter 2, section 2.S
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4.4RESULTS
4.4.1 Phase 1: Pilot study
Determination of the effectiveness of Primostar iLED in comparison with
conventional light and fluorescence microscopy using evaluation slide panels.
Four panel slide sets including 110 slides each were examined under light microscope
(IOOX), conventional fluorescent microscope (40X), iLED microscope (40X) and
iLED microscope (20X), by a single technician with time to result recorded. The
sensitivity and specificity of iLED 40X microscope against Phase 1 panel slide
reference results were 94.67% and 100%, respectively; and 94.67% and 97.14%,
respectively for iLED 20X microscope. There was no significant difference among
the methods in terms of sensitivity, specificity, PPV, NPV, identical rate,
corresponding rate, false positive and false negative rates (table 4.2).
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Table 4.2 Effectiveness of light microscope (ZN), conventional fluorescent
microscope (FM 40X) and iLED microscope (40X and 20X) in M.tuberculosis
detection by panel slides
ZN FM40X iLED 40X iLED 20X
(N=110) (N=110) (N=110) (N=110)
Sensitivity Pl=0.74 P2=0.63 P3=0.87 P4=O.87
% 97.3 94.7 94.7 94.7
(95%Cn 92.8":"99.9. 86.9 -_2_8.5 86.9 - 98.5 86.9 - 98.5
Specificity
% 100 lOO 100 97.1
(95%CI) 90.0 -100.0 90.0 -100.0 89.9 -100.0 85.0 - 99.0
PPV
% 100 100 100 98.6
(95%CI) 95.1 ~ 100 94.9- J1)_O 94.9 - 100 95.2 - 99.9_
NPV Pl=0.80 P2=1.00 P3=0.80 P4=0.99
0/0 94.6 89.7 89.7 89.5
(95%CI) 85.5 - 99.9 75.8 - 97.1 75.8 - 97.1 75.2 -97.0
False positive P4=1.00
% 0.0 0.0 0.0 1.39
(95%CI)
Pl=0.36 P2=1.00 P3=O.22 P4=1.00
2.8 10.3 10.3 . 10.5
Pl=0.74 P2=O.63 P3=0.87 P4=0.87
88.2 82.7 90.9 88.2
80.6- 88.2 4.3 - 89.3 83.9 -95.6 80.6-9 .6
Corresponding rate Pl=0.88 P2=1.00 P3=O.88 P4=0.96
% 99.9 96.4 96.4 95.5
(95%CI) 95.0""' 99.9 90.9 - 99.0 90.9 - 99.0 89.7 - 98.5
110 panel slides were read by one technician with high experience in fluorescence
microscopy. All measurements were compared against Phase 1panel slide reference results.
Pairwise comparisons between groups were performed by Fisher's exact test. P1,' ZN vs FM
40X, P2: FM 40Xvs iLED 40X, P3: ZNvs iLED 40X and P4,' iLED 40Xvs iLED 20X No
significant difference was found between the groups.
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The time to identical result and time to corresponding result was also recorded for
each slide to compare the reading time between methods. Our data shows that 54.6%
(n=60/110) and 53.7% (n=59/110) of slides examined by iLED 40X and iLED 20X,
respectively had results available which were identical to the reference results, within
30 seconds of examination. These rates increased to 90.9% and 88.2% respectively
for iLED 40X and iLED 20X after 5 minutes. This trend was also observed for the
light microscope and conventional fluorescent microscope. Similar results were also
found when analyzing the correlation between corresponding rate and time to result
(figure 4.2).
In general, there was no advantage in terms of efficacy or speed when using iLED for
a technician highly experienced with both ZN and FM in comparison with
conventional light microscope and conventional fluorescence microscope.
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Figure 4.2 Identical (a) and corresponding (b) results in association with time to
result in panel slide reading.
a.
Identical results vs time to result
100.00- 80.00 A=
~
~~...- 60.00~ ...,....~... ...--- - --= 40.00~"0~
~ 20.00e
0.00
30 sec 1 min 3 min 5 min
-+-ZN 43.64 54.55 56.36 88.18
...... FM40X 50.00 50.91 50.91 82.73
..... iLED40X 54.55 59.09 59.09 90.91
-*-iLED 20X 53.64 57.27 57.27 88.18
b.
Corresponding results vs time to results
.= 100.00= /~e 80.00bJ) /= ........ -"0 60.00= ... --eQ"~e 40.00...
Q
U 20.00
~
0.00
30 sec 1 min 3 min 5 min
"'-ZN 60.00 65.45 59.50 99.09
_FM40X 64.55 64.55 58.68 96.36
...... iLED40X 64.55 64.55 58.68 96.36
-++-oiLED 20X 64.55 64.55 58.68 95.45
Accumulated percentage of slides with available results by time was recorded for each
reading method. No significance in time to positive was found between microscopy methods.
Time to result available was not different between the methods.
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4.4.2 Phase 2: Operational study - Programmatic implementation of iLED
microscope.
The programmatic implementation of Primostar iLED was conducted in three routine
microscopy centers in Ho Chi Minh City without prior experience in fluorescence
microscopy, to determine operational and clinical performance as well as laboratory
staff appraisal.
4.4.2.1 Establishing ZN baseline
One thousand eight-hundred and twenty-seven smears were made during the ZN
baseline sub-phase by the 3 demonstration sites. The detection rates of DTU1, DTU5
and DTU8 were 9.6% (n=671700), 16.5% (n=35/212) and 16.4% (n=150/915);
generating an average detection rate across all sites of 13.8% (n=252/1827). The
sensitivity was varying between peripheral laboratories, ranging from 71.3%to 100%.
The specificity was almost 100% for all DTUs. False negative rates were in
acceptable range (~2%) except for one site (DTUl) with 4.3%. Results for each DTU
are shown in table 4.3.
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Table 4.3 Rechecking result in ZN baseline
DTUI DTU5 DTU8 All sites
N=700 N=212 N=915 N=1827
Sensitivity
% 71.3 100.0 96.1 88.4
(95%CI) 61.0 - 80.1 89.9 - 100 91.7 - 94.9 84.1-91.9
Specificity
% 100.0 100.0 99.9 99.9
(95%CI) 99.3 - 100 97.9 - 100 99.2 - 99.9 99.6 - 99.9
False positive
% 0.0 0.0 0.7 0.4
(95%Cn 0.0 -5.3 0.0 -10.0 0.0 - 3.6 0.01- 2.2
False negative
% 4.3 0.0 0.8 2.1
(95%Cn 2.8 -6.1 0-2.0 0.2 - 1.7 1.4 - 2.9
Identical rate
% 93.1 93.4 92.4 92.8
(95%Cn 91.0 -94.9 89.1- 96.3 90.4 - 93.9 91.5 - 93.9
Corresponding rate
0/0 96.1 100.0 99.2 98.1
(95%CI) 94.4 - 97.4 98.3 - 100 98.4 - 99.6 97.4 - 98.7
Detection rate
% 9.6 16.5 16.4 13.8
(95%CI) 7.4 - 11.9 11.8 - 22.2 14.0 - 18.9 12.2 - 15.4
All measurements were calculated against PNT laboratory as the reference results.
4.4.2.2 Validation phase
In this phase (one month duration), slides were read at peripheral sites by iLED 40X
but were rechecked at PNT laboratory by conventional FM 40X. The overall detection
rate, sensitivity, specificity, false positive and false negative rates were 16.2%
(n=304/1879, 95%CI: [14.5%, 17.9%]), 93.l % (n=296/318, 95%CI: [89.7, 95.6]),
99.5% (n=1553/1561, 95%CI: [98.9, 99.8]), 2.6% (n=8/304, 95%CI: [1.1, 5.1]) and
1.4% (n=22/1575, 95%CI: [0.9, 2.1]), respectively. No significant difference was
observed in comparison with the ZN baseline data, except for the false positive rate.
Reading by iLED 40X generated more false positive results than ZN reading under
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the study condition, which was 2.6% vs 0.4%, respectively, P=0.046. Further analysis
was undertaken to determine if any individual site had yielded a high false positive
rate that inflated the overall false positive rate. DTU 5 yielded the highest false
positive rate (6.1%, n=3/49) in comparison with DTU I (0%, n=O/IOS,P=O.OI)and
DTU 8 (3.3%, n=S/IS0, P=0.41). Importantly, all false positive results were mis-
reading from negative to scanty or 1+ (low positive).
We found that in the first month working with iLED 40X microscope, more false
positive results were generated in comparison with ZN reading under the study
condition in the technician group with no prior experience on FM microscopy. The
remaining measurements were comparable to those from the ZN baseline.
4.4.2.3 The implementation phase
This phase lasted for 3 months. In this phase, both peripheral and supervision sites
used iLED 40X for smear reading and rechecking. Since low positive smears resulted
in all false positive results in the previous phase (validation phase), all low positive
smears (n=321) and 20% of all negative smears from each site were rechecked by the
supervisory site in the first two months of this phase. The false positive rate was 2.8%
(n=9/321). In the last month of this phase, slides were rechecked according to LQAS
guidelines - the routine QA system of Vietnamese TB programme recommended by
WHO (254). The overall detection, sensitivity, specificity, false positive and false
negative rates at peripheral sites of the implementation phase were 14.0%
[n=767/5458, 95%CI: 13.1, 15.0], 97.25% [n=318/327, 95%CI: 94.8, 98.7], 98.5%
[n=572/581, 95%CI: 97.0, 99.3], 2.7% [n=9/327, 95%CI: 1.3, 5.2] and 1.6%
[n=9/581, 95%CI: 0.7, 2.9], respectively. No significant difference was observed in
comparison with results obtained from the validation phase (P=0.053 for detection
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rate, P=0.69 for sensitivity, P=0.87 for specificity, P=I.0 for false positive and P=0.83
for false negative). When compared with the ZN baseline phase, all parameters except
the false positive rate were similar between the two phases. The implementation phase
generated a higher false positive rate than the ZN baseline phase (2.7% vs 0.4%,
respectively) (P=0.049). To understand if reading by iLED 40X affected the detection
rate and yielded higher false positive/negative errors in comparison with routine ZN
reading, the respective rates of this phase were compared with those from the same
quarter last year (table 4.4). Our data showed that the overall detection rate, false
positive and false negative rates of all sites during this phase (3 months) were not
different from respective measurements recorded under routine LQAS system during
the same period of time last year (P=O.4, P=I.00 and P=0.6, respectively).
Importantly, only the detection rate of DTU 8 was improved under the study
conditions when iLED 40X was used (16.3% vs. 12.9%, P=0.OQ2) compared to ZN
reading under LQAS system of the same quarter last year.
In brief, the false positive rate in this phase was significantly higher than that of the
ZN baseline phase but comparable to the validation phase. All of the measurements
from the implementation phase, including false positive rate, were comparable to
those from the same quarter last year when LQAS system was routinely conducted,
except the detection rate was improved in one microscopy center.
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Table 4.4 Effectiveness of iLED40X in the study condition compared with ZN in
routine condition.
Routine condition Study condition
ZN reading - rechecking iLED40X reading - P values
Study Feb-April2008 rechecking
site Feb-April2009
% % % % % % PI P2 P3
Detection False(+) False(-) Detection False(+) Falset-)
DTUI 11.8 0.0 0.0 9.9
4.3 1.6 0.08 0.57 1.00
(n=x/y) (21011774) (233/2333) (4/94) (4/258)
DTU5 19.7 19.8 0.0 0.0(n=x/y) (116/608)
0.0 0.0 (146/739) (0/33) (0/67)
0.79 NA NA
DTU8 12.9 0.0 0.0 16.3
2.5 1.9 0.002 1.00 1.00
(n=x/y) (370/2874) (388/2386) (5/200) (5/256)
All sites 13.2 13.9
2.7 1.5
(n=xly) (696/5256)
0.0 0.0 (767/5458)
(9/327) (9/581)
0.40 1.00 0.60
Data of reading and rechecking from the study was compared with data from the same
quarter last year.
P values were calculated for comparison between two time points by Fisher's exact test.
PI for comparison of detection rate.
P2 for false positive rates.
P3for false negative rates.
Only detection rate of DTU8 was significantly increased (PI =0.002) when performing
iLED40X in comparison with ZN.
4.4.2.4 The Continuation phase
This phase lasted for 6 months (from May 1st to October 30th 2008). During this
time, both the peripheral and supervision sites used iLED 40X for reading and
rechecking. The rechecking followed the LQAS system. The overall detection,
sensitivity, specificity, false positive and false negative rates at peripheral sites were
14.9% [n=1595/10707, 95%CI: 14.2, 15.6], 100% [n=19/19, 95%CI: 82.4, 100],
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100% [n=1611161, 95%CI: 97.7, 100], 0.0% [n=0/19] and 0.0% [n=0/161],
respectively. By the end of this phase, all measurements were not significantly
different from the ZN baseline measurements, including the false positive rate.
The effectiveness and accuracy of iLED 40X during the study period, by sites, is
described in figure 4.3.
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Figure 4.3 Effectiveness and accuracy of iLED in the 4 phases of the study.
a. Effectiveness of iLED fluorescence microscope
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h. Accuracy of iLED fluorescence microscope
ACCURACY OF iLED IN TUBERCULOSIS DETECTION
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The effectiveness and accuracy ofiLED were observed over 4phases:
Phase 1:ZN baseline.
Phase 2: Evaluation or Validation.
Phase 3: Implementation.
Phase 4: Continuation.
The overall detection, sensitivity, specificity and false negative rates were not statistically
different between phases when compared between each individual site and in combination of
all three demonstration sites, by Fisher's exact test.
False positive increased in the early phases. By the end of the study, false positive rate was
0% and comparable to the ZN baseline phase
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In general, iLED 40X did not show any advantage against conventional light
microscope and conventional fluorescence microscope in terms of sensitivity,
specificity and false negative rates in technicians with no prior FM-experience in our
study. A relatively high false positive rate (using iLED 40X) was generated in the
early phases (2.6% in the validation phase and 2.7% in the implementation) compared
with ZN microscopy (0.4% in the ZN baseline, P<0.05). The overall detection rate for
ZN was 13.8% in ZN-baseline phase. For FM, the overall detection rates fluctuated
during the study period (Validation: 16.2%, Implementation: 14% and Continuation:
14.9%). No statistically significant difference was observed between phases (P=0.08
for ZN baseline vs Validation, P=0.053 for Validation and Implementation, P=0.21
for Implementation vs Continuation, P=0.809 for Implementation vs ZN baseline and
P= 0.28 for Continuation vs ZN). By the end of the study, all parameters measured for
iLED were comparable to the routine values described in the ZN baseline phase.
4.4.2.5 Fading assessment
To evaluate if AFB colour intensity affects reading accuracy of technicians, we
collected 90 routine slides (priority was for slides selected for LQAS from June to
August 2009 and the remaining slides were selected randomly and sequentially from
LQAS collection so that the final set contained 45 positive smears and 45 negative
smears) and stored the slides under routine conditions at Pham Ngoc Thach
laboratory. These slides were then rechecked and AFB subjective colour intensity and
quantitative results were recorded. Our data showed that with the median storage time
of 113 days (83 days - 140 days), a median of 60% AFB on each of 45 positive slides
was still in good color. After such a storage time, 28.9% (n=13/45) positive smears
had a two level-difference in quantitative result between initial reading result and the
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final rechecking result, of which only 15.4% (n=2/13) smears had AFB still in good
colour. A two level-difference refers to 2+ and scanty (n=8/13), 3+ and 1+ (n=2/13),
and scanty and negative (n=3/13). The colour of AFB affected quantitative reading
results, P=0.002 [95%CI: -0.07, -0.01].
An attempt was made to investigate possible factors that would affect AFB colour.
Sample processing method and storage condition were evaluated in this study. The
colour of AFB was likely to be faded if the sample was processed by concentrated
method (NaOH-NALC) and the slide was stored at room temperature (28°C - 32°C,
70% - 85% humidity). Under this condition, almost 70% AFB on each slide were
faded after 39 days and fading reached 100% by 2 months (figure 4.4).
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Figure 4.4 Effect of storage conditions and sample processing methods on AFB
colour observed under fluorescence iLED microscope.
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This graph shows % of AFB in faded condition on each slide by processing method and
storage conditions. Color of AFB was likely to be faded if the sample was processed by
concentrated method (homogenous smear) and the slide was stored at room temperature.
Time difference was measured in days
Homo: refers to concentrated method (Homogenous smear)
Homo+formal: refers to NaOH + NALC + formaldehyde for preparation of panel slides
Direct: refers to no processing method used (unprocessed samples)
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Overall, under the routine storage conditions at microscopy centers and Pham Ngoc
Thach laboratory, with a median storage time of 113 days, 28.9% positive smears
were incorrectly read as a two level reduction in quantitative result compared with the
initial reading result; and only 15.4% of these slides had AFB still retaining good
colour intensity. A slide with AFB showing good colour intensity was defined as ~
70% AFB on that slide retaining good colour intensity according to the subjective
routine experience of staff. We concluded that AFB fading was probably related to
NaOH-NALC processing method and room temperature.
4.4.2.6 Reading assessment
The reading accuracy on ZN-LM and FM-iLED using panel slides were compared.
The sensitivity, specificity, identical, corresponding, false positive and false negative
rates were not significantly different between the two reading methods (table 4.5.a).
Of note, all of the false positive or false negative results yielded by the two methods
were scanty or 1+. Time to result was shorter for ZN than FM among positive smears
only (P=0.007, 95%CI: 0.40, 0.86). Focusing time was similar for the two groups
(table 4.5.b)
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Table 4.5 Reading assessment (Combined data of both sites peripheral site and
supervisory site).
a. Efficacy of ZN compared to FM in iLED microscope
iLED 40X, N=150 ZN-LM, N=150 P value
%(n) 95%CI % (n) 95%CI
False (+) 5.6 (3/54) 1.2, 15.4 0.0 (0/55) N/A 0.24
False (-) 6.3 (6/96) 2.3, 13.1 5.3 (5/95) 1.7,11.8
Sensitivity 89.5 (51157) 78.5,96.0 91.7 (55/60) 81.6,97.2 0.9
Specificity 96.8 (90/93) 90.8,99.3 100 (90/90) 95.9, lOO 0.9
Identical results 84.0 (1261150) 71.1,89.5 84.0 (126/150) 71.1,89.5
Corresponding 88.9,97.2 96.7 (145/150) 92.4,98.9 0.9
results
Efficacy ofZN-LM microscopy and FM-iLED microscopy were similar, by Fisher's exact test.
All offalse positive andfalse negative results were from smears scanty or 1+.
b. Time to result and focusing time
iLED 40X, N=150 ZN-LM, N=150
Median IQR Median IQR
Time to results (in second)
Negative 101 80-141 100 64 - 149.25
Scanty 113.5 82.5 - 128.75 91 51.5 -113.5
1+ 60 39.5 - 80 36 29 - 58.25
2+ 40 32 - 45 30 18 - 35
3+ 22 14.5 - 31.5 20 14.25 - 27
All slides 92 57 - 124.5 68 40.5 - 120
Focusing time (in seconds) 8 6 - 10 8 6 - 12
ZN-LM reading was faster than FM-iLED reading, especially for positive smears (P=0.007,
95%Cl: 0.40, 0.86), by Wilcoxon Rank-sum test.
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When data was stratified by peripheral site and supervisory site, no significant
difference between ZN-LM and FM-iLED 40X was observed between the two groups
in terms of sensitivity, specificity, identical, corresponding, false positive and false
negative rates. The reading time of ZN-LM and FM-iLED40X was comparable for
both supervisor group (p=O.25) and peripheral group (p=O.l) (figure 4.5).
In general, the accuracy of ZN-LM compared to FM-iLED was comparable for both
supervision site and microscopy centers. The reading time was shorter for ZN-LM
than FM-iLED 40X in positive smears only when observed at both sites in
combination, but it was comparable when data was stratified by sites or groups.
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Figure 4.5 Time to result of reading assessment (data stratified by sites)
READING ASSESSMENT - READING TIME
o
LED DTU LED PNT ZN DTU ZN PNT
LED: Reading FM40X-iLED microscope.
ZN: reading ZN-light microscope (ZN-LM).
DTU peripheral group.
PNT: supervisor group.
Reading time o/ZN-LM and iLED40Xwere comparable/or peripheral group (p=O.l) and
supervisor group (p=O.25), by Wilcoxon Rank-sum test.
4.4.2.7 Proficiency testing for peripheral site
Proficiency testing was done at microscopy centers at the end of each sub-phase
(validation, implementation and continuation phase). Each technician read 10 ZN
slides and 10 FM slides by iLED microscope. By the end of the continuation phase (or
completion of the study), reading accuracy and false positive/negative rates were
comparable for the two reading methods. The reading time of FM- iLED40X was
faster than ZN-iLED, 38.5 second vs 51.5 second, respectively, (p=0.01). The testing
results are summarized in table 4.6.
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Table 4.6 Proficiency testing in the 4 study phases.
Validation Implementation Continuation
ZN- iLED P ZN- iLED P
ZN.. iLED pI)
iLED 40X ilED 40X iL.ED 40X
Accuracy
% 100 100 1.00 90 85 0.87 92.5 97.5 0.87
(n=x/y) (40/40) (40/40) (36/40) (34/40) (37/40) (39/40)
'-
False(+)
% 0 0 - 0 0 0 0 -
(n=:xiv) (0/28) (0/28)' (0122) _(QL24) (0/25) (0/27)
False(-)
% 0 0 - 33.3 25 0.69 20 7.7 0.61
(n=x/y) (0/12) (0/12) (6/18) (4/16) (3/15) (1113)
.-
Reading
time 39.5 35 0.18 60.5 40.5 0.14 51.5 38.5 0.01
Median(sec) ( 19-64) (2248) (30.5~99.5)(19.5·65,5) (33-86) (20·49.5)
(IQR)
The accuracy of reading results and reference results (positive or negative results), false
positive andfalse negative rates and median of reading time were evaluated during the
proficiency testing of each Phase.
By the end of the study (end of continuation Phase), FM-iLED40Xreadingwasfaster than
ZN-iLED reading (p=0. 01). The percentages of accuracy, false positive and false negative
were comparable for both reading methods.
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4.4.2.8 Laboratory staff appraisal
The laboratory staff appraisal was evaluated based on a questionnaire designed by
FIND (table 4.7}. In brief, laboratory staffs were satisfied with the design of the iLED
microscope and found that it was easy to use. Satisfaction with the contrast, colour
intensity and background of the iLED microscope also increased over time, from 43%
at the validation phase to 100% at the end of continuation phase, without modification
of the microscope or the staining method. The homogeneity of reading field was
comparable to the standard fluorescent microscope. Interestingly, in the continuation
phase (the last phase of the operational study), all technicians agreed that they spent
less time on smear reading with FM-iLED microscope than standard light
microscope; and the advantage of fluorescence microscopes over light microscopes in
terms of reading time was recorded in the proficiency testing of this phase (38.5s vs
sl.ss, respectively) but FM-iLED and light-iLED microscope (rather than standard
light microscope) was used for evaluation. The light-iLED microscopes have lower
clarity lenses than the standard light microscopes (subjective assessed by technicians)
and therefore the comparison may be biased in favour of FM-iLED. Study
participants found that a dark room was not required for iLED use. The participants
preferred to use iLED-FM 40X rather than iLED-FM 20X for reading. In addition,
AFBs were less well distinguished by light-iLED microscope than standard light
microscope. Therefore, the technicians would prefer to use iLED-FM 40X rather than
iLED-FM 20X or light-iLED microscopes for TB detection if possible. During the
study period, the manufacturer improved the battery-life of the Primostar iLED
microscope, approximately 22 hours vs 1.5 hours. Last but not least, participants
suggested that 5 to 7 days are required for iLED training for staff with smear
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experience but for staff narve to this technique, they suggested a full training course
Validation Implementation t::ontinuatlon
phase phase phase
of25 - 30 days. Details of the appraisal form results are shown in table 4.7.
Table 4.7 Results of staff appraisal questionnaire
Questions (N=6)(N=7)
0/0 %
(N=4)
%
--------- ------------ ----------
--------- ------------ ----------
Part I: Installation and first use
1. Was the installation/first use of Primostar iLED by a
_~~!~~c~p~!~ _
_~e!{-<!x.pll!f!.a.!,!ryt.~~n_~e_~'!l!.e:'Y~~'!1!.t!~~djI.!~~e_1!.s~~~!.1\:~I__
_~X,_ ~1!.t_a_1!.s~~~~~l_~i!~ !.n_S!.J!l~ti~n_s_i~r~'luir~~ _
Rather difficult; some problems were faced during
installation/first use----------------------------------------------
100
1. Was the installation/first use of the battery pack by a
_~~!~~C~p~!~ _
_~eJ(-<!x.pll!f!.a!~ryto ~~n_~~ ~~I!.e_'Y~'!1!.t !~~<!'iI_!~!h_e_1!.s~~~~!.l~~I__
_~X ,_~1!.t_a_1!.s~~~~!.ll;!~l_~i!~~n!~~t!~n_s_i~ r~qu!r~~ _
Rather difficult; some problems were faced during
installation/first use----------------------------------------------
86 67------------
14
l. How satisfied were you with the Primostar iLED user
manual:-EM;-~ -read~d understOOd; covers ail-qu""estions- ihad during
installation/use-----------------------------~---------------- 100
Most sections easy to read and understand, with some
weaknesses in sections: Missing topics:----------------------------------------------Rather cumbersome to read (information required is not found
easily; not enough pictures that allow understanding at first
glance), weaknesses especially in the following sections:
_~ts~i!lj_t~eiE~: - - - -
Comments:
Part II: Training
la. For a microscopist trained in ZN microscopy, how
Intensive should the training for Primostar iLED be?
......••.days
100
33
100
100
100
100
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1.How satisfied are you with contrast, color intensity and
Illnal-to-noise (background) ratio of Primostar iLED?
Very satisfied (better than for the available light microscope and
where applicable fluorescence microscope) 43 67 100---------------------------------------------- --------- ------------ ----------
____~l ~~ _
--------- ------------ ----------
--------- ------------ ----------
_________________________________________? ~ay~
7 days
lb. For someone without prior training in smear microscopy,
bow intensive should the training for Primostar iLED
be1 days
________________________________________)9_~ay~
________________________________________~~_~ay~
________________________________________ ~~_~ay~
________________________________________~?_~ay~
30 days
2. How satisfied were you with the Primostar iLED training
manual:
Can be used by NTPs for implementation of LED microscopy_~i~~u!~~~~~~~g~~ _
Can be used by NTPs for implementation of LED microscopy
_b_u!~q,ujr~~~ I!l~ ~aj<.?r_~h_8!1gczs _
_~q_u!r~~ ~<.?I!lp~e!~t:ey!sl~l!. - - - -
Suggestions for changes:
Part III:Optics and Handling
Satisfied (comparable to available light microscope and where
_appti~~blcz!111~t:e~~t:.n~~!1!i t:0~~~e) - - - - -
Not satisfied (not as good compared to those of the available
light microscope and where applicable fluorescence_~~!~~~e~ _
Comments:
2. How satisfied are you with the color impression for ZN
ltaln of the Primostar iLED (white LED) in comparison to a
ltandard light microscope (halogen bulb)?
_~~~!.~1!;11_~~ ~~~e!.?is!i!lg~i_s~CZ~ -------
Same.._-------------------------------------------
57
100
100
17
75
100
AFBs can be less well distinguished
--------- ------------ ----------
3. How satisfied are you with the resolution and depth of
rocus of Primostar iLED?
43
50------------
50
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17------------o------------ 25----------
100 33
100
14 50
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____~7 ~~ 199 _
--------- ------------ ----------
Very satisfied (better than for the available light microscope and
where applicable fluorescence microscope)----------------------------------------------
Satisfied (comparable to available light microscope and where
_app!i~~bl~!1!,~~e~~e_n~~.!l!i~t:.0_s~~e) _
Not satisfied (not as good compared to those of the available
light microscope and where applicable fluorescence_~~!~SE~E~ _
Comments:
4. Was there a difference between the homogeneity of
Ouorescence illumination in the field ofview compared to
your standard microscope?
Field of view of Primostar iLED is more homogenously
illuminated----------------------------------------------
Same-Fieiro{vi;; ;'fP~i;;osi~ iLED-i; iesshomoge~ousiy- - - - - --
illuminated .
S. How satisfied are you with the overall handling features of
the microscope (on/off switch, intensity regulation of bright
Hlbt and fluorescence light, variable viewing height, focus
mechanism (coarse and fine focus)?
Very satisfied (better than for the available light microscope and
where applicable fluorescence microscope)----------------------------------------------
Satisfied (comparable to available light microscope and where
_app!i~~bl<1!1!'~r:.e~~e_n~~.!l!i~r:.o_S~~p"e) -
Not satisfied (not as good compared to those of the available
light microscope and where applicable fluorescence_~~!~SE~E~ _
Comments:
6. Is tbe procedure for switching between bright field and
Ouorescence light convenient and do you easily understand
tbe .ymbols used for white light and fl,:,orescence light?
_y~ry_~O}J~~~~~ _
Convenient----------------------------------------------
Not convenient----------------------------------------------
Comments:
7. b focusing with the fluorescence unit (due to black
background):
_y~!y"~iftj~l!.lt - - - - - - - - - - - - - - -
_Pif['_c!1~~l!l!.t_o,!1!y..!!lla!t~~ !?f ~i!t!nA __ - - - - - - - - - - - - - - - -
Easy. I quickly got used to it
43
57
43
57
43
71
------------ ----------
100 100
67
67
33
67
33
100
43---------
57
29---------
67------------
33------------
100
100
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9. Are tbe blue LEOs on botb sides of tbe microscope that
iadicate tbe intensity level of the bright field illumination
coDveDieDtor ratber disturbiDg/dazzling?
_~!!ye_nl~f!.t . 1~Q__ _ _ 1_0_0__ __ _ 1pg _
DisturbingIDazzling
I. Do you use tbe option of opening tbe slider on the white
li&bt source to focus witb tbe fluorescence unit (dark
blcqround gets structured wbich makes focusing easier)
X~Sl !!1~ay~~<!!h_i~!O_fa~~~l!t~ _f<.?~u_s!nA _
Sometimes-----------------------------~----------------
Never
10.Are the 4pcs objectives witb magnifications: lOx, 20x 40x
IDd 100x the best choice for the applications Auramine 0
fluorescence and Ziebl Neelsen bright field detection of
pulmonary tuberculosis?
Yes----------------------------------------------
_!:l~i!~!>~~d_l!r~[e!~<!~~,::e_~.; '':'_'~:;'':::~~&.11if.!~a}~0!l _
Comments:
II. Which magnification do you prefer for fluorescence
detection of AFBs: 20 times or 40 times?
20x----------------------------------------------
40x
12. ID your opinion, can Primostar iLED be used without a
dlrkroom?
No darkroom is needed----------------------------------------------
Darkroom is needed
13. Do you use tbe dazzliDg protection for tbe eyepieces?
- ¥~'_~'!Y..I!f~_~~f}ll - - - - - - - - - - - - - - - - - - - - -
_~~L !~'!!lQtI!e_e~_~~~ S~'!~~li.!lgl - - - - - - - - - -
No, Iwould need them, but they are not comfortable/convenient
14. Did you bave any teehnical problems with your
microscope until now (repair, replacement)?
Yes, describe:----------------------------------------------
No 57 100
100
100
29
71
100
17------------
17------------
64
100
100
100
25----------
75----------
100
57---------
43
33------------
67
100
100
100
25
75
Part IV: Application questions
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2. For which applications would you use the Primostar
fLED?
_f~~T!\_c!e!~c!i2!l_op!Y.. :.---------------_.---19Q---
!~~~~~i~~~~~!_~~~~P!l_Op!y"--------------------- ---------
for various applications (such as TB, Malaria, Blood Cell
_~~!S.I.!1!ip~!l!,l~ly~i~,_Tl)'p~I}~s2!l!i~~i~ - - - --------- ------------ ----------
3. Do you see a significant gain in speed when reading slides
with Primostar iLED (40 fields) compared to ZN (100
fields)?
Yes 86 67 100---------------------------------------------- --------- ------------ ----------
_y~!,_f~~~,!~a!i'y~!l!,lg!<!"Y pf>!i!iy~~~g~s_~n.!~__ _____ ______ _ 11- - - - - - - -~~- - - - - - - - - - - - - --
No..._-_ ...._--------------------------------------------------------_. -------------- ------------------ -----_ ..•....••
_9!l!>:.{or .!ti&h_ ,::'?I~~ _l1}i2!'?s2~eY..~~n_t~r~~~~Sf>~~:_~':"~'':::- - - - - - - - - - - -
_9!1!Y_i.!t_sp~£i!i2_s~~i.!tB~·_I;?~f!~e_~e!ti~&:_'':~~~l!s2!1~:_'':'':::- - - -. - - - - - - - --
•No. Reasons: .No: Bui iwouid -sWitch -centers iiiat-currently-have·aiici uie-; - - - - - - - - .
conventional fluorescence microscope to LED fluorescence.
Reasons:...................... 43(4)
1. In your daily work, do you plan to switch between bright
field and fluorescence contrast using just the Primostar
lLED microscope or would you rather use the iLED for
fiuorescence detection only and a second microscope for
bri&bt fleld detection (Ziehl-Neelseo)?
I would use the Primostar iLED for both fluorescence and bright
field and would switch between the two modes at least once per
.~y---------------------------------------.---
Iwould use the Primostar iLED for fluorescence only and will
.~ ~_s~£'?n_d_l!l~c!<;?s_c~p~f,!r_l?r~~! !iB~tl!lic_r~~c.!>py _
Ido not think a bright field microscope will be needed in the
future anymore for TB detection, Le. Iwill only use it for
fluorescence
4. If you had to decide whether to change a majority of
microscopy centers in your country from light microscopy to
LED based fluorescence microscopy, would you recommend
to tbe Head of the National Health Program to switch to
LED?
Yes. Reasons: .----------------------------------------------
In principle, yes. But I would prefer using another microscope
and not the Primostar iLED. Reasons: .·onii- -fo; - i~~--;~I~i'tie - - ~i~r~s~opy- - ~~~te;s~ • -R;a;~~s~
...............----------------------------------------------
14 17
100----------
100(2)83(2)------------
100
100(3)
(1) Mechanical stage movement
(2) Due to low clarity lenses of light-iLED microscopes compared with standard light
microscopes.
(3) Because iLED isfaster
(4) Because iLED is cheaper and more conveninent
sil)---------
Chapter 4 - iLEDstudy Page 288
4.5 SUMMARY OF FINDINGS
Sensitivity, specificity, and false negative rates of the iLED 40X were comparable to
those of ZN reading (ZN-light microscope) under the study condition (ZN baseline)
and routine LQAS system (previous quarter data).
Overall detection rates of iLED 40X were comparable over the phases in comparison
with ZN reading (ZN baseline). Although the raw data showed slight variation from
FM results using iLED 40X (ZN baseline: 13.8%, Validation: 16.2%,
Implementation: 14% and Continuation: 14.9%), the difference was borderline
significant in the early phases (P=0.08 for ZN baseline vs Valuation and P=O.OS3 for
Validation and Implementation) and non-significant for the late phases (P=0.21 for
Implementation vs Continuation, P=0.809 for Implementation vs ZN baseline and P=
0.28 for Continuation vs ZN). The detection rate of FM-iLED reading at one
peripheral site (DTU8) was increased by 3.4% in comparison with routine ZN (light
microscope, data from previous quater) (16.3% vs 12.9%, p=O.002).
False positive rates using iLED increased in the early stages (Validation and
Implementation phases) but then were comparable to the ZN-baseline value and the
routine value (continuation phase).
Colour of AFB affected quantitative smear reading results (P=0.002). Sample
processing method (NaOH-NALC) and slide storage condition at room temperature
(2SoC - 32°C, 70%-85% humidity) were probably responsible for 70% of AFB fading
on each positive slide after 39 days; and the fading reached 100% by 2 months.
Reading time of FM-iLED 40X was shorter than light-iLED in proficiency testing but
reading by standard light microscope was faster than FM-iLED 40X in reading
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assessment. By the end of the study, the reading time ofFM-iLED 40X was improved
compared with at the initiation (38s recorded in the proficiency testing of the
continuation phase compared with 92s in the reading assessment phase); and this FM-
iLED 40X reading time (38 seconds) was faster than the one recorded for reading
standard light microscope in the reading assessment phase (68 seconds). All staff
agreed that FM reading saved more time than ZN reading when completing the
questionnaire.
4.6 DISCUSSION
The first part of our study showed that the efficacy of Primostar iLED fluorescent
microscope was similar to that of conventional fluorescent microscope and light
microscope in the hands of microscopists experienced working with a fluorescent
microscope. The sensitivity and specificity of iLED 40X against phase I panel slide
reference results were more than 94% and 97% respectively. The same was observed
for iLED 20X. Interestingly, no significant differences were observed in terms of
identical, corresponding rates, false positive and false negative rates for the ilED 40X
in comparison with conventional FM microscope and conventional light microscope.
In terms of reading time, over 95% of slides had correct results available in 5 minutes
for all methods. The technician performing this evaluation had 5 five years experience
with both FM and ZN. and reads approximately 100 ZN slides and 30 FM slides per
day using conventional light and fluorescent microscopes in daily work, which is
much higher than the minimum number of slides recommended to be read daily by
WHO. According to WHO recommendations, at least 2-3 smears should be read by a
microscopist daily, with a maximum of20 to maintain and improve their reading skill
(254). Therefore, continuously working with smear reading under high workload
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pressure probably improved his reading skill in both ZN and FM smears. It is likely
that the pre-existing high proficiency of this technician on both ZN and FM
microscopy, contributed to the results showing no difference in terms of efficacy and
reading time. Another probable reason to explain the comparable efficacy between
ZN and FM is closely following the ZN and FM procedures recommended by WHO.
Proficiency testing results from 167 laboratories in the United States and Switzerland
showed that the sensitivity of ZN staining method and fluorochrome staining methods
can be similar if slides are prepared and examined according to the standard
recommendations in terms of stain concentration, decolorization time, counterstaining
time and number of field examined (174). Therefore, a high level of experience and
close monitoring of smear performance may result in equal performance between ZN
and FM reading on conventional LM, conventional FM and FM-iLED microscopes.
In technicians without FM experience, iLED 40X still did not show advantages
against conventional LM and conventional FM in terms of sensitivity, specificity and
false negative at any stage of the study. Although the detection rate fluctuated slightly
during the study period this was not statistically significant, furthermore the false
positive rate increased in the early stages of the study but all parameter measurements
were comparable to the routine values at the end of the study period. World TB day
(24th March) occurred during the study period and during that time a media campaign
was conducted to raise awareness of TB symptoms and increased presentation of
patients to TB clinics. More patients were detected than usual during the period of this
campaign (routine NTP data). Furthennore, lack of familiarity with the FM
microscope may influence the reading capacity of technicians, reducing detection
rates and yielding more false positives. Finally, it is possible that working with the
FM microscope for one year (the study period), the experience of technicians with FM
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accumulated during the study was insufficient to gam advantages over ZN
microscopy
Our findings were interestingly opposite to previous studies. One study from Uganda
suggested that fluorescence microscope was 11% more sensitive than conventional
light microscope (P<O.OOI)(30). However, in this study, fluorescence smears were
prepared from processed samples while ZN smears were from unprocessed (direct)
samples. Studies in the literature have shown that sputum processing methods
increase the detection rate by approximately 9% in comparison with direct smear
(181). Therefore, the processing method is likely to have affected the sensitivity of
FM observed in the Ugandan study and FM itself may not have been responsible for
the improvement over conventional LM. The Ugandan study also found that more
false positives were observed using FM than LM with culture as the gold standard.
We also recognized that high false positive (by using iLED 40X) was generated in the
early phases (Validation and Implementation) compared with ZN reading under the
study conditions (ZN baseline); and the gold standard in our study was the rechecking
process from the supervision site (PNT laboratory). Of note, like the study from
Uganda, all of the false positives in our study were smear scanty or 1+, such errors
usually result from lack of e~perience. Our peripheral technicians did not have any
experience with FM before participating in the 5-day study training course; which
may have been too brief. In addition, different gold standards may yield different
levels of false results. The best gold standard for rechecking is not clear, LQAS
system and culture have been used by different studies. In the National TB program,
smearmicroscopy is the main microbiology test for TB diagnosis and therefore LQAS
system is widely applied. First, the same smear preparation and reading system is
followed by both peripheral and supervision sites. Second, no further equipment is
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needed for supervisory site. Last, it is relatively cheap and not labour intensive. In a
research or reference laboratory, culture yields higher sensitivity than microscopy and
therefore it is a preferred gold standard to establish if positive results by a new
microscopy methodology are true positives. However, not all TB laboratories are
equipped for culture performance. In addition, time to culture positive, training,
human resource, reagent/media supply and cost are important draw backs to the wide
implementation of culture for QA. Moreover, it is unreasonable to use culture as the
gold standard for smear microscopy because culture detects viable TB bacilli while
smear microscopy detects both viable and dead TB bacilli. Patients on treatment may
expectorate dead bacilli and furthermore, during the sample processing procedure,
approximately 30% to 60% of viable TB bacteria will be killed depending on the
decontamination method (214). These bacteria cannot be detected by culture but they
can be observed by microscopy. Therefore, some smear positive cases will be
incorrectly classified as false. positive using culture as a gold standard, although a
positive smear result is clinically misleading if detecting bacilli which are not viable.
In order to minimize bias we applied the LQAS system at the supervisory site as the
gold standard and only staff experienced with smear microscopy at supervisory site
(PNT hospital) were involved in the study, although microbiological methods are
widely used to identify the presence of bacteria in samples, neither smear or culture
are 100% reliable for TB diagnosis. Patient management is not only based on
laboratory results but also on clinical symptoms and radiology. However, clinical
symptoms are subjective and radiology only shows possible pathological sign of the
disease. Therefore, no perfect gold standard for TB diagnosis is available.
Interestingly, a recent study from Uganda reported that FM-LED was more sensitive
than standard light microscope (5.6% vs 9.4%) and FM-LED was also more sensitive
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than conventional/routine FM (69.8% vs 54.7%) against culture as the gold standard.
In addition, examination time for FM-LED was 2 and 4 times less than for standard
light microscope (2). However, the readers performing conventional/routine FM were
from Mulago hospital and were not under the quality assurance management of the
study because they were out of the study team. Two readers performing ZN-LM and
FM-LED smears were from FIND tuberculosis research laboratory and under quality
assurance system. Therefore, there was an inequivalent comparison of conventional
FM with ZN-LM and FM-LED due to differences in staff proficiency. Furthermore,
ZN reading skill of the two readers from FIND laboratory may not have been optimal
because major errors were detected through intra and inter rechecking, leading to the
reading result favouring FM-LED. The study also showed that the difference in
sensitivity and specificity among these reading methods was not significant. If all
readers had similar skill in ZN reading or FM reading and quality assurance was
tightly managed, the sensitivity of detection of AFB among these methods would not
vary.
Peripheral technicians in our study only had a one year period to learn, familiarize and
work with FM-iLED microscope, which may be a short time in comparison with the
experience gained working with ZN-LM reading, the advantage of FM reading
against ZN reading may not h~\Vebeen maximized. FM-iLED should be performed as
a routine test to replace for ZN-LM reading over at least one or two years for further
evaluation. Therefore, the replacement of conventional light microscope with
iLED40X at the moment should be carefully considered in high TB burden countries
where most of the laboratory technicians are familiar with and have high experience
using the ZN method. A full cost:benefit analysis is needed examining costs including
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training, equipment replacement and maintenance and reagent requirements in
operational settings.
A sub-study to understand if routine storage conditions (temperature, humidity)
results in fading, which reduces the reading performance, was also conducted. We
found that if direct FM smears were stored for one month at room temperature (DTU
conditions, (28oe - 32oe) with a relative humidity of 80% - 85%, followed by storage
in an air conditioned room (22°e - 250e, 60% humidity) during working hours after
approximately 4 months, 28.9% of positive smears had a 2 level difference in
quantitative results compared to previous reading results and only 15% of these
smears still retained AFB in good colour intensity after a median storing time of 113
days. Storage conditions in terms of temperature, duration and humidity were proven
to be a risk for slide fading. A study from Bangladesh showed that the fading process
occurred on ZN stained smears in 2-5 months if smears were stored at a high degree
of relative humidity (at least 80%), combined with temperature of 300e (209).
Therefore, our routine storage conditions favored the fading process, especially after 3
months for FM smears. Interestingly, if samples were processed with NaOH-NALC
before smear preparation and smears were stored at room temperature for at least one
month, the slides faded. It is likely that NaOH-NALC, room temperature and
humidity affected the process of fluorescence decay in our study.
However, under the study conditions (not in fading assessment section) and routine
LQAS system, direct routine slides from 3 study sites were stored at room
temperature but they were stored at PNT condition for one month only, which is too
short to cause AFB fading and cause reading errors. We therefore excluded fading as
the reason of the high false positive rate at some DTUs during the study time.
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The reading time assessment was conducted to compare time to results of ZN reading
and FM-iLED reading. Two types of assessment were conducted during the study
period: reading assessment (at the first month of the implementation phase for
comparison between ZN-LM and FM-iLED) and proficiency testing (at the end of
validation phase, implementation phase and continuation phase for comparison
between ZN-iLED and FM-iLED). We showed that in the reading assessment, ZN-
LM reading was faster than FM-iLED 40X reading, especially in positive smears
(p=0.007) when data was combined from both peripheral site and supervisory site.
However, when data was stratified by site, ZN-LM reading time and FM-iLED40X
reading time were comparable for peripheral sites (69 second vs 95.5 second,
respectively, p=O.l) and supervisory site (64 second and 84 second, respectively,
p=O.2S). Some observations may explain this finding. First, all of the participants at
peripheral sites had a median of 28.5 years working with a light microscope; and read
approximately 20 - 50 ZN slides per day. Therefore, adapting to operating the FM
microscope was simple. The important issue was to recognize fluorescent acid-fast
bacilli and to distinguish between AFB and artifacts with similar shape and colour
present on the slide. Second, none of peripheral technicians had experience with a
fluorescence microscope prior to the five days of iLED training, and at the time of the
reading assessment, all participants from microscopy centers had used a fluorescence
microscope for only one month, which may be too short to achieve a reading speed
as expected. Third, concern about incorrectly recognizing AFB by FM- iLED
microscope may have slowed down the reading speed on FM-iLED microscope and
resulted in similar reading times on ZN-iLED and iLED40X. Last but not least,
psychological factors during the reading assessment such as trying to avoid false
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reading and the feeling of "being closely observed" by supervisors may have
influenced the observed reading time.
When conducting proficiency testing at the end of each study phase, we found that
FM-iLED40X reading was faster than ZN-iLED reading in staff with no prior FM
experience. By the end of continuation phase, the reading time of FM-iLED and ZN-
iLED was 38.5 second vs 51.5 second, respectively, P=O.Ol). This may suggests that
time to result was improved when FM reading experience increased during the study
period (9 months) in non-FM-experienced staff. However, there is an important point
about the 100X objective of iLED microscope that might slow down the reading time
of ZN-iLED. The objective 100X of iLED microscope was not as clear as that of the
conventional light microscope. Therefore, it took more time to confirm both positive
and negative results on ZN-iLED reading. Our finding was similar to the report from
a systematic review in 2006, which showed that FM reading was faster than ZN
reading, and 1 minute is required to record a result for FM microscopy compared to 4
minutes for conventional light microscopy (180). Interestingly, although our reading
time was half that described in the review, we generated a high false positive rate in
the early phase. Further evaluation should be conducted to clarify if faster reading
time is related to high false positive rate. More studies should address the reading
time recommended for FM reading to limit the false reading rate.
Unfortunately, we did not conduct proficiency testing for the supervisory site at the
end of the study so we are unable to determine if there was an improvement of
reading time for this group. However, we conducted an experiment on panel slides for
this group to compare the percentage of slides with correct results available after 30
second, 1 minute, 3 minutes .and 5 minutes. This evaluation showed no difference
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between FM-iLED 40X, conventional light microscope and conventional fluorescence
microscope 40X. It is possible that if we had conducted proficiency testing for this
group at the end of the study, we would not have observed a reading improvement
because this group was already familiar with FM reading prior to the study.
We also did not conduct an assessment to compare reading time between FM-iLED
40X and conventional LM in routine samples for non FM-experienced staff to
determine if replacing conventional LM with FM-iLED 40X 'in the NTP system
would practically result in time savings. Data showed that reading time reduced with
experience (92s for FM-iLED in reading assessment - early phase vs 38.5s for FM-
iLED in proficiency testing -late phase) and by the end of the study, the reading time
of FM-iLED (38.5s) was shorter than that of standard light microscope recorded in the
reading assessment phase (68s). Large scale studies should be conducted to evaluate
time saving ofFM-iLED in comparison with standard light microscope.
The design of the iLED microscope met the requirements of the microscopists such as
good contrast, no requirement for a dark room, power saving and good battery-life.
Another advantage of the iLED microscope is that the cost is al~ost 10 times lower
than the conventional FM, which is promising for wide application. However, the
100X objective lens had rather poor clarity compared with the conventional light
microscopes currently in use (AFB colour is less well distinguished by white LED
(iLED 100X) in comparison with conventional light microscope, recorded from staff
appraisal forms and discussion with Catharina Boehme during her visits. Therefore,
currently, iLED microscope only shows high performance using fluorescence.
Assessment and improvements should be made to the 100x objective lens, although
this may increase costs of the microscope.
Chapter4 - iLED study Page 298
In general, although the Primostar iLED microscope presented many advantages
against conventional fluorescence microscopes in terms of design and construction,
the proposal to replace the conventional light microscope which is currently used in
high TB burden countries should be carefully considered. First, the sensitivity,
specificity and detection rates of the Primostar iLED microscope did not show
improvements over the conventional light microscope (data during the study period
was compared to those from the same period of previous year). A higher false positive
rate was generated by the FM-Primostar iLED microscope in comparison with ZN-
LM (ZN baseline phase), especially; most of the false positive results were incorrectly
read as scanty and 1+ smears. Second, although by the end of the study, reading time
of FM-iLED 40X was shorter than that of ZN-iLED (proficiency testing), we cannot
conclude that FM reading will save more time than ZN reading because the 100X
objective of iLED was not as clear as expected and this may prolong the reading time
of ZN-iLED. In addition, we did not conduct an assessment to compare the efficacy of
FM-iLED40X with conventional light microscope in non FM-experienced group,
although data showed that reading time reduced with experience by the end of the
study. Therefore, further evaluation should be conducted before replacing
conventional LM with FM-iLED 40X. However, the comparison was made in FM-
experienced group and the results were comparable for conventional light microscope,
conventional fluorescence microscope, FM-iLED 40X and FM-iLED 20X.
Conversely, in countries where fluorescence microscope is routinely implemented at
some clinics and well-trained, FM-experienced staff is available, FM-iLED should
replace damaged/out of order conventional FM because it has advantages over the
conventional FM, as discussed above. In 2009, World Health Organization has
endorsed the replacement of conventional fluorescent microscope by LED microscope
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in laboratories where conventional fluorescent microscopes are available. In settings
where ZN staining is the main method for use in TB diagnosis, the implementation of
FM-LED has also been encouraged for stepwise replacement of light microscopes by
WHO (238). However, prior to wide application of FM-LED, each setting should
conduct studies to optimize training material preparation and training time as these
will vary between settings due to different background experience of technicians,
evaluation and monitoring of detection rate and outcome of cases diagnosed by FM-
LED to determine the accuracy of FM-LED, establishment of quality control and
quality assurance procedure for technical control and management, waste
management (because auramine is considered possibly carcinogenic to humans
although there is inadequate evidence for carcinogenic effect (41, 255), and
microscope maintenance.
4.7 CONCLUSION
The option of replacing light microscopes with FM microscopes for wide application
in national TB programs should be carefully considered in settings where ZN
microscopy performance is high. Further studies should be conducted in routine
conditions over a longer period of time for better evaluation of iLED performance.
The relative costs of implementing programs to improve and maintain ZN microscopy
performance vs. implementation of FM microscopy should be carefully evaluated in
our setting.
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Chapter 5
OVERVIEW DISCUSSION - CONCLUSION - FUTURE DIRECTIONS
The aim of this thesis was to address two questions:
1. What is the efficacy and feasibility of MODS in diagnosis of paucibaciliary
TB and multi drug resistant TB?
2. What are the accuracy and performance characteristics of the iLED
fluorescence microscope in comparison to light microscope and traditional
fluorescence microscopes in diagnosis ofTB?
The purpose of this thesis was to evaluate if MODS and fluorescence iLED
microscope are accurate as routine TB diagnostic tests in high burden settings with
limited resources and to contribute to the development of a roadmap for the
implementation of these methods in these countries. The following discussion
summarises the principal conclusions of this thesis, the outstanding questions and
presents an overview of the potential impact on the TB epidemic of improved
diagnosis and the challenges in assessing and implementing novel TB diagnostics in
national TB programmes of resource poor settings.
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5.1 SUMMARY OF FINDINGS
The MODS study showed that with a turnaround time of 7 - 8 days and a pooled
sensitivity, across all sub-studies, of 13% higher than homogenous smear microscopy
but comparable to MGIT culture, MODS is an appropriate test for early diagnosis of
paucibacilary TB in resource limited settings.
In terms of diagnosis of MDR-TB, MODS had low sensitivity (77.8%) and low PPV
(87.5%) but high specificity (99.7%) and high NPV (99.3%). The low sensitivity and
PPV of DST-MODS in this study was probably due to low bacterial load samples and
a high critical INH concentration (O.4J.lglml rather than the now recommended
0.1 ug/ml) and the low MDR- TB rate in this community (3.8%), respectively. MODS
is also a reliable method for MDR- TB detection if a critical concentration of 0.1 ug/ml
is used for INH.
The expected advantages of fluorescence iLED 40X microscope against light
microscope and conventional fluorescence microscope were not clearly observed in
this study in terms of accuracy. The reading time of FM-iLED microscope (38s,
recorded in the last phase of the study) showed an improvement compared with that of
the standard light microscope (68s recorded in the early phase of the study). Further
studies should be conducted to determine if a real time-saving occurs with FM-iLED
compared with standard light microscope in routine use. AFB fading of auramine
stained smears was shown to be related to homogenous smear preparation and storage
conditions at room temperature.
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5.2 OUT STANDING QUESTIONS
5.2.1 What needs to be done for scale- up of MODS in resource constrained
settings?
MODS has been proven to be an effective, accurate and reliable test for diagnosis of
TB in Viet Narn, where it was evaluated at the reference laboratory for this thesis. An
operational study in Peru demonstrated increased sensitivity of the MODS assay
against MBBacT and LJ culture (132). However, for rolling out MODS in large scale
implementation, more evidence is needed to assure the validity of MODS in national
TB programmes, including the reproducibility of MODS, percentage of TB patients
diagnosed and receiving benefits from early detection by MODS, treatment outcome
of MDR-TB patients detected by MODS and the cost effectiveness of MODS in
NTPs. An evaluation of decentralization of MODS in Peru showed that MODS was
reliable and effective for use at regional TB laboratories within the NTP (119).
Recently, accreditation of MODS was performed for 2 urban regional TB reference
laboratories in Peru and Universidad Peruana Cayetano Heredia (UPCH, where the
MODS technique was developed) with GenoType® MTBDRplus as the gold standard
(47). This study showed that concordance between the two methods for detection of
INH resistant isolates and RIF resistant isolates were 94.5% and 97.0%, respectively;
and consistency of findings was observed across evaluated laboratories. This
accreditation scheme should be duplicated in other settings. The decentralization and
accreditation processes contribute to the stepwise implementation and external quality
assurance (EQA) of MODS. This data is encouraging and suggests MODS may be
successfully scaled-up to routine laboratories.
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5.2.2 Can MODS distinguiSh M.tuberculosis and Mycobacterium other than
tuberculosis (MOTT) based on cording characteristic?
The presumptive identification of Mtuberculosis by cording development has a wide
range of sensitivity, from 64% to 99% (8, 93). In the MODS evaluation (chapter 3),
of 29 positive MODS cultures presenting with atypical cording (very short cording,
slow cording or yellow colonies), only one sample was confirmed as MaTT by
INNO-LiPA. In addition, of 22 positive cultures identified as MOTT by INNO-LiPA,
none had atypical cording observed in the MODS assay. The ability to distinguish
specific cording of M tuberculosis from atypical cording of MOTT may vary between
observers due to the level. of experience. Mycobacterium species other than
M tuberculosis can produce loose, incomplete "pseudocords" that may be
misinterpreted as true cording. In settings with a very low prevalence of MaTT
infection, few MOTT will occur in routine samples; therefore less experience
differentiating cording is gained, especially in early growth cultures. In settings with a
high prevalence Mituberculosis, incubation of 4 days or less may be not enough to
determine non-cording (101). In addition, TB treatment affects the cording
characteristic of Mtuberculosis. In a study carried out by McCarter et al. (115),
almost 11% of M tuberculosis did not exhibit cording. Of them, 54% were isolated
from patients on TB treatment. Interestingly, all isolates previously isolated from
these patients had exhibited cording. This study also found that less than 7 days
incubation time may not be sufficient for cording formation.
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In general, it is challenging to differentiate MOTT from Mruberculosis based on
cording formation observed in the MODS assay. However, the current diagnostic test,
smear microscopy, also does not differentiate MOTT from Msuberculosis. The
addition of rapid speciation tests, such as MPT64 antigen tests, will add cost and
complexity to the test and may not be cost-effective in high burden settings. Further
studies are required to determine if a simple speciation technique can be applied.
5.2.3 Can samples other than sputum samples be used for MODS assay?
The MODS study described in this thesis has shown that CSF (n=332) and gastric
fluid (n=35 samples) are appropriate for diagnosis of TB by MODS. However, more
studies should be conducted to confirm this conclusion, particularly for gastric fluid
samples because of the small sample size in these studies.
Currently, most accurate TB diagnostic tests have been developed for use on sputum
samples rather than other specimens (nasopharyngeal aspirate, bronchial lavage,
gastric fluid, urine, stool, blood or other body fluids) and the majority of publications
for evaluation of diagnostic tools were conducted in adults. However, specimens other
than sputum are often more appropriate for diagnosis of extrapulmonary TB in the
most vulnerable patient groups: children, HIV infected individuals and patients with
TBM. No serological tests have proven to be accurate (178) and therefore there is an
urgent need to determine which microbiological or molecular tests can be applied to
samples from these patient groups. MODS appears to be suitable for application to
paucibacillary fluids and more extensive evaluation of extrapulmonary specimens is
warranted.
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5.2.4 What is the appropriat~ volume of processed sample for inoculation on
MODS to achieve a high sensitivity?
The MODS experiments performed with 100111processed sample yielded a non-
significant higher detection rate than with 250111sample, when the MODS assay was
done on 48 well-plates. This observation was described for sputum and CSF samples.
The 100J.11volume was also recommended in the MODS SOP (90). Practically, not
only the volume of processed sample but also the quantity and the quality of clinical
sample affect the recovery rate of a test. Therefore, all of the requirements related to
sampling, processing and testing should be strictly followed to achieve the highest
yield.
5.2.5 Is contamination a major concern when performing the MODS assay?
Although the contamination rate and cross-contamination of MODS were less than
2% in this study and also low in reports from other groups using MODS (33, 131,
144), the technique is considered as a method with a potentially high risk of
contamination when attempted for wide application because MODS is a liquid culture
based technique; and manipulations related to sample transfer ,to the MODS plate
increase the risk of contamination and cross-contamination. To minimize the
contamination rate, technical issues related to handling the plate, opening the lid of
the plate, transferring samples to wells and manipulations with pipettes should be
performed following aseptic technique and this needs to be included in training. Data
from this and previous studies shows that contamination is not an issue in controlled
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settings, however, contamination will be more difficult to both control and evaluate in
wide-scale implementation.
5.2.6 Can MODS be used for screening or ruling out active TB in HIV-infected
individuals?
The potential of MODS for screening for active TB among HIV -infected individuals
prior to Isoniazid Preventive Therapy (IPT) is an important consideration. In our
study, the sensitivity of MODS in detection ofTB among people living with HIV was
70.7% which is lower than that ofMGIT (74.9%, P<O.03); and the negative predictive
values (NPV) of MODS and MGIT were 22.4% and 25.3%, respectively, P=0.71 I).
However, the sensitivity of MODS was higher than that of smear (56.9%, P<O.OOl).
The NPV values of MODS and MGIT in our study were rather low because we did
not have a true non-TB group for comparison, all patients enrolled in our study had
clinical symptoms suspected of tuberculosis due to the referral setting. Therefore,
from our data, MODS can add sensitivity to smear microscopy in screening for active
TB among HIV -infected patients. Although MGIT is more sensitive than MODS,
MODS is cheaper and faster than MGIT. Therefore, MODS is more appropriate than
MGIT in screening for active TB in the HIV infected population in resource-limited
settings. For better screening results, MODS and smear or two MODS cultures can be
used in combination. A higher NPV will be obtained in a general population of HIV
patients. A study from Peru showed that in screening TB among HIV positive
patients, MODS detected more cases (6.2%, n=27/435) than smear (1.6%, n=7/435)
and LJ (5.1%, n=22/435). All MODS cultures were positive by day 21; NPV value of
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MODS was 100% for 2 sputum samples which is higher than that of2 smears (95.3%)
and 2 LJ cultures (93.8%) (161). This study demonstrated that an algorithm for TB
screening combining clinical presentation, chest X-ray and smear microscopy is less
effective than two liquid cultures in detection and exclusion of active TB; and MODS
may have a potential role in ruling out TB in people living with HIV prior to IPT
initiation. People living with HIV are at high risk of TB infection and at high risk of
loss to follow-up during diagnosis and treatment. Therefore, if a screening algorithm
is insensitive or the screening procedure takes too long, NTP might lose these
infectious cases in the TB control and management system. Additionally, MODS has
an advantage in terms of lower reagent and consumable costs, therefore, MODS can
potentially be widely applied in high burden settings for screening and ruling out
active TB in HIV -infected individuals.
5.2.7 Can MODS be used for screening or ruling out MDR-TB in TB suspects?
Although the sensitivity of DST -MODS for detection of INH resistant and RIF
resistant isolates was rather low (72.6% and 72.7%, respectively) in our study, data
from previous studies showed that DST -MODS is sensitive and specific in detection
of INH and RIF resistant isolates as well as MDR-TB isolates (33, 132, 133). In
addition, its specificity was very high (97.9% for INH resistance and 99.7% for RIF
resistance) and the agreement between DST -MODS and DST -LJ for detection of
MDR-TB isolates was very high (99%, kappa: 0.8, P<O.OOI).MODS can be used for
screening patients suspected of infection with MDR- TB or early diagnosis of MDR-
TB patients in low income countries where an accurate, cheap and rapid screening
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method is currently not available. In this study, the low PPV of MODS in diagnosis of
MDR-TB (87.5%) may result in substantial mis-diagnosis which would result in
patients receiving inappropriate treatment. To achieve higher accuracy, if resources
permit, alternative methods can be combined in an algorithm; such as two MODS
DST tests, 1 MODS-DST and confirmation of MDR- TB positives with
Genotype@MTBDRp/us or confirmation of RIF resistance using GeneXpert; and
laboratory results should be considered in conjunction with the clinical picture and
assessment of risk-factors for MDR-TB.
5.2.8 Does MODS need speeifie training, quality control and quality assurance?
For wide implementation of the MODS assay, training materials as well as quality
control (QC) and quality assurance (QA) for MODS assay should be carefully
developed and applied to ensure sustained accuracy. In laboratories where staff have a
high level of experience working with microscopy, training on MODS reading and
recognition of M tuberculosis cording should take approximately 3 weeks to one
month, in our experience. For staff who have no experience with microscopy, a longer
training period will be required dependent on individual ability. Training materials
should cover all issues related to sample handling, microscopy skills, pipetting and
CUlturing, biosafety and biohazard. Proficiency testing at the completion of training
should be standardized. QC-QA should also ideally cover all of these issues. Although
QC and QA for the MODS assay have been developed by David Moore (130),
countries intending to perform the MODS assay should assess local requirements and
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resources in developing and applying modified QA-QC materials to achieve the
highest effectiveness.
S.2.9 What is the advantage of the LED microscope?
The LED microscope assessed in this thesis (manufactured by Carl Zeiss, Germany)
has some advantages in design (use of LED bulb, no requirement for a dark room
during operation, battery powered and electricity saving) and a competitive cost that
makes it feasible for replacement of conventional fluorescence microscope (4825USS
on the market but special pricing of 1250USS for high burden countries) (126). The
LED microscope weighs 9.5kg which may not be appropriate for portability,
especially for use in remote areas. Recently, a compact size (7.5 x 13 x 18cm),
minimal-weight (lkg), battery powered (2 AA batteries) and low cost (240USS)
fluorescence microscope has been developed and evaluated (Global Focus
microscope) (123). These characteristics of a fluorescence microscope may contribute
to the expansion of using fluorescence microscope in low income countries.
S.2.10 Does the fluorescence microscope practically increase case detection?
It was unclear from the study presented in chapter 5 if application of the FM-LED
microscope would increase case detection in Vietnam. A multi-country, cross-
sectional evaluation in Africa (51) reported that the FM-LED microscope was 10%
more sensitive than the standard light microscope in culture positive samples; and
FM-LED detected 1% more cases than the standard FM-microscope. However, the
number of patients with a correct diagnosis was lower by FM-LED (89%) than using
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a standard FM-microscope (91%). The majority of incorrectly diagnosed cases by
FM-LED had scanty smear results. The balance between advantages and
disadvantages of FM-LED implementation to specific TB control programnmes
should be evaluated carefully before implementation.
5.2.11 Should fluorescence LED microscopes replace standard light microscopes
inNational TB programmes?
Fluorochrome acid-fast microscopy is currently assumed to be the most rapid
microbiological method for detection of acid-fast bacilli in clinical specimens. Acid-
fast microscopy is a useful tool for initiating treatment and monitoring the progress of
anti-tuberculous drug therapy and the smear microscopy networks are currently the
keystone of TB diagnosis and management in high burden settings. Although data in
this LED study showed that the accuracy of the LED microscope was comparable to
that of the light microscope and conventional fluorescence microscope, data from
other studies strongly suggested advantages of fluorescence microscope over light
microscope in terms of sensitivity (31, 171) although a significant difference has not
always been shown (2). In addition, data from WHO describes an increase in
sensitivity of FM-LED microscopy of 6% compared to ZN microscopy and by 5%
compared to conventional fluorescence microscopy but the specificity was
comparable between these methods (242). Therefore, fluorescence LED microscope
was endorsed by WHO in 2011 to replace ZN microscopy in both high and low
volume laboratories (238, 242).
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The reading time of both methods observed in the LED study was rapid «2 minutes),
therefore it will be challenging to further increase the speed of detection without
introducing reading errors.
In general, little advantage from FM-LED microscope in comparison with the
standard light microscope was observed in the LED study of this thesis. Therefore, the
replacement of light microscope by FM LED microscope for wide application in
national TB programmes should be considered carefully, especially in settings where
the light microsope is being used as the main tool for diagnosis of TB and technicians
are very experienced in working with standard light microscopes. Further studies
should be conducted to evaluate LED microscope in routine conditions for a longer
period of time to have a precise conclusion on large scale implementation of this
method.
5.2.12 If FM-LED microscopes replace standard light microscopes, what should
be considered in terms of QC-QA?
An important consideration in designing QC-QA for auramine stained smears is the
fading of colour intensity over time (91). The iLED study found that the sample
processing agent (NaOH-NALC) and room temperature (2SoC- 32°C) lead to AFB
fading after 39 days. Recently, Minion et al also observed the fading of auramine
stained mycobacterial smears over time when these slides were exposed to light and
temperature. The study showed that among positive slides exposed to light at room
temperature (22°C), only 24% still had positive results after 4 weeks. When exposed
to room temperature (22°C), humidified incubator (30°C) and refrigerator (4°C), the
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fading rates per month (with changing result from positive to negative) determined by
linear least square regression were 21%, 23% and 26%, respectively (125).
Therefore, auramine staining smears should be kept away from high temperature,
daylight, sunlight and humidity to minimize fading. This is a huge challenge for
settings in the tropical and subtropical regions. This evidence will help to develop
external quality assurance guidelines for fluorescence microscopy.
For quality control and quality assurance of FM-LED microscopy, all staining,
reading, recording and reporting procedures must comply with WHO guidelines
(216). Blind rechecking should be applied to all positive smears and at least 20% of
negative smears until quality targets are met (eg, <2% false positive and negative
results) to confirm diagnosis at the individual level and investigate errors. Slides with
reading errors should be restained with ZN staining method for final confirmation.
When technical issues are controlled, blind rechecking by Lot quality assurance
system (LQAS) method should be applied to assess overall laboratory performance.
This QA-QC strategy has been successfully applied in implementation and monitoring
of the ZN-staining method. The AFB fading should be taken into account when
developing QA-QC manual for Auramine-stainingmethod.
5.2.13 Is there any concern about waste management in Auramine staining
procedure?
Auramine is classified as an industrial chemical related to human cancer (165, 200).
The implementation of LED microscope should be carefully considered in terms of
waste management because auramine is a carcinogenic agent. Since the LED
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microscope is intended for use at all laboratory levels, it is important to have a waste
management system under strict control to prevent or minimize environmental
contamination with Auramine. The waste management system at peripheral level
laboratories in resource constrained settings may lack sufficient regulation.
5.3 OVERVIEW CHALLENGES
Although MODS has advantages in the early diagnosis of TB as demonstrated in this
thesis, some challenges remain in implementation of this method which need to be
addressed. First, since liquid cultures pose an increased risk of infection and
transmission, biosafety should be considered when handling MODS assay and a
culture laboratory equipped with class I cabinet is required. Second, MODS is a
relatively laborious technique because of the need for frequent plate reading (alternate
days from day 5 to day 15, then twice a week from day 16 to day 30), it is probably
not appropriate for use in laboratories with a high workload and personnel shortages.
Most peripheral TB laboratories in high burden countries have one to two technicians
working full-time, so there may not be sufficient staff for implementation of MODS
in these laboratories. Third, the availability of a MODS kit may assist in ease of
implementation. Recently, a TB MODS kit™ has been developed by Hardy
Diagnostics Company and is now under evaluation by PATH (www.PATH.org).This
kit may be a suitable solution for scaling up standardized MODS in TB diagnosis
worldwide but the cost may be increased. Fourth, waste management and biohazard
are important issues because all end-products of the MODS culture procedure need to
be autoclaved before discard 'as medical waste. Last, for MODS implementation, a
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laboratory should be equipped with centrifuge, vortex, incubator, Gilson pipettes,
inverted light microscope, autoclave, biosafety cabinet, refrigerator and inverted
microscope which are not routine laboratory tools at peripheral laboratories, in high
burden countries. Periodic maintenance of this equipment is also a major concern.
These are challenges in scaling up MODS in resource constrained settings. An
inverted microscope costs approximately $US 5000 which is more expensive than a
normal light microscope. Recently, a group of scientists in Peru attempted to develop
a low-cost inverted microscope for use in resource limited settings, which would
encourage the use of MODS assay in low income countries (264).
It is challenging to scale up the implementation of FM-LED microscopes in high
burden countries. The fading of auramine stained slides may compromise the external
quality assurance (EQA) system. If all auramine stained slides are restained for EQA,
the increased costs of FM-LED implementation will reduce its cost-effectiveness. In
addition, the benefit of FM-LED versus light microscope in terms of case detection
and the cost of false positive diagnosis remain unclear. Therefore, further studies of
the operational impact ofFM-LED microscope are required.
Tuberculosis diagnosis and management is a complex and interactive process, in
which novel diagnostic tests are only a single component. Therefore, to achieve global
targets for TB elimination, efforts from many fields must be co-ordinated. National
TB programmes are attempting to implement many new interventions across
diagnosis, prevention and management and competitive demands for resources
must be carefully considered to prioritise strategies with the biggest potential
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impact. Improvements in diagnosis will have little effect if NTPs are unable to cope
with the increased case-load and especially, to treat drug-resistant cases appropriately.
The effectiveness of novel diagnostic tests therefore depends not only on their
efficacy, but on integration of investment across all aspects of TB control
programmes.
5.4 POTENTIAL IMPACT OF IMPROVED DIAGNOSTIC TESTS ON THE
TBPANDEMIC
New diagnostic tools with increased sensitivity and shortened turnaround time may
have positive impacts on TB epidemiology within a community. However, a rapid and
widely available diagnostic for tuberculosis with ~ 85% sensitivity for smear-positive
and smear-negative cases, and 97% specificity, which could save approximately
400,000 lives annually, is not· yet available (96). Mathematical models exploring the
potential impact of novel diagnostics either alone or in combination with other
enhanced intervention strategies, can assist policy makers to determine the optimal
strategy and allocation of resources. However, there is no standardised consensus
model for tuberculosis, where latency complicates the derivation of appropriate
models. An age-structure mathematical model of TB applied for the WHO South East
Asia region (1) estimated that without novel interventions of vaccination, drug
regimens or diagnostics tools, the cumulative incidence for 2015-2050 would be
approximately 100 million active TB cases and 18 million TB-related deaths. The
intervention of new diagnostic tools could have an important impact on reduction of
TB incidence and mortality by 2050. In this model, LED microscope, nucleic acid
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amplification tests or a hypothetical dipstick for antigen or antibody methods would
reduce the TB incidence by 13%, 42% and 28% respectively. The increase in case
detection will shorten the infectious duration, reduce infectious reservoirs and
enhance the decrease in mortality if diagnosed patients receive effective therapy.
However, even with a combined triple intervention of novel diagnostics, shortened
treatment and vaccination, the reductions in incidence were insufficient to reach
STOP TB partnership target for TB elimination «1 case per million/year) by 2050.
The introduction of new tools and current diagnostic algorithms do not help people
who do not access health services (107). The poorest and most vulnerable groups are
known to face barriers when accessing health services. Therefore, advocacy and
community action play an important role in targeting this population and maximizing
the uptake of novel diagnostics to reduce the infection source in the community.
Those diagnosed must also receive immediate and effective treatment for a novel
diagnostic test to have an impact on the epidemic.
5.5 ACTION FROM NATIONAL TB PROGRAMMES
Despite the systematic evaluation and endorsement by WHO of many novel TB
diagnostic tests over the last decade (229, 235, 238, 248) there is no perfect TB
diagnostic test available. While the ideal 'dipstick-style' point of care diagnostic test
remains elusive, action must be taken by TB control programmes now using existing
strategies to target tuberculosis and so a choice must be made between imperfect
solutions.
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MODS is simple, sensitive, specific, rapid and low cost but labourious; Fluorescence
microscope (LED microscope) is rapid, sensitive and specific but its benefit relative
to cost of implementation is unclear in settings where the existing ZN staining method
is of high quality; Commercial liquid culturelDST method is sensitive, specific and
rapid but the cost remains beyond the reach of poor patients; GeneXpert is simple,
sensitive, specific and extremely fast (2 hours) but the cost remains high
(17USD/cartridge); and the Line probe assay is sensitive, specific and rapid but is
only applicable on smear positive sputum samples and technical skill is required.
Commercial serological tests currently on the market have been proven to be
inaccurate and in 2010, WHO issued an unprecedented negative policy statement
regarding these tests. National TB control programmes and governments should take
action to eliminate the use of these tests (250). TB control programmes should
develop capacity to adopt the implementation of new validated diagnostic tests which
are appropriate for local conditions.
Ethically, every TB patient has a right to receive equal access to high quality health
care services (204). Every service in the TB control system must be strengthened to
accomplish this mission. Although laboratory services are known as the "backbone"
of TB programmes, they have long been neglected and are not sufficiently invested.
The weakness of these services is now accentuated in the context of MDR-TB and
XDR-TB; and this weakness is a major bottleneck for scaling up management and
control of TB in high burden countries which receive limited funds for this activity.
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The current condition of TB laboratories can vary dramatically depending on national
investment (249). First, many TB laboratories in high burden countries are equipped
with inadequate and unsafe infrastructure such as small rooms, no or poorly
maintained biosafety cabinet, no or unreliable electricity supply. Second, Staff
usually work with no or limited personal protective equipment. Third, country-level
strategic decision makers often do not include laboratory services as an important part
in the national development plans because annual reports rarely include laboratory
efficiency data. Fourth, there is a lack of skilled staff. Fifth, the current diagnostic
tools, smear microscopy and culture, are ineffective in the drug resistant era. Last
but not least, there is a lack of technical assistance and technology transfer from
national and international levels which could strengthen the laboratory "backbone" of
TB control programmes. The Global Laboratory Initiative (GLI) is attempting to
address this problem (www.stoptb.org/wg/gli).
All of these drawbacks contribute to the inaccurate and unreliable results reported
from laboratories and insufficient case detection. An annual report from the Western
Pacific region (240) (Cambodia, China, Laos, Mongolia, Papua New Guinea,
Philippines and Viet Nam) showed that in 2007, among 7997 laboratories that can
perform smear microscopy (generating 0.5 lab/l 00,000 pop), only 78%
(n=626217997) of them were in external quality assessment programmes (EQA) and
over 80% of laboratory in the EQA system needed to take corrective actions.
Furthermore, only 6% (n=46317997) and 3% (n=22417997) of microscopy
laboratories were equipped for performing culture (generating 1.3 lab/S million pop.)
and OST (generating 1.3 lab/IO million pop.) According to WHO, at least 2000 new
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laboratories capable of doing culture and DST and 20,000 newly trained lab
technicians worldwide are needed to ease the current global laboratory bottleneck
(38).
With the current microbiological diagnostic tests, it will be difficult to achieve the
Millennium Goal Development (MGD6) and the Stop TB partnership targets (by
2015, to reduce TB prevalence and death by 50% compared with a baseline of 1990
and by 2050, to eliminate TB as a public health problem) due to the emergence and
spread of HIV and MDR-TB in Africa and Eastern Europe after 1999 (201) and the
limitations of the current diagnostic tests. To improve diagnostic efficiency globally,
in terms of research, it is crucial to develop novel diagnostic tests which can
overcome the disadvantages of the current methods, target the population who are
responsible for 90% of the TB epidemic worldwide and are appropriate for use in low
income countries. If the endorsed novel tests (229, 235, 238, 248) are introduced
immediately, they could potentially have an impact on increasing case detection,
enrolling more TB cases into treatment promptly, reducing infectious source, and for
long term benefit, the TB incidence and prevalence would decrease and the
Millennium Goal could be achieved.
One of the important considerations in development of a new test is evaluation of the
test using samples collected from the target population. To facilitate this, a bank of
reference clinical materials to support the development and evaluation of new
diagnostic methods was created in 1999 and led by the Special Programmes for
Research and Training in Tropical Diseases (TDR). In this project, samples of 2587
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TB suspects have been collected, including sputum, saliva, blood and urine, from 12
countries (South Africa, Uganda, Gambia, Brazil, Canada, Spain, Viet Nam,
Bangladesh, Kenya, Columbia, Peru and Zambia). Among 95 requests from the test
manufacturers which were approved by TDR, 63% (n=60) were related to
immunological methods and only a very small number of. requests related to
microbiological tests (n=4). Unfortunately, results from these studies did not have any
impact on utility for global TB diagnosis (139). It can be inferred that although there
is clearly an urgent need for a more sensitive TB diagnostic, no novel test was
introduced because, of those developed, none were appropriate for use in samples
collected from high burden countries. Aside from accuracy of the test, cost is clearly
an important issue in selecting new tests for use in low resource settings. Since TB is
a disease of poverty, expensive tests are not feasible for application in resource
constrained settings. Recognizing this problem, FIND and WHO have negotiated
preferential pricing to high burden countries for novel tests approved by WHO
(Genotype®MTBDR-plus and GeneXpert). This contributes to the scaling up novel
diagnostic methods worldwide.
Tests may be introduced into NTPs individually or in combination. Significant
achievements have been made since the millennium, but novel diagnostic
technologies have yet to reach the majority of people at risk of TB. Sustained
commitment from international donors, national governments and expert technical
advisors will be required to ensure that implementation of tests proven to be effective
is achieved and reaches the high-burden settings.
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5.6 PROPOSED ALGORITHM FOR EARLY DIAGNOSIS OF TB AND MDR-
TB (applying smear, culture and molecular methods)
The peripheral tuberculosis unit is the first health care centre that the majority of TB
suspects contact. Peripheral laboratories within these units use direct ZN -smear
microscopy, read using a light microscope. Direct auramine staining smear
microscopy (LED microscope) should gradually replace ZN staining to improve
efficacy of smear microscopy according to WHO recommendations (238). If the
smear result is positive, the patient should be recruited for TB treatment according to
WHOINTP guidelines (220). For smear negative results, culture methods and
molecular testing are suggested by WHO for further diagnosis. Diagnosis of smear
negative TB is potentially done at intermediate/regional or reference laboratories. At
the present time, due to financial shortages, personnel shortages and insufficient
infrastructure in high burden countries, it is more feasible to implement MODS
culture, MOlT culture, LJ culture or OeneXpert MTBIRIF at regional or reference
levels. OeneXpert MTBIRIF is recommended for use at peripheral laboratories
because of its simplicity and safety. Although the negotiations between WHOIFIND
and Ceiphed company have reduced the price of the GeneXpert system to 25% of the
market prices for low and middle income countries, the running cost of each test is
still high (18US$) compared with other novel tests (eg. MODS: :s 2US$ for in house
test or around 6 US$ for commercial tests, excluding labour costs). The decision of
which method should be used is dependent on the internal capacity of the individual
NTP programme. In the future, if the "call for action" (147) receives positive
feedback from government, policy makers, international organizations, more funds
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may be available to TB control Programmes which could allow novel diagnostic tests
to be applied at all laboratory levels recommended by WHO. Figure 5.1 depicts a
suggested algorithm for initial introduction of microbiological and novel molecular
diagnostic tests endorsed by WHO for TB diagnosis.
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Figure 5.1 Initial implementation of new diagnostic tests in TB laboratory
network for early diagnosis of tuberculosis
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As for TB diagnosis, the diagnosis of MDR-TB should be centralised at
provincial/regional or reference laboratories. For sputum samples, a direct DST
method is recommended. The Line probe assay endorsed by WHO in 2008 (235) is
recommended for use in smear positive sputum samples only. Direct DST-MODS and
OeneXpert MTBIRIF performed on both smear positive and smear negative sputum
samples. For samples other than sputum, indirect DST method is required because the
majority of these samples are paucibacillary. MODS culture, MOlT culture or LJ
culture can be used for isolation of mycobacteria. Line probe assays or traditional
DST methods can be used for drug susceptibility testing of positive cultures,
depending on local capacity (figure 5.2).
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Figure 5.2 Initial implementation of new diagnostic tests in the TB laboratory
network for early diagnosis of multidrug resistant tuberculosis
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Although novel tests have been endorsed by WHO for implementation in high burden
countries, the impact of these tests may vary among settings due to differential skills
and experience of staff. Therefore, individual TB control Programmes should develop
comprehensive plans for evaluation and roll-out of the" intended to use tests" in a
stepwise approach.
» Include the "intended to use" tests in the annual strategic plan under the
MDG6 goal by 2015.
» Advocate and access support from international organizations for the
investment and conduct of operational evaluation of the tests.
» Advocate to ensure sustained financial and political commitment from
government, policy makers, public and private.
» Develop human and financial resources for implementation of new tests in
parallel with current diagnostic tests.
» Revise the recording and reporting systems to accommodate any novel
technologies implemented.
» Select the first implementation site to maximize technical skill and the impact
on case detection rates.
» Evaluate the first implementation stage, in terms of satisfaction from both
patients and staff for accuracy, cost, technical issues and ease of use.
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~ Introduce further novel tests or multiply the implementation of the first test to
further sites, depending on individual NTP capacity.
The most feasible test, in my opinion, is MODS, because it provides sensitive,
specific and reliable results in one week. Especially, TB and MDR-TB can be
diagnosed by this method with a low cost. The infrastructure needed is the basic
equipment for a culture laboratory plus an inverted microscope and tissue culture
plates; and this test may be easy to adopt in settings that have a strong resource of
experienced microscopists. In 2009, WHO recommended that MODS should be used
as an 'interim solution' on the way to automated molecular test (GeneXpert) for
detection of MDR-TB (238). However, large scale implementation of MODS will
require enormous investment including training, supplies of reagents and equipment,
quality control assurance, maintenance, biosafety and personnels. The magnitude of
investment will not reflect the duration of implementation if MODS is applied only as
'interim' solution. In addition, GeneXpert is still out of reach of the poor because of
its high cost (despite preferential pricing). Therefore, I believe MODS should be
applied as an alternative solution rather than an interim one.
5.7 IMPLEMENTATION IN VIET NAM
The TB laboratory network in Viet Nam is constructed of three levels: National level,
provincial level and peripheral level (district level). The provincial laboratory in Ho
Chi Minh City based at Pham Ngoc Thach Hospital is functioning as the regional
laboratory of Southern provinces.
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The microbiological methods for diagnosis of tuberculosis in Viet Nam are smear
microscopy (light microscope and conventional fluorescence microscope), LJ culture
and MGIT culture. Light microscopes are supplied to all laboratory levels by the
NTP. Fluorescence microscopes and MGIT culture must be funded by local
tuberculosis programme budgets, rather than centrally by the NTP. For LJ culture, all
equipment and reagents (with the exception of some centrifuges) must be purchased
with local budgets. At the present time, not all routine' gold standard' diagnostic tests
available in Viet Nam are functioning at provincial laboratories due to budget
limitation.
Since the national budget for the TB control and prevention programme is limited,
report by WHO as gaps for implementation DOTS and gaps for supplies of first-line
anti-TB drugs (244), and there is a chronic shortage of personnel at all laboratory
levels, the approved novel diagnostic methods cannot be implemented widely at all
laboratory levels. These technologies should be used in appropriate case finding
strategies as suggested by WHO (243) at sites with sufficient local infrastructure
investment. In my opinion, these methods should be prioritized for implementation at
national and regional levels for operational evaluation. The integration of new
diagnostic tests can be applied as presented in the figure 5.1 and figure 5.2. If the
operational evaluation shows this model works well, the NTP can then multiply this
model at other provincial laboratories and then peripheral laboratories following
WHO recommendations on the appropriate laboratory level for each technology.
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5.8 FUTURE WORK
Novel diagnostic tests which were endorsed by WHO for improving TB diagnosis
cannot replace traditional diagnostic methods at least in the near future because no
single test satisfies all the characteristics of an ideal test suggested by WHO and
studies on large scale implementation, clinical impact and cost effectiveness of these
new tools should be locally performed to verify their benefit. At the present time, the
role of novel tests, in combination with smear microscopy and culture, is to target
patients presenting to health services to increase case detection and reduce the
transmission source. The most effective strategy is to detect and manage index cases
first present in the community. Currently, all approved new tests are only suitable for
implementation from the peripheral laboratory level upwards. "Futuredevelopment
efforts will focus on a point of care diagnostic test which can be applied at clinic
level. FIND aim to develop such a test by 2013, however this is probably optimistic
given the current results from biomarker discovery projects (256). The introduction of
diagnostic tools at all levels of the health care system and community will have a
major impact on the global epidemiology of tuberculosis providing parallel
investment in treatment programmes ensures those diagnosed receive effective
treatment (96).
Systematic efforts to evaluate new TB diagnostics in the last decade have clearly
demonstrated that more effective tools are available than those"currently applied in
high burden settings, where smear microscopy remains the only widely applied test.
The greatest challenge in the next decade will be to sustain political commitment to
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investing in the scale-up of application of these tests to those most at need. Without
significant scale-up and investment in TB control, the tuberculosis pandemic will
continue to claim 2 million lives a year,
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